

=> e mcintyre graham/au

E1 1 MCINTYRE GOULD C/AU  
E2 1 MCINTYRE GRAEME N/AU  
E3 10 --> MCINTYRE GRAHAM/AU  
E4 2 MCINTYRE GRANT S/AU  
E5 4 MCINTYRE GRANT T/AU  
E6 4 MCINTYRE GREG/AU  
E7 7 MCINTYRE GREGORY/AU  
E8 2 MCINTYRE GREGORY ALAN/AU  
E9 1 MCINTYRE GREGORY L/AU  
E10 3 MCINTYRE GREGORY R/AU  
E11 2 MCINTYRE GREGORY T/AU  
E12 5 MCINTYRE GWENDA/AU

=> s e3

L1 10 "MCINTYRE GRAHAM"/AU

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 8 DUP REM L1 (2 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AN 2006:57282 CAPLUS

TI Vaccine

IN Bottasso, Oscar Adelmo; Mcintyre, Graham; Stanford, Cynthia Ann;  
Stanford, John Lawson

PA Argent.

SO U.S. Pat. Appl. Publ.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006013830	A1	20060119	US 2004-893524	20040719
	AU 2004203226	A1	20060202	AU 2004-203226	20040719
PRAI	US 2004-893524	A	20040719		

AB The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

L2 ANSWER 2 OF 8 USPATFULL on STN

AN 2006:158606 USPATFULL

TI Whole bacterial cells as immune modulator

IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA

PI US 2006134136 A1 20060622

AI US 2003-526228 A1 20030905 (10)

WO 2003-GB3873 20030905

20051116 PCT 371 date

PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LREP STEPTOE & JOHNSON LLP, 1330 CONNECTICUT AVENUE, N.W., WASHINGTON, DC,  
20036, US  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 2607  
AB An immune modulator composition and/or pharmaceutical composition  
comprising a whole cell of a bacterium from the genera Rhodococcus,  
Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, wherein said  
immune modulator composition in use modifies a cellular immune response.

L2 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:471977 CAPLUS  
TI Immune modulator  
IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann;  
Bottasso, Oscar Adelmo  
PA UCL Biomedica PLC, UK  
SO PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005049056	A2	20050602	WO 2004-GB4783	20041112
	WO 2005049056	A3	20051103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2475190	AA	20060119	CA 2004-2475190	20040719
	EP 1684803	A2	20060802	EP 2004-798504	20041112
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	GB 2422544	A1	20060802	GB 2006-7956	20041112
PRAI	GB 2003-26620	A	20031114		
	GB 2004-4102	A	20040224		
	WO 2004-GB4783	W	20041112		

AB Use of an immune modulator composition and/or pharmaceutical composition  
comprising a whole cell of a bacterium from the genera Rhodococcus,  
Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, for use in the  
manufacture of a medicament for the treatment of an autoimmune disease or  
autoimmune disorder, including certain vascular disorders.

L2 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:215566 CAPLUS  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia  
Ann; Bottasso, Oscar Adelmo  
PA University College London, UK  
SO PCT Int. Appl.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022093	A1	20040318	WO 2003-GB3873	20030905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497644	AA	20040318	CA 2003-2497644	20030905
	AU 2003263319	A1	20040329	AU 2003-263319	20030905
	EP 1534330	A1	20050601	EP 2003-793906	20030905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503022	T2	20060126	JP 2004-533662	20030905
	CN 1735431	A	20060215	CN 2003-824914	20030905
	US 2006134136	A1	20060622	US 2005-526228	20051116
PRAI	GB 2002-20809	A	20020906		
	GB 2003-17144	A	20030722		
	WO 2003-GB3873	W	20030905		
AB	An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L2 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:325818 CAPLUS  
DN 130:343032

TI Mycobacterium vaccae preparation comprising cold-shock proteins for treatment of Raynaud's disease, hypothermia, and other cold-associated conditions

IN Stanford, John Lawson; McIntyre, Graham

PA Stanford Rook Limited, UK

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924067	A1	19990520	WO 1998-GB3346	19981109
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9910430	A1	19990531	AU 1999-10430	19981109
PRAI	GB 1997-23630	A	19971107		
	WO 1998-GB3346	W	19981109		
AB	The invention provides a composition which comprises cold-shocked M. vaccae or cold-shock proteins from M. vaccae together with a pharmaceutically acceptable carrier or diluent. Compns. of the invention are used for a				

method of treatment of the human or animal body, particularly conditions associated with exposure to cold including Raynaud's phenomenon, Raynaud's disease, hypothermia and frostbite.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 1996:485209 BIOSIS  
DN PREV199699200465  
TI Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis.  
AU Carman, William F. [Reprint author]; Trautwein, Christian; Van Deursen, Frederick J.; Colman, Kathryn; Dornan, Edward; McIntyre, Graham; Waters, Jenny; Kliem, Volker; Muller, Rainer; Thomas, Howard C.; Manns, Michael P.  
CS Inst. Virol., Church St., Glasgow G11 5JR, UK  
SO Hepatology, (1996) Vol. 24, No. 3, pp. 489-493.  
CODEN: HPTLD9. ISSN: 0270-9139.  
DT Article  
LA English  
ED Entered STN: 24 Oct 1996  
Last Updated on STN: 24 Oct 1996  
AB Hepatitis B virus (HBV) replicates via an intermediate RNA step. High frequency of polymerase errors with additional selection pressure leads to mutations in the HBV genome. We investigated the number, type, and antigenic effects of mutations in the coding region of the HBV surface antigen in eight patients who underwent orthotopic liver transplantation (OLT) for HBV-related end-stage liver disease and were experiencing infection of the graft and who received hepatitis B surface antigen antibody (anti-HBs) prophylaxis (hepatitis B immune globulin (HBIG)) after OLT. Controls were chronic HBV patients who underwent kidney transplantation and received the same immunosuppressive regime but no HBIG. The S-gene was amplified from serum before and after transplantation, sequenced, and changes in the genome were analyzed. In the five patients who experienced reinfection while receiving anti-HBs, clear mutations occurred in the S-gene. In the patient who did not receive HBIG and those who experienced reinfection only after termination of HBIG, no mutations were found in the S-gene. In the kidney recipients, mutations in the S-gene occurred in only one of eight patients. Because the a determinant contains neutralizing epitopes, this region was chosen for antibody binding to quantify antigenic effects of the mutations. The two patients who selected mutations in the a determinant and became reinfected while receiving HBIG had reduced antibody binding after OLT. Our results suggest that HBIG after OLT imposes a selection pressure on the S-gene, and that mutations are one mechanism for reinfection while receiving HBIG.

L2 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 2  
AN 1995:553982 BIOSIS  
DN PREV199698568282  
TI Hepatitis B virus precore/core variation and interferon therapy.  
AU Fattovich, Giovanna; McIntyre, Graham; Thursz, Mark; Colman, Kathryn; Giulian, Giustina; Alberti, Alfredo; Thomas, Howard C.; Carman, William F. [Reprint author]  
CS Inst. Virol., Church St., Glasgow G11 5JR, UK  
SO Hepatology, (1995) Vol. 22, No. 5, pp. 1355-1362.  
CODEN: HPTLD9. ISSN: 0270-9139.  
DT Article  
LA English  
ED Entered STN: 31 Dec 1995  
Last Updated on STN: 31 Dec 1995  
AB Precore/core genes from hepatitis B e antigen (HBeAg)-positive and antibody to HBeAg (anti-HBe) positive individuals with active hepatitis



have been analyzed to search for correlations with response to interferon before and after treatment. Pretreatment, no precore stop codon mutants were detected, even at the 3% level, in HBeAg-positive responders or nonresponders. In anti-HBe-positive patients, precore mutants did not influence response. No significant core amino acid variability was observed in HBeAg-positive patients, irrespective of interferon response. However, anti-HBe-positive cases had multiple core protein substitutions, mostly in B- and T-helper cell epitopes, but responders had fewer ( $P = .02$  for responders versus nonresponders and reactivators). None of four responders, three of seven reactivators, and three of three nonresponders had mutations within the major T-helper epitope from aa50 to aa69 ( $P = .03$ ). Precore mutants appeared in eight of nine natural seroconverters compared with 3 of 10 interferon-induced anti-HBe seroconverters ( $P = .01$ ). Those in whom precore wild-type remained after treatment often tested negative in the last available sample using polymerase chain reaction (PCR), whereas emergence of mutants led to ongoing viremia in all cases. In anti-HBe-positive cases, precore sequences remained stable during therapy, except for 2 cases in whom a precore mutant appeared accompanied by reactivation. In the core protein, anti-HBe-positive cases selected a mean of 3.5, 1.6, and 1.7 amino acid substitutions in responders, nonresponders, and reactivators respectively ( $P = \text{NS}$ ). In conclusion, core but not precore sequence before therapy may predict response. Appearance of precore mutants during therapy usually predicts failure to clear virus but substitution in core does not influence outcome.

L2 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:421632 CAPLUS

DN 119:21632

TI Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2

AU McGeoch, Duncan J.; Cunningham, Charles; McIntyre, Graham; Dolan, Aidan

CS Inst. Virol., Univ. Glasgow, Glasgow, G11 5JR, UK

SO Journal of General Virology (1991), 72(12), 3057-75  
CODEN: JGVIAI; ISSN: 0022-1317

DT Journal

LA English

AB The DNA sequence of the long repeat (RL) region and adjacent parts of the long unique (UL) region in the genome of herpes simplex virus type 2 (HG52) was determined. The DNA sequences and genetic content of the extremities of HSV-2 UL were found to be closely similar to those determined previously for HSV-1. The 5658 bp sequenced at the left end of HSV-2 UL contained coding regions for genes UL1 to UL4 plus part of UL5. The 4355 bp sequenced at the right end of UL contained coding regions for part of gene UL53, and the whole of genes UL54 to UL56. Comparison of the HSV-1 and HSV-2 UL56 sequences led to a correction in the published HSV-1 UL56 reading frame. The HSV-2 RL region, including one copy of the  $\alpha$  sequence, was determined to be 9263 bp, with a base composition of 75.4% G+C and with many repetitive sequence elements. In HSV-2 RL, sequences were identified corresponding to HSV-1 genes encoding the immediate early IE110 (ICP0) transcriptional regulator and the ICP34.5 neurovirulence factor; the former HSV-2 gene was proposed to contain two introns, and the latter one intron. Downstream of the HSV-2 immediate early gene, the RL sequence encoding the latency-associated transcripts (LATs) was found to be dissimilar to that in HSV-1; the probable LAT promoter regions, however, showed similarities to HSV-1. Properties of the LAT sequences in both HSV-1 and HSV-2 were consistent with LATs being generated as an intron excised from a longer transcript.

=> e stanford joh lawson/au

E1 3 STANFORD JOEL R/AU

E2 1 STANFORD JOEY/AU

```

E3      0 --> STANFORD JOH LAWSON/AU
E4     18      STANFORD JOHN/AU
E5     52      STANFORD JOHN A/AU
E6      1      STANFORD JOHN ANDERSON/AU
E7      1      STANFORD JOHN B/AU
E8      1      STANFORD JOHN C/AU
E9      1      STANFORD JOHN D/AU
E10     1      STANFORD JOHN E/AU
E11     1      STANFORD JOHN EDWARD/AU
E12     94     STANFORD JOHN L/AU

```

=>

<-----User Break----->

=> e stanford john lawson/au

```

E1      94     STANFORD JOHN L/AU
E2     11     STANFORD JOHN LAWRENCE/AU
E3     23 --> STANFORD JOHN LAWSON/AU
E4      1     STANFORD JOHN LEONARD/AU
E5      1     STANFORD JOHN M/AU
E6      1     STANFORD JOHN P/AU
E7      4     STANFORD JOHN R/AU
E8     15     STANFORD JOHN W/AU
E9      1     STANFORD JON/AU
E10     2     STANFORD JON G/AU
E11     2     STANFORD JON L/AU
E12     1     STANFORD JOSEPH/AU

```

=> s e3

L3 23 "STANFORD JOHN LAWSON"/AU

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 20 DUP REM L3 (3 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

```

L4  ANSWER 1 OF 20  CAPLUS  COPYRIGHT 2006 ACS on STN DUPLICATE 1
AN  2006:57282  CAPLUS
TI  Vaccine
IN  Bottasso, Oscar Adelmo; McIntyre, Graham; Stanford, Cynthia Ann;
    Stanford, John Lawson
PA  Argent.
SO  U.S. Pat. Appl. Publ.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 1

```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006013830	A1	20060119	US 2004-893524	20040719
	AU 2004203226	A1	20060202	AU 2004-203226	20040719
PRAI	US 2004-893524	A	20040719		

AB The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera *Rhodococcus*, *Gordonia*, *Nocardia*, *Dietzia*, *Tsukamurella* and *Nocardioides*, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera *Rhodococcus*, *Gordonia*, *Nocardia*, *Dietzia*, *Tsukamurella* and

Nocardioïdes, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

L4 ANSWER 2 OF 20 USPATFULL on STN  
 AN 2006:158606 USPATFULL  
 TI Whole bacterial cells as immune modulator  
 IN McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
 PI US 2006134136 A1 20060622  
 AI US 2003-526228 A1 20030905 (10)  
 WO 2003-GB3873 20030905  
 20051116 PCT 371 date  
 PRAI GB 2002-20809 20020906  
 GB 2003-17144 20030722  
 DT Utility  
 FS APPLICATION  
 LREP STEPTOE & JOHNSON LLP, 1330 CONNECTICUT AVENUE, N.W., WASHINGTON, DC,  
 20036, US  
 CLMN Number of Claims: 22  
 ECL Exemplary Claim: 1  
 DRWN 21 Drawing Page(s)  
 LN.CNT 2607  
 AB An immune modulator composition and/or pharmaceutical composition  
 comprising a whole cell of a bacterium from the genera Rhodococcus,  
 Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioïdes, wherein said  
 immune modulator composition in use modifies a cellular immune response.

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:471977 CAPLUS  
 TI Immune modulator  
 IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann;  
 Bottasso, Oscar Adelmo  
 PA UCL Biomedica PLC, UK  
 SO PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005049056	A2	20050602	WO 2004-GB4783	20041112
	WO 2005049056	A3	20051103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2475190	AA	20060119	CA 2004-2475190	20040719
	EP 1684803	A2	20060802	EP 2004-798504	20041112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	GB 2422544	A1	20060802	GB 2006-7956	20041112
PRAI	GB 2003-26620	A	20031114		
	GB 2004-4102	A	20040224		
	WO 2004-GB4783	W	20041112		

AB Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideae, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:215566 CAPLUS  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann; Bottasso, Oscar Adelmo  
PA University College London, UK  
SO PCT Int. Appl.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022093	A1	20040318	WO 2003-GB3873	20030905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497644	AA	20040318	CA 2003-2497644	20030905
	AU 2003263319	A1	20040329	AU 2003-263319	20030905
	EP 1534330	A1	20050601	EP 2003-793906	20030905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503022	T2	20060126	JP 2004-533662	20030905
	CN 1735431	A	20060215	CN 2003-824914	20030905
	US 2006134136	A1	20060622	US 2005-526228	20051116
PRAI	GB 2002-20809	A	20020906		
	GB 2003-17144	A	20030722		
	WO 2003-GB3873	W	20030905		

AB An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideae, wherein said immune modulator composition in use modifies a cellular immune response.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 20 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 2002:512001 BIOSIS  
DN PREV200200512001  
TI Prophylactic and therapeutic method.  
AU Stanford, John Lawson [Inventor, Reprint author]; Rook, Graham A. W. [Inventor]  
CS Marden, UK  
ASSIGNEE: Stanford Rook Limited, London, UK  
PI US 6432714 20020813  
SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug. 13, 2002) Vol. 1261, No. 2. <http://www.uspto.gov/web/menu/patdata.html>. e-file.  
CODEN: OGUPE7. ISSN: 0098-1133.  
DT Patent  
LA English  
ED Entered STN: 2 Oct 2002

Last Updated on STN: 2 Oct 2002

AB Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.

L4 ANSWER 6 OF 20 USPATFULL on STN

AN 2002:3623 USPATFULL

TI Prophylactic and therapeutic method

IN Stanford, John Lawson, Marden, UNITED KINGDOM

Rook, Graham A.W., Haverhill, UNITED KINGDOM

PI US 2002001596 A1 20020103

US 6432714 B2 20020813

AI US 2001-793713 A1 20010227 (9)

RLI Continuation-in-part of Ser. No. US 1995-442298, filed on 16 May 1995, GRANTED, Pat. No. US 6210684 Continuation of Ser. No. US 1994-312673, filed on 28 Sep 1994, ABANDONED Continuation of Ser. No. US 1993-31307, filed on 15 Mar 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-820684, filed on 27 Mar 1992, ABANDONED

PRAI GB 1992-19425 19920914

GB 1989-17256 19890728

WO 1990-GB1169 19900727

DT Utility

FS APPLICATION

LREP PILLSBURY WINTHROP LLP, 1600 TYSONS BOULEVARD, MCLEAN, VA, 22102

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.

L4 ANSWER 7 OF 20 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 2

AN 2001:448656 BIOSIS

DN PREV200100448656

TI Method for delaying the onset of AIDS.

AU Stanford, John Lawson [Inventor, Reprint author]; Rook, Graham

Arthur William [Inventor]

CS Marden, UK

ASSIGNEE: Stranford Rock Limited, UK

PI US 6210684 20010403

SO Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 3, 2001) Vol. 1245, No. 1. e-file.

CODEN: OGUPE7. ISSN: 0098-1133.

DT Patent

LA English

ED Entered STN: 19 Sep 2001

Last Updated on STN: 22 Feb 2002

AB Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful for delaying the onset of AIDS with or without associated tuberculosis.

L4 ANSWER 8 OF 20 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 3

AN 2000:499048 BIOSIS

DN PREV200000499169

TI Immunotherapeutic agent and its use.

AU Rook, Graham Arthur William [Inventor, Reprint author]; Stanford,

John Lawson [Inventor]

CS London, UK

ASSIGNEE: Stanford Rook Limited, UK

PI US 6056964 20000502

SO Official Gazette of the United States Patent and Trademark Office Patents,  
(May 2, 2000) Vol. 1234, No. 1. e-file.  
CODEN: OGUPE7. ISSN: 0098-1133.

DT Patent

LA English

ED Entered STN: 15 Nov 2000

Last Updated on STN: 10 Jan 2002

AB A method for delaying or preventing the growth or spread of a malignant neoplasm by administering to a subject in need material which comprises killed cells of Mycobacterium vaccae in an amount sufficient at least to delay or prevent the growth or spread of the neoplasm.

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:587088 CAPLUS

TI Treatment of chronic viral infections with m. vaccae

IN Stanford, John Lawson; Rook, Graham Arthur William

PA Stanford Rook Limited, UK

SO PCT Int. Appl.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048615	A2	20000824	WO 2000-GB544	20000216
	WO 2000048615	A3	20001214		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2361925	AA	20000824	CA 2000-2361925	20000216
	AU 2000025611	A5	20000904	AU 2000-25611	20000216
	AU 766113	B2	20031009		
	BR 2000008269	A	20011106	BR 2000-8269	20000216
	EP 1152768	A2	20011114	EP 2000-903857	20000216
	EP 1152768	B1	20030813		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	TR 200102388	T2	20021021	TR 2001-2388	20000216
	JP 2002537266	T2	20021105	JP 2000-599405	20000216
	AT 246930	E	20030815	AT 2000-903857	20000216
	PT 1152768	T	20031231	PT 2000-903857	20000216
	NZ 513320	A	20040430	NZ 2000-513320	20000216
	ES 2204508	T3	20040501	ES 2000-903857	20000216
	ZA 2001006248	A	20020123	ZA 2001-6248	20010730
	NO 2001003939	A	20011004	NO 2001-3939	20010814
	US 6596282	B1	20030722	US 2001-913523	20010913
	HK 1038697	A1	20040319	HK 2002-100237	20020114
PRAI	GB 1999-3539	A	19990216		
	WO 2000-GB544	W	20000216		

AB The present invention provides the use of an M. vaccae preparation for the manufacture of a medicament for use in the treatment of a chronic viral infection, excluding an HIV infection. Chronic viral infections include HPV infection, such as HPV infection associated with cervical dysplasia, herpes virus infection, subacute sclerosing pan-encephalitis and hepatitis virus infection.

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:325818 CAPLUS

DN 130:343032

TI Mycobacterium vaccae preparation comprising cold-shock proteins for treatment of Raynaud's disease, hypothermia, and other cold-associated conditions

IN Stanford, John Lawson; McIntyre, Graham

PA Stanford Rook Limited, UK

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924067	A1	19990520	WO 1998-GB3346	19981109
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9910430	A1	19990531	AU 1999-10430	19981109
PRAI	GB 1997-23630	A	19971107		
	WO 1998-GB3346	W	19981109		

AB The invention provides a composition which comprises cold-shocked M. vaccae or cold-shock proteins from M. vaccae together with a pharmaceutically acceptable carrier or diluent. Compsns. of the invention are used for a method of treatment of the human or animal body, particularly conditions associated with exposure to cold including Raynaud's phenomenon, Raynaud's disease, hypothermia and frostbite.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 USPATFULL on STN

AN 1999:36720 USPATFULL

TI Mycobacterium vaccae for treatment of long term autoimmune conditions

IN Stanford, John Lawson, Claygate, United Kingdom

Rook, Graham Arthur William, Haverhill, United Kingdom

PA University College London, London, United Kingdom (non-U.S. corporation)

PI US 5885588 19990323

WO 9316727 19930902

AI US 1995-290813 19950214 (8)

WO 1993-GB351 19930219

19950214 PCT 371 date

19950214 PCT 102(e) date

PRAI GB 1992-3814 19920221

DT Utility

FS Granted

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer

LREP IP Group of PillsburyMadison & Sutro LLP

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 242

AB Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the treatment of mental diseases associated with an autoimmune reaction initiated by an infection and/or the auto immunologically mediated consequences (other than uveitis) of chronic infection.

L4 ANSWER 12 OF 20 USPATFULL on STN

AN 1998:138448 USPATFULL

TI Treatment of psoriasis using dead cells of Mycobacterium vaccae

IN Stanford, John Lawson, Marden, United Kingdom

Rook, Graham Arthur William, Haver Hill, United Kingdom  
 PA University College London, London, England (non-U.S. corporation)  
 PI US 5833996 19981110  
 AI US 1995-441980 19950516 (8)  
 RLI Continuation of Ser. No. US 1994-238795, filed on 6 May 1994, now  
 abandoned which is a continuation of Ser. No. US 1992-835948, filed on  
 13 Apr 1992, now abandoned  
 PRAI GB 1989-19321 19890825  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Cunningham, Thomas M.  
 LREP Armstrong, Westerman, Hattori, McLeland & Naughton  
 CLMN Number of Claims: 3  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 220

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunoregulatory material derived from Mycobacterium vaccae, especially  
 dead cells of M. vaccae, are useful for the treatment of pathological  
 conditions (other than mycobacterial disease and arthritic disease) in a  
 patient in which the patient's IgG shows an abnormally high proportion  
 of agalactosyl IgG and for the treatment of chronic inflammatory  
 disorders (other than an arthritic disease) caused or accompanied by an  
 abnormally high release from macrophages of interleukin-6 and/or tumor  
 necrosis factor.

L4 ANSWER 13 OF 20 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN

AN 1998:102615 BIOSIS

DN PREV199800102615

TI The immunological cause, prevention, and treatment of tuberculosis.

AU Stanford, John Lawson [Reprint author]

CS Dep. Bacteriol., Univ. Coll. London Med. Sch., London W1P 7LD, UK

SO Gangadharam, P. R. J. [Editor]; Jenkins, P. A. [Editor]. (1998) pp.  
 258-291. Chapman and Hall Medical Microbiology Series; Mycobacteria I:  
 Basic aspects. print.

Publisher: Chapman and Hall, Inc., 29 West 35th Street, New York, New  
 York, USA; Chapman and Hall Ltd., 2-6 Boundary Row, London SE1 8HN,  
 England.

ISBN: 0-412-05451-5.

DT Book

Book; (Book Chapter)

LA English

ED Entered STN: 3 Mar 1998

Last Updated on STN: 3 Mar 1998

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:770899 CAPLUS

TI Immunotherapeutic agent and its use

IN Rook, Graham Arthur William; Stanford, John Lawson

PA University College London, UK

SO PCT Int. Appl., No pp. given

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9526742	A1	19951012	WO 1995-GB715	19950329
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,				



LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,  
SN, TD, TG

CA 2186851	AA	19951012	CA 1995-2186851	19950329
AU 9520785	A1	19951023	AU 1995-20785	19950329
AU 699081	B2	19981119		
EP 752870	A1	19970115	EP 1995-913247	19950329
EP 752870	B1	20020605		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1150388	A	19970521	CN 1995-193357	19950329
CN 1121874	B	20030924		
HU 75835	A2	19970528	HU 1996-2661	19950329
BR 9507338	A	19970916	BR 1995-7338	19950329
JP 09511737	T2	19971125	JP 1995-525497	19950329
RU 2139728	C1	19991020	RU 1996-119793	19950329
NZ 282863	A	20010629	NZ 1995-282863	19950329
AT 218355	E	20020615	AT 1995-913247	19950329
PT 752870	T	20020930	PT 1995-913247	19950329
ES 2177638	T3	20021216	ES 1995-913247	19950329
ZA 9502644	A	19960111	ZA 1995-2644	19950330
FI 9603866	A	19960927	FI 1996-3866	19960927
FI 111223	B1	20030630		
NO 9604075	A	19961125	NO 1996-4075	19960927
US 6056964	A	20000502	US 1996-716189	19961025
PRAI GB 1994-6301	A	19940330		
WO 1995-GB715	W	19950329		

AB Unavailable

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:768147 CAPLUS

TI Mycobacterium vaccae for treatment of long term autoimmune conditions

IN Stanford, John Lawson; Rook, Graham Arthur William

PA University College London, UK

SO PCT Int. Appl., No pp. given

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9316727	A1	19930902	WO 1993-GB351	19930219
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9336377	A1	19930913	AU 1993-36377	19930219
	AU 675421	B2	19970206		
	EP 630259	A1	19941228	EP 1993-905460	19930219
	EP 630259	B1	19970416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
	JP 07506093	T2	19950706	JP 1993-514636	19930219
	HU 69941	A2	19950928	HU 1994-2422	19930219
	EP 763361	A2	19970319	EP 1996-201912	19930219
	EP 763361	A3	19970326		
	EP 763361	B1	20000426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
	AT 151641	E	19970515	AT 1993-905460	19930219
	CZ 282651	B6	19970813	CZ 1994-2023	19930219
	ES 2104131	T3	19971001	ES 1993-905460	19930219
	BR 9305946	A	19971021	BR 1993-5946	19930219
	RU 2124367	C1	19990110	RU 1994-45825	19930219
	AT 192046	E	20000515	AT 1996-201912	19930219
	ES 2145968	T3	20000716	ES 1996-201912	19930219
	NO 9403082	A	19941017	NO 1994-3082	19940822

	NO 311169	B1	20011022		
	US 5885588	A	19990323	US 1995-290813	19950214
	AU 9671887	A1	19970206	AU 1996-71887	19961120
	AU 706122	B2	19990610		
	GR 3033772	T3	20001031	GR 2000-401468	20000623
PRAI	GB 1992-3814	A	19920221		
	EP 1993-905460	A3	19930219		
	WO 1993-GB351	A	19930219		
AB	Unavailable				

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:766815 CAPLUS  
 TI Mycobacterium vaccae in the treatment of uveitis  
 IN Rook, Graham Arthur William; Stanford, John Lawson  
 PA University College London, UK  
 SO PCT Int. Appl., No pp. given  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9208484	A1	19920529	WO 1991-GB1970	19911108
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9188644	A1	19920611	AU 1991-88644	19911108
	AU 665177	B2	19951221		
	EP 556241	A1	19930825	EP 1991-919487	19911108
	EP 556241	B1	19960110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
	JP 06501478	T2	19940217	JP 1991-517436	19911108
	JP 3107568	B2	20001113		
	AT 132755	E	19960115	AT 1991-919487	19911108
	CA 2095854	C	20030819	CA 1991-2095854	19911108
PRAI	GB 1990-24320	A	19901108		
	WO 1991-GB1970	A	19911108		
AB	Unavailable				

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1991:221393 CAPLUS  
 DN 114:221393  
 TI Antigenic or immunoregulatory material from Mycobacterium vaccae for treatment of chronic inflammatory conditions and pathological conditions associated with agalactosyl IgG  
 IN Stanford, John Lawson; Rook, Graham Arthur William  
 PA University College, London, UK  
 SO PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9102542	A1	19910307	WO 1990-GB1318	19900824
	W: AU, CA, FI, GB, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2065286	AA	19910226	CA 1990-2065286	19900824
	CA 2065286	C	20000516		
	AU 9062897	A1	19910403	AU 1990-62897	19900824
	AU 644813	B2	19931223		
	ZA 9006753	A	19910626	ZA 1990-6753	19900824
	EP 489072	A1	19920610	EP 1990-912793	19900824

EP 489072 B1 19960320  
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE  
JP 05501870 T2 19930408 JP 1990-512187 19900824  
JP 2987197 B2 19991206  
AT 135588 E 19960415 AT 1990-912793 19900824  
GB 2252044 A1 19920729 GB 1992-3904 19920221  
NO 9200722 A 19920424 NO 1992-722 19920224  
US 5833996 A 19981110 US 1995-441980 19950516  
PRAI GB 1989-19321 A 19890825  
WO 1990-GB1318 A 19900824  
US 1992-835948 B1 19920413  
US 1994-238795 B1 19940506  
AB Pathol. conditions (other than tuberculosis, leprosy, and rheumatoid arthritis) in which the patients' IgG shows an abnormally high proportion of agalactosyl IgG or chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high release of interleukin 6 and/or tumor necrosis factor from macrophages are treated by administering an effective amount of immunoregulatory material derived from M. vaccae. Cultured M. vaccae NCTC 11659 was suspended in M/15 borate-buffered saline at pH 8 and autoclaved at 10 psi in 5 mL vials to kill the microorganisms. After cooling, tuberculin was added to make an injectable therapeutic agent.

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:765293 CAPLUS  
TI Biological preparation and its use  
IN Stanford, John Lawson; Rook, Graham Arthur William  
PA University College London, UK  
SO PCT Int. Appl., No pp. given  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9101751	A1	19910221	WO 1990-GB1169	19900727
	W: AU, CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2064029	AA	19910129	CA 1990-2064029	19900727
	CA 2064029	C	19981229		
	AU 9061883	A1	19910311	AU 1990-61883	19900727
	AU 644376	B2	19931209		
	ZA 9005927	A	19910529	ZA 1990-5927	19900727
	EP 484438	A1	19920513	EP 1990-912314	19900727
	EP 484438	B1	19960410		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 05500803	T2	19930218	JP 1990-511377	19900727
	AT 136467	E	19960415	AT 1990-912314	19900727
	ES 2088431	T3	19960816	ES 1990-912314	19900727
	NO 9200331	A	19920124	NO 1992-331	19920124
PRAI	GB 1989-17256	A	19890728		
	WO 1990-GB1169	A	19900727		
AB	Unavailable				

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:763043 CAPLUS  
TI Biological preparations and their use  
IN Stanford, John Lawson; Rook, Graham Arthur William  
PA University College London, UK  
SO PCT Int. Appl., No pp. given  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8503639	A1	19850829	WO 1985-GB64	19850215
	W: AU, DK, JP, NO, US				
	RW: AT, BE, CH, DE, FR, LU, NL, SE				
	AU 8539388	A1	19850910	AU 1985-39388	19850215
	GB 2156673	A1	19851016	GB 1985-3939	19850215
	GB 2156673	B2	19871028		
	EP 172212	A1	19860226	EP 1985-901026	19850215
	R: AT, BE, CH, DE, FR, LI, LU, NL, SE				
	US 4724144	A	19880209	US 1985-791143	19851016
PRAI	GB 1984-4280	A	19840217		
	WO 1985-GB64	A	19850215		
AB	Unavailable				

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:63965 CAPLUS

DN 72:63965

TI Bacteriological and serological studies of fast growing mycobacteria identified as Mycobacterium friedmannii

AU Stanford, John Lawson; Beck, Adolf

CS Guy's Hosp. Med. Sch., London, UK

SO Journal of General Microbiology (1969), 58(Pt. 1), 99-106

CODEN: JGMIAN; ISSN: 0022-1287

DT Journal

LA English

AB Examination of new isolates of fast-growing Mycobacteria by serol. and bacteriol. tests showed them to be M. friedmannii. Among the biochem. parameters examined were fermentation of sugars, utilization of acids (benzoate, citrate, lactate, malate, oxalate, and succinate), nitrate reduction, and presence of amidases (acetamide, benzamide, urea, isonicotinamide, nicotinamide, pyrazinamide, salicylamide, allantoin, succinamide, and malonamide).

=> e stanford cynthia ann/au

E1 7 STANFORD CYNTHIA/AU

E2 7 STANFORD CYNTHIA A/AU

E3 5 --> STANFORD CYNTHIA ANN/AU

E4 82 STANFORD D/AU

E5 28 STANFORD D A/AU

E6 29 STANFORD D C/AU

E7 1 STANFORD D C L/AU

E8 2 STANFORD D D/AU

E9 53 STANFORD D F/AU

E10 20 STANFORD D G/AU

E11 12 STANFORD D J/AU

E12 16 STANFORD D P/AU

=> s e1-e3

L5 19 ("STANFORD CYNTHIA"/AU OR "STANFORD CYNTHIA A"/AU OR "STANFORD CYNTHIA ANN"/AU)

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 14 DUP REM L5 (5 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AN 2006:57282 CAPLUS

TI Vaccine

IN Bottasso, Oscar Adelmo; McIntyre, Graham; Stanford, Cynthia Ann;

Stanford, John Lawson  
PA Argent.  
SO U.S. Pat. Appl. Publ.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006013830	A1	20060119	US 2004-893524	20040719
	AU 2004203226	A1	20060202	AU 2004-203226	20040719
PRAI	US 2004-893524	A	20040719		

AB The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

L6 ANSWER 2 OF 14 USPATFULL on STN

AN 2006:158606 USPATFULL

TI Whole bacterial cells as immune modulator

IN McIntyre, Graham, Kent, UNITED KINGDOM

Stanford, John Lawson, Kent, UNITED KINGDOM

Stanford, Cynthia Ann, Kent, UNITED KINGDOM

Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA

PI US 2006134136 A1 20060622

AI US 2003-526228 A1 20030905 (10)

WO 2003-GB3873 20030905

20051116 PCT 371 date

PRAI GB 2002-20809 20020906

GB 2003-17144 20030722

DT Utility

FS APPLICATION

LREP STEPTOE & JOHNSON LLP, 1330 CONNECTICUT AVENUE, N.W., WASHINGTON, DC, 20036, US

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 21 Drawing Page(s)

LN.CNT 2607

AB An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, wherein said immune modulator composition in use modifies a cellular immune response.

L6 ANSWER 3 OF 14 MEDLINE on STN

AN 2006244784 IN-PROCESS

DN PubMed ID: 16278080

TI Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.

AU Dlugovitzky Diana; Fiorenza Gladys; Farroni Miguel; Bogue Christine; Stanford Cynthia; Stanford John

CS Catedra de Microbiologia, Virologia y Parasitologia, Facultad de Ciencias Medicas, Universidad Nacional de Rosario, Santa Fe 3100, 2000 Rosario, Argentina.

SO Respiratory medicine, (2006 Jun) Vol. 100, No. 6, pp. 1079-87. Electronic Publication: 2005-11-08.

Journal code: 8908438. ISSN: 0954-6111.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals

ED Entered STN: 3 May 2006

Last Updated on STN: 10 Jun 2006

AB We report the first study of triple-dose immunotherapy with heat-killed *Mycobacterium vaccae* (SRL 172) combined with short-course, directly observed chemotherapy in newly diagnosed pulmonary tuberculosis patients. The study was carried out in Rosario, Argentina, where single-dose immunotherapy with *M. vaccae* has previously been shown effective. Twenty-two HIV seronegative patients, sputum-positive for tubercle bacilli, entered a randomised and partly blinded trial. Twelve patients received injections of SRL 172 and 10 patients received placebo on days 1, 30 and 60 of chemotherapy. All patients were followed up clinically, by sputum bacteriology, chest radiography and haematology. Patients receiving SRL 172 showed faster and more complete clinical improvement, accelerated disappearance of bacilli from sputum, better radiological clearance and a more rapid fall in ESR, than did those receiving placebo. Follow-up continued for a year after therapy and no patient failed treatment or relapsed. Special investigations included longitudinal assessments of respiratory bursts and expression of CD11b on separated polymorphonuclear and mononuclear leukocytes. Tumour necrosis factor alpha (TNF-alpha) was measured in the supernates of cultured cells and both TNF-alpha and interleukin-4 (IL-4) were measured in serum samples. Immunotherapy recipients showed a significantly faster return towards normal values in all the immunological parameters, than did placebo recipients. The results are consistent with a regulatory activity on cellular immunity, reducing the influence of Th2 and enhancing Th1 to the benefit of the patients. This could allow a reduced period of chemotherapy without loss of efficacy and help to prevent the development of multi-drug resistance.

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:471977 CAPLUS

TI Immune modulator

IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann; Bottasso, Oscar Adelmo

PA UCL Biomedica PLC, UK

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005049056	A2	20050602	WO 2004-GB4783	20041112
	WO 2005049056	A3	20051103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2475190	AA	20060119	CA 2004-2475190	20040719
	EP 1684803	A2	20060802	EP 2004-798504	20041112
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			

GB 2422544 A1 20060802 GB 2006-7956 20041112  
 PRAI GB 2003-26620 A 20031114  
 GB 2004-4102 A 20040224  
 WO 2004-GB4783 W 20041112  
 AB Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:215566 CAPLUS  
 TI Whole bacterial cells as immune modulator  
 IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann  
 ; Bottasso, Oscar Adelmo  
 PA University College London, UK  
 SO PCT Int. Appl.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022093	A1	20040318	WO 2003-GB3873	20030905
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2497644	AA	20040318	CA 2003-2497644	20030905
AU 2003263319	A1	20040329	AU 2003-263319	20030905
EP 1534330	A1	20050601	EP 2003-793906	20030905
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
JP 2006503022	T2	20060126	JP 2004-533662	20030905
CN 1735431	A	20060215	CN 2003-824914	20030905
US 2006134136	A1	20060622	US 2005-526228	20051116
PRAI GB 2002-20809	A	20020906		
GB 2003-17144	A	20030722		
WO 2003-GB3873	W	20030905		

AB An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, wherein said immune modulator composition in use modifies a cellular immune response.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
 AN 2004:552300 CAPLUS  
 DN 141:275781  
 TI Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis  
 AU Stanford, John; Stanford, Cynthia; Grange, John  
 CS Department of Medical Microbiology, Windeyer Institute of Medical Sciences, University College London, London, W1T 4JF, UK  
 SO Frontiers in Bioscience (2004), 9(2), 1701-1719  
 CODEN: FRBIF6; ISSN: 1093-4715  
 URL: <http://www.bioscience.org/2004/v9/af/1292/pdf.pdf>  
 PB Frontiers in Bioscience  
 DT Journal; General Review; (online computer file)

LA English

AB A review. All the trials of immunotherapy of tuberculosis with killed Mycobacterium vaccae, published or not, that are known to the authors are reviewed here. Following an introduction giving a brief account of some earlier immunotherapies for tuberculosis, the origins of the concept of immunotherapy with M. vaccae are considered. Progress is traced from the early work with irradiation-killed organisms in leprosy to the study in London of modulation of tuberculin skin-test responses, and the first comparative trials in the Gambia and Kuwait. In the last of these studies, dosages and different preps. were compared. As a result of this subsequent studies have used 109 heat-killed organisms, equivalent to 1 mg wet-weight of bacilli, as a standard dose. A series of small trials in Argentina, India, Nigeria, Romania, South Africa and Vietnam have pioneered the way forward, disclosing geog. variability, with South Africa as the only country where almost no effects were recorded. Together the studies have shown that a single dose may not be sufficient. These studies have confirmed the mode of action of M. vaccae to be regulation of cell-mediated immunity with enhancement of Th1 and down-regulation of Th2, and they have shown benefits in faster bacteriol. conversion, reduction in ESR, recovery of body weight and resolution of radiol. opacities, leading to better recovery from the disease even when given to patients receiving directly observed therapy, short-course (DOTS). Three major randomized, placebo-controlled and partly blinded trials have been carried out in Africa. The first, in South Africa showed no M. vaccae-related effects. The second trial, in Uganda, confirmed the observations made in the earlier studies of faster sputum conversion and better radiol. clearance. The third trial, in Zambia and Malawi, showed a trend towards benefits in the treatment of HIV seroneg. patients but failed to show beneficial effects in HIV seropos. patients. Studies in patients with multi-drug-resistant tuberculosis have shown that multiple doses of immunotherapy are required in most cases, and that these markedly improve cure-rates for these patients. This is especially so when they are also treated with chemotherapy tailored to the resistance pattern of their infecting organisms. A small study has just commenced in which repeated doses of M. vaccae are being administered to a group of patients who have failed treatment with DOTS-Plus (directly observed therapy with drugs selected on the basis of drug susceptibility profiles). Late in the investigation came publications from China supporting and confirming the data in both drug-sensitive and drug-resistant disease, by the use of multiple injections of their own different preparation of M. vaccae. The trial that is now almost complete in Vietnam of 3 doses of M. vaccae in the treatment of newly diagnosed pulmonary tuberculosis, is accompanied by a chemotherapeutic regimen with a shortened continuation phase. If this important study is successful, immunotherapy with killed M. vaccae should be introduced into the treatment regimens for tuberculosis worldwide.

RE.CNT 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 3

AN 2003:378334 BIOSIS

DN PREV200300378334

TI Treatment of chronic viral infections with M. vaccae.

AU Stanford, John L. [Inventor, Reprint Author]; Rook, Graham A. W.  
[Inventor]; Stanford, Cynthia A. [Inventor]

CS Kent, UK

ASSIGNEE: Stanford Rook Limited, London, UK

PI US 6596282 20030722

SO Official Gazette of the United States Patent and Trademark Office Patents,  
(July 22 2003) Vol. 1272, No. 4. <http://www.uspto.gov/web/menu/patdata.htm>  
1. e-file.

ISSN: 0098-1133 (ISSN print).

DT Patent

LA English



ED Entered STN: 13 Aug 2003  
 Last Updated on STN: 13 Aug 2003

AB The present invention provides the use of an M. vaccae preparation for the manufacture of a medicament for use in the treatment of a chronic viral infection, excluding an HIV infection. Chronic viral infections include HPV infection, such as HPV infection associated with cervical dysplasia, herpes virus infection, subacute sclerosing pan-encephalitis and hepatitis virus infection.

L6 ANSWER 8 OF 14 MEDLINE on STN  
 AN 2003389023 MEDLINE  
 DN PubMed ID: 12893854  
 TI Vaccination strategies to reduce the risk of leukaemia and melanoma.  
 AU Grange John M; Stanford John L; Stanford Cynthia A; Kolmel Klaus F  
 CS Department of Medical Microbiology, Royal Free and University College Medical School, Windeyer Institute for Medical Sciences, 46 Cleveland Street, London W1T 4JF, UK.  
 SO Journal of the Royal Society of Medicine, (2003 Aug) Vol. 96, No. 8, pp. 389-92. Ref: 33  
 Journal code: 7802879. ISSN: 0141-0768.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200309  
 ED Entered STN: 21 Aug 2003  
 Last Updated on STN: 17 Sep 2003  
 Entered Medline: 16 Sep 2003

L6 ANSWER 9 OF 14 MEDLINE on STN  
 AN 2002495654 MEDLINE  
 DN PubMed ID: 12356983  
 TI Immunotherapy for cancer.  
 AU Grange John; Stanford John; Stanford Cynthia  
 SO Journal of the Royal Society of Medicine, (2002 Oct) Vol. 95, No. 10, pp. 525.  
 Journal code: 7802879. ISSN: 0141-0768.  
 CY England: United Kingdom  
 DT Commentary  
 Letter  
 LA English  
 FS Priority Journals  
 EM 200211  
 ED Entered STN: 2 Oct 2002  
 Last Updated on STN: 14 Dec 2002  
 Entered Medline: 26 Nov 2002

L6 ANSWER 10 OF 14 MEDLINE on STN  
 AN 2002301433 MEDLINE  
 DN PubMed ID: 12042378  
 TI Campbell De Morgan's 'Observations on cancer', and their relevance today.  
 AU Grange John M; Stanford John L; Stanford Cynthia A  
 CS Department of Medical Microbiology, Royal Free and University College Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, London W1T 4JF, UK.  
 SO Journal of the Royal Society of Medicine, (2002 Jun) Vol. 95, No. 6, pp. 296-9.  
 Journal code: 7802879. ISSN: 0141-0768.  
 CY England: United Kingdom  
 DT Biography  
 Historical  
 Journal; Article; (JOURNAL ARTICLE)

LA English  
FS Priority Journals  
EM 200207  
ED Entered STN: 4 Jun 2002  
Last Updated on STN: 14 Dec 2002  
Entered Medline: 9 Jul 2002

L6 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 4  
AN 2001:429043 BIOSIS  
DN PREV200100429043  
TI Environmental echoes.  
AU Stanford, John L. [Reprint author]; Stanford, Cynthia A.  
[Reprint author]; Grange, John M. [Reprint author]  
CS Department of Medical Microbiology, Windeyer Institute of Medical  
Sciences, Royal Free and University College Medical School, 46 Cleveland  
Street, London, W1T 4JF, UK  
SO Science Progress, (2001) Vol. 84, No. 2, pp. 105-124. print.  
CODEN: SCPRAY. ISSN: 0036-8504.  
DT Article  
LA English  
ED Entered STN: 12 Sep 2001  
Last Updated on STN: 22 Feb 2002

L6 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 1998:364134 BIOSIS  
DN PREV199800364134  
TI Studies of vaccination of persons in close contact with leprosy patients  
in Argentina.  
AU Bottasso, Oscar [Reprint author]; Merlin, Victor; Cannon, Leslie; Cannon,  
Helen; Ingledew, Nicholas; Keni, Manjusha; Hartopp, Richard;  
Stanford, Cynthia; Stanford, John  
CS Inst. Immunol., Fac. Ciencias Med., Univ. Nacl. Rosario, Santa Fe 3100,  
Rosario 2000, Argentina  
SO Vaccine, (July, 1998) Vol. 16, No. 11-12, pp. 1166-1171. print.  
CODEN: VACCDE. ISSN: 0264-410X.  
DT Article  
LA English  
ED Entered STN: 27 Aug 1998  
Last Updated on STN: 27 Aug 1998  
AB A total of 670 adults living or working with leprosy patients, were  
examined for a BCG vaccination scar, and skin-tested with four new  
tuberculin. Based on the results 513 were vaccinated, 65 with Bacille de  
Calmette et Guerin (BCG) alone, 66 with BCG plus killed Mycobacterium  
vaccae and 382 with killed M. vaccae alone. Skin-testing was repeated 2-3  
years later on 344 subjects, when all three vaccines were found to have  
been highly successful in increasing responses to Tuberculin and Leprosin  
A ( $p < 0.0005$ ) with increased immune recognition of common and  
species-specific antigens. Mean diameters of induration to each skin-test  
were greatest in recipients of BCG alone ( $p < 0.05$ ), which suggests that  
better immuno-regulation occurs after receiving vaccines that incorporate  
M. vaccae. The results suggest 108 M. vaccae alone might prove a valuable  
future vaccine, which would not require selective pre-vaccination  
procedures.

L6 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 5  
AN 1998:319518 BIOSIS  
DN PREV199800319518  
TI Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis.  
AU Lehrer, Amira; Bressanelli, Amalia; Wachsmann, Viviana; Bottasso, Oscar;  
Bay, Maria-Luisa; Singh, Mahavir; Stanford, Cynthia; Stanford,  
John [Reprint author]

CS Dep. Bacteriol., Windeyer Inst. Med. Sci., Univ. Coll. London Med. Sch.,  
46 Cleveland St., London W1P 6DB, UK

SO FEMS Immunology and Medical Microbiology, (May, 1998) Vol. 21, No. 1, pp.  
71-77. print.  
ISSN: 0928-8244.

DT Article

LA English

ED Entered STN: 22 Jul 1998  
Last Updated on STN: 22 Jul 1998

AB A placebo-controlled study of immunotherapy with Mycobacterium vaccae for  
chronic plaque psoriasis showed improvement in the psoriasis area severity  
index in 19 of 21 immunotherapy recipients ( $P < 0.005$ ). Minor improvement,  
not reaching statistical significance for the group, occurred in nine of  
14 placebo recipients. There were losses to follow-up and the placebo  
used, tetanus toxoid, was not ideal. Clinical improvement after  
immunotherapy persisted for 6 months and another injection of the  
immunotherapeutic given to a few volunteers from either group resulted in  
benefits lasting a year. Lymphoproliferative tests were carried out at  
each clinic visit, and on 50 matched controls. Starting with reduced  
responses to mycobacterial antigens and concanavalin A, both treatment  
groups showed a fall after 3 months, and diverged at 6 months with M.  
vaccae recipients rising to values similar to those of healthy controls,  
whereas placebo recipients continued to fall. Conclusions reached were  
that immunotherapy with M. vaccae gave long-lasting clinical benefit to  
most patients, with minimal side effects. This accompanied a return  
towards normal cellular immune responsiveness to mycobacterial antigens,  
which did not follow the use of the placebo.

L6 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 1995:64039 BIOSIS

DN PREV199598078339

TI Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659.

AU Stanford, John L. [Reprint author]; Stanford, Cynthia A.

CS Dep. Med. Microbiol., Univ. College London Med. Sch., 67-73, Riding House  
St., London W1P 7LD, UK

SO Immunobiology, (1994) Vol. 191, No. 4-5, pp. 555-563.  
CODEN: IMMND4. ISSN: 0171-2985.

DT Article

General Review; (Literature Review)

LA English

ED Entered STN: 8 Feb 1995  
Last Updated on STN: 8 Feb 1995

AB The history of immunotherapy for tuberculosis is briefly reviewed, and the  
early appreciation of the importance of secreted antigens, common  
mycobacterial antigens and stress proteins is noted. The methods by which  
Mycobacterium vaccae strain NCTC 11659 was selected for special attention  
are mentioned, and results of some of the pilot studies of its use as an  
immunotherapeutic for tuberculosis are reviewed. The results suggested  
that immunotherapy with M. vaccae may be an important step forward in the  
treatment and eventual control of tuberculosis. Used in combination with  
modern short course chemotherapy, treatment failures and deaths during  
treatment can be significantly reduced. Preliminary data suggests that  
shortened courses of chemotherapy may be possible when combined with  
immunotherapy, and such treatment may also be effective in patients  
co-infected with HIV. Studies at several centers show that M. vaccae may  
have an important part to play in the treatment of multi-drug resistant  
tuberculosis, especially when resistance is of the primary type. The  
mechanism by which M. vaccae achieves these results may be through adrenal  
endocrine influences on immunity, but remains speculative.

=> e bottasso oscar adelmo/au

E1 33 BOTTASSO OSCAR/AU

E2 12 BOTTASSO OSCAR A/AU  
 E3 8 --> BOTTASSO OSCAR ADELMO/AU  
 E4 1 BOTTASSO S/AU  
 E5 1 BOTTASSO STEFANIA/AU  
 E6 3 BOTTASSOL O A/AU  
 E7 1 BOTTASU G/AU  
 E8 3 BOTTAU A/AU  
 E9 2 BOTTAU D/AU  
 E10 2 BOTTAU FRANCOISE/AU  
 E11 1 BOTTAU O/AU  
 E12 11 BOTTAU P/AU

=> s e1-e3

L7 53 ("BOTTASSO OSCAR"/AU OR "BOTTASSO OSCAR A"/AU OR "BOTTASSO OSCAR ADELMO"/AU)

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 33 DUP REM L7 (20 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 33 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AN 2006:57282 CAPLUS

TI Vaccine

IN Bottasso, Oscar Adelmo; McIntyre, Graham; Stanford, Cynthia Ann; Stanford, John Lawson

PA Argent.

SO U.S. Pat. Appl. Publ.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006013830	A1	20060119	US 2004-893524	20040719
	AU 2004203226	A1	20060202	AU 2004-203226	20040719
PRAI	US 2004-893524	A	20040719		

AB The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideles, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideles, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

L8 ANSWER 2 OF 33 USPATFULL on STN

AN 2006:158606 USPATFULL

TI Whole bacterial cells as immune modulator

IN McIntyre, Graham, Kent, UNITED KINGDOM

Stanford, John Lawson, Kent, UNITED KINGDOM

Stanford, Cynthia Ann, Kent, UNITED KINGDOM

Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA

PI US 2006134136 A1 20060622

AI US 2003-526228 A1 20030905 (10)

WO 2003-GB3873 20030905

20051116 PCT 371 date

PRAI GB 2002-20809 20020906  
 GB 2003-17144 20030722  
 DT Utility  
 FS APPLICATION  
 LREP STEPTOE & JOHNSON LLP, 1330 CONNECTICUT AVENUE, N.W., WASHINGTON, DC,  
 20036, US  
 CLMN Number of Claims: 22  
 ECL Exemplary Claim: 1  
 DRWN 21 Drawing Page(s)  
 LN.CNT 2607  
 AB An immune modulator composition and/or pharmaceutical composition  
 comprising a whole cell of a bacterium from the genera Rhodococcus,  
 Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, wherein said  
 immune modulator composition in use modifies a cellular immune response.

L8 ANSWER 3 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 DUPLICATE 2  
 AN 2006:414977 BIOSIS  
 DN PREV200600423236  
 TI Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in  
 children with extra-pulmonary tuberculosis, but not the pulmonary disease  
 - A case-control study in Rosario, Argentina.  
 AU Bonifachich, Elena; Chort, Monica; Astigarraga, Ana; Diaz, Nora; Brunet,  
 Beatriz; Pezzotto, Stella Maris; Bottasso, Oscar [Reprint  
 Author]  
 CS Sch Med Sci, Inst Immunol, Rosario, Argentina  
 bottasso@uolsinectis.com.ar  
 SO Vaccine, (APR 5 2006) Vol. 24, No. 15, pp. 2894-2899.  
 CODEN: VACCDE. ISSN: 0264-410X.  
 DT Article  
 LA English  
 ED Entered STN: 23 Aug 2006  
 Last Updated on STN: 23 Aug 2006  
 AB A hospital-based case-control study was carried out at the Vilela  
 Children's Hospital in Rosario, Argentina, to measure the protection  
 conferred by BCG vaccination against tuberculosis (TB). The study  
 included 148 newly diagnosed cases of TB (75 males and 73 females, mean  
 age 3.34 +/- 2.97 years, S.D.). 134 of them with Pulmonary TB and 14 cases  
 with extra-pulmonary disease. Controls (425 males and 357 females, 3.39  
 +/- 2.98 years) were selected randomly among children who attended to the  
 Hospital showing, neither respiratory diseases nor any other infectious  
 illnesses. Information on BCG vaccination history was assessed from scars  
 or immunisation records. All participants were negative to human  
 immunodeficiency virus and belonged to the lower and upper-lower  
 socioeconomic status, being similar in place of residence and ethnic  
 characteristics. Rate of vaccinated children was 92.6% of cases and 94.5%  
 of controls (3.4 and 3.9% of them without scars, respectively). Regarding  
 the total cases, the protective association between BCG and TB was  
 statistically insignificant, as was for the pulmonary form. Among cases  
 with extra-pulmonary disease, vaccine effectiveness attained significance  
 [79% (95% CI = 26-94)], no matter their age, sex or nutritional status.  
 BCG vaccination exerted a beneficial role in extra-pulmonary TB, even in  
 children not seriously undernourished. (c) 2005 Elsevier Ltd. All rights  
 reserved.

L8 ANSWER 4 OF 33 MEDLINE on STN  
 AN 2006475902 IN-PROCESS  
 DN PubMed ID: 16899582  
 TI Endogenous glucocorticoids cause thymus atrophy but are protective during  
 acute Trypanosoma cruzi infection.  
 AU Roggero Eduardo; Perez Ana R; Tamae-Kakazu Maximiliano; Piazzon Isabel;  
 Nepomnaschy Irene; Besedovsky Hugo O; Bottasso Oscar A; Del Rey  
 Adriana  
 CS Instituto de Inmunologia, Facultad de Ciencias Medicas, Santa Fe 3100,

Universidad Nacional de Rosario, 2000 Rosario, Argentina.  
 SO The Journal of endocrinology, (2006 Aug) Vol. 190, No. 2, pp. 495-503.  
 Journal code: 0375363. ISSN: 0022-0795.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 11 Aug 2006  
 Last Updated on STN: 11 Aug 2006  
 AB The cytokine-mediated stimulation of the hypothalamus-pituitary-adrenal (HPA) axis is relevant for survival during bacterial endotoxemia and certain viral infections. However, only limited information is available regarding the effects of endogenous glucocorticoids on parasite diseases. We have studied this issue using, as a model, C57Bl/6 and Balb/c mice infected with *Trypanosoma cruzi*, the causal agent of Chagas' disease. These two mouse strains differ in the susceptibility to infection with the parasite. An intense stimulation of the HPA-axis was observed 3 weeks after infection in both strains, but glucocorticoid levels were already increased two- to threefold in the less susceptible Balb/c strain during the first week. Blockade of glucocorticoid receptors with the glucocorticoid antagonist RU486, starting on day 10 after infection, partially reversed the thymic atrophy and decreased the number of CD4(+)CD8(+) thymocytes without affecting parasitemia and the number of inflammatory foci in the heart. However, tumor necrosis factor-alpha blood levels were increased in infected mice of both strains treated with RU486. Furthermore, the blockade of glucocorticoid receptors accelerated death in C57Bl/6J mice and increased lethality to 100% in Balb/c mice. The results obtained represent the first evidence that an endocrine host response that is coupled to the immune process can strongly affect the course of a parasite infection.

L8 ANSWER 5 OF 33 MEDLINE on STN  
 AN 2006275090 MEDLINE  
 DN PubMed ID: 16704757  
 TI HLA class II DRB1 polymorphism in Argentinians undergoing chronic *Trypanosoma cruzi* infection.  
 AU Garcia Borrás Silvia; Díez Cristina; Cotorruelo Carlos; Pellizon Oscar; Biondi Claudia; Beloscar Juan; Bottasso Oscar; Racca Amelia  
 CS Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario Suipacha 531, 2000 Rosario, Argentina.. sigarcia@fbioyf.unr.edu.ar  
 SO Annals of clinical biochemistry, (2006 May) Vol. 43, No. Pt 3, pp. 214-6.  
 Journal code: 0324055. ISSN: 0004-5632.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200606  
 ED Entered STN: 18 May 2006  
 Last Updated on STN: 30 Jun 2006  
 Entered Medline: 29 Jun 2006  
 AB DNA typing of human lymphocyte antigen (HLA)-dicloro-1-[beta]-D-ribofuranosyl-benzimidazole 1 (DRB1) alleles in 35 individuals serologically positive for *T. cruzi* and in 41 healthy controls was performed. DRB1\*0409 allele was significantly more prevalent in seropositive individuals, with a trend being also observed for the DRB1\*0701 and DRB1\*1503 alleles. Although statistically insignificant, the latter was found more frequent in cases with cardiomyopathy.

L8 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:471977 CAPLUS  
 TI Immune modulator  
 IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann; Bottasso, Oscar Adelmo  
 PA UCL Biomedica PLC, UK

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005049056	A2	20050602	WO 2004-GB4783	20041112
	WO 2005049056	A3	20051103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2475190	AA	20060119	CA 2004-2475190	20040719
	EP 1684803	A2	20060802	EP 2004-798504	20041112
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	GB 2422544	A1	20060802	GB 2006-7956	20041112
PRAI	GB 2003-26620	A	20031114		
	GB 2004-4102	A	20040224		
	WO 2004-GB4783	W	20041112		

AB Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

L8 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:215566 CAPLUS

TI Whole bacterial cells as immune modulator

IN McIntyre, Graham; Stanford, John Lawson; Stanford, Cynthia Ann; Bottasso, Oscar Adelmo

PA University College London, UK

SO PCT Int. Appl.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022093	A1	20040318	WO 2003-GB3873	20030905
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2497644	AA	20040318	CA 2003-2497644	20030905
	AU 2003263319	A1	20040329	AU 2003-263319	20030905
	EP 1534330	A1	20050601	EP 2003-793906	20030905
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006503022	T2	20060126	JP 2004-533662	20030905

	CN 1735431	A	20060215	CN 2003-824914	20030905
	US 2006134136	A1	20060622	US 2005-526228	20051116
PRAI	GB 2002-20809	A	20020906		
	GB 2003-17144	A	20030722		
	WO 2003-GB3873	W	20030905		

AB An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioideis, wherein said immune modulator composition in use modifies a cellular immune response.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 3

AN 2005:247195 BIOSIS

DN PREV200510039687

TI Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice.

AU Pascutti, Maria Fernanda; Pitashny, Milena; Nocito, Ana Lia; Guernonprez, Pierre; Amigorena, Sebastian; Wietzerbin, Juana; Serra, Esteban; Bottasso, Oscar; Revelli, Silvia [Reprint Author]

CS Fac Ciencias Med, Inst Inmunol, Santa Fe 3100, RA-2000 Rosario, Santa Fe, Argentina  
revelli@arnet.com.ar

SO Life Sciences, (DEC 24 2004) Vol. 76, No. 6, pp. 685-697.  
CODEN: LIFSAK. ISSN: 0024-3205.

DT Article

LA English

ED Entered STN: 8 Jul 2005

Last Updated on STN: 8 Jul 2005

AB Benznidazole (BZL) is a drug currently used for treating Chagas' disease. Given our earlier demonstration in which BZL downregulated cytokine and nitric oxide (NO) synthesis by LPS and/or IFN-gamma-stimulated murine macrophages, we have now analysed whether this compound could exert beneficial effects in a model of LPS-induced inflammation in C57BL/6 mice. The lethal model consisted of two LPS intraperitoneal injections, 200 mug each separated by 2 h, with BZL given orally at a dose of 200 mg/kg, 18 and 2 h before the first challenge and 20 and 44 hr following the second one. In this model, BZL treatment led to a significantly decreased mortality in comparison with untreated counterparts. Remaining experiments were carried out in mice given a unique LPS dose, pretreated with BZL or not, since those subjected to the lethal protocol were unsuitable for laboratory handling. Analysis of IL-1beta, IL-6, TNF-alpha, IL-12 and NOS mRNA expression in liver samples taken at 90 min post-LPS showed a marked reduction of the two latter mRNAs in BZL-treated mice. These animals also displayed significantly decreased levels of serum TNF-alpha and IL-6, accompanied by a diminished number of IL-6-producing peritoneal macrophages. Present effects may broaden the potential usefulness of BZL in situations accompanied by an excessive inflammatory response. (C) 2004 Elsevier Inc. All rights reserved.

L8 ANSWER 9 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 4

AN 2004:324187 BIOSIS

DN PREV200400324257

TI Thymocyte depletion during acute Trypanosoma cruzi infection in C57BL/6 mice is partly reverted by lipopolysaccharide pretreatment.

AU Roggero, Eduardo; Piazzon, Isabel; Nepomnaschy, Irene; Perez, Ana; Velikovsky, Alejandro; Revelli, Silvia; Bottasso, Oscar [Reprint Author]

CS Inst Inmunol, Fac Ciencias Med, Rosario, Argentina  
bottasso@uolsinectis.com.ar

SO FEMS Immunology and Medical Microbiology, (June 1 2004) Vol. 41, No. 2, pp. 123-131. print.



ISSN: 0928-8244 (ISSN print).

DT Article

LA English

ED Entered STN: 21 Jul 2004

Last Updated on STN: 21 Jul 2004

AB Infection with *Trypanosoma cruzi* in C57BL/6 mice leads to a progressive fatal disease accompanied by thymocyte depletion, which is not related with a higher parasite burden but with increased serum levels of tumour necrosis factor alpha (TNF-alpha). Because this situation may result from an excessive inflammatory syndrome, mice were now given anti-TNF-alpha mAbs throughout their acute infection, or subjected to a LPS desensitization protocol before parasite challenge. Treatment with anti-TNF-alpha mAbs failed to ameliorate thymocyte depletion but shortened survival time and increased parasite load. Pretreatment with LPS (desensitization followed by a sublethal LPS dose) prolonged survival time with a trend to reduce parasitemias and TNF-alpha serum concentrations. Given that pentoxifylline (PTx) interferes with in vitro LPS tolerance, experiments by administering PTx in combination with the tolerance-inducing LPS doses were also performed. Such schedule significantly reduced mortality, TNF-alpha and IL-6 serum concentrations, and CD4+ CD8+ thymocyte loss. LPS pretreatment allowed a better infection control and protected from the accompanying tissue damage. Copyright 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.

L8 ANSWER 10 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 5

AN 2003:174164 BIOSIS

DN PREV200300174164

TI Cyclophosphamide adjuvant arthritis in *Trypanosoma cruzi* infected rats with inflammatory cytokine effects.

AU Didoli, Griselda; Bay, Maria Luisa; Rondelli, Flavia; del Rey, Adriana; Besedovsky, Hugo; Bottasso, Oscar [Reprint Author]

CS Instituto de Inmunologia, Facultad de Ciencias Medicas, Santa Fe 3100, Rosario, 2000, Argentina

SO Journal of Rheumatology, (March 2003) Vol. 30, No. 3, pp. 497-504. print. ISSN: 0315-162X (ISSN print).

DT Article

LA English

ED Entered STN: 2 Apr 2003

Last Updated on STN: 2 Apr 2003

AB Objective. To analyze whether the cyclophosphamide (CYC) induced reestablishment of adjuvant arthritis (AA) in chronically *Trypanosoma cruzi* infected rats correlates with changes in the secretion of pro- and antiinflammatory cytokines by popliteal lymph node cells. Methods. Inbred "1" rats infected with *T. cruzi* 90 days earlier and age matched controls were given CYC (25 mg/kg body weight) or physiologic saline 48 h before arthritis induction. Popliteal lymph node cells were collected at the time of AA induction (48 h after CYC treatment) or during the peak response, to study the concanavalin-A (ConA) or *Mycobacterium tuberculosis*-driven in vitro proliferation of several cytokines in their culture supernatants. Results. Infected rats given CYC were recovered from the otherwise decreased ConA induced proliferation seen at the time of peak AA. The CYC mediated reestablishment of AA in *T. cruzi* infected rats coexisted with an increased presence of tumor necrosis factor-alpha in supernatants from either antigen or ConA stimulated cultures as well as interleukin 12 (IL-12) in the latter case. CYC also lowered to normal the increased IL-10 levels from ConA stimulated cultures that the *T. cruzi* group displayed at the time of inducing AA. Conclusion. The process by which CYC restores the clinical expression of AA affects the balance between cytokines that influence the regulation of arthritis in favor of the inflammatory component.

L8 ANSWER 11 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

STN

DUPLICATE 6

AN 2003:193145 BIOSIS

DN PREV200300193145

TI Impaired neutrophil function in patients with pulmonary tuberculosis and its normalization in those undergoing specific treatment, except the HIV-coinfected cases.

AU Fiorenza, Gladys; Bottasso, Oscar Adelmo; Rateni, Liliana; Farroni, Miguel Angel; Dlugovitzky, Diana [Reprint Author]

CS Catedra de Microbiologia, Facultad de Ciencias Medicas de Rosario, Rosario, Santa Fe, 2000, 3100, Argentina  
schenquer@yahoo.com

SO FEMS Immunology and Medical Microbiology, (20 March 2003) Vol. 35, No. 2, pp. 159-164. print.  
ISSN: 0928-8244 (ISSN print).

DT Article

LA English

ED Entered STN: 16 Apr 2003

Last Updated on STN: 16 Apr 2003

AB Our study investigated whether the respiratory burst (RB) of polymorphonuclear neutrophils from tuberculosis (TB) patients was related with the disease severity or treatment, as well as the circulating levels of TNF-alpha. The sample comprised 57 patients with moderate (n=21) or advanced disease (n=36, 13 of them with HIV coinfection, TB-HIV) and 12 controls. Patients were newly diagnosed (n=27) or under treatment (moderate=14, advanced=10, TB-HIV=6). Cytometric analysis showed that untreated patients had a depressed RB in response to Candida albicans, being more pronounced in the advanced group and nearly absent in TB-HIV cases. A recovered RB was observed in treated patients, except for the TB-HIV cases that continued to show a poor response. TNF-alpha serum levels were increased in untreated patients, mostly in the advanced and TB-HIV groups, and showed an inverse and significant correlation with the RB. Disease severity and anti-TB therapy exerted negative and positive influences on the reactive oxygen intermediates production, respectively.

L8 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:695187 CAPLUS

DN 135:366364

TI Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kappaB activation

AU Piaggio, Eliane; Sanceau, Josiane; Revelli, Silvia; Bottasso, Oscar; Wietzerbin, Juana; Serra, Esteban

CS Instituto de Immunologia, Facultad de Ciencias Medicas, Rosario, 2000, Argent.

SO Journal of Immunology (2001), 167(6), 3422-3426  
CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

AB In murine macrophages, inducible NO synthase II (NOSII) gene expression is promoted at a transcriptional level by LPS and/or IFN-gamma with benznidazole (BZL), a trypanocidal drug, acting to down-regulate NOSII gene induction and hence inhibiting NO production. By performing transient transfection expts., we now report that BZL also inhibited the expression of NOSII gene promoter or multimerized NF-kappaB binding site controlled reporter genes. By contrast, no effect was observed on the expression of a reporter gene under the control of the NOSII promoter-derived IFN regulatory factor element. EMSAs demonstrated that BZL inhibited the nuclear availability of NF-kappaB in stimulated macrophages. NF-kappaB is activated in macrophages by phosphorylation, ubiquitination, and subsequent proteolysis of I-kappaB. Within this setting, Western blot was also performed to show that BZL blocked I-kappaB degradation. Collectively, these results demonstrate that BZL is able to specifically inhibit macrophage NF-kappaB activation after



AB We demonstrated that administration of interferon gamma (IFN-gamma) to pregnant rats conferred partial resistance in their offspring to further challenge with *Trypanosoma cruzi*. Because of the effects of IFN-gamma on macrophage activation and immunoglobulin isotype selection, offspring were now studied to ascertain whether this intervention modifies the in vitro replication of *T. cruzi* and nitric oxide (NO) production by peritoneal macrophages (PE), together with the anti-*T. cruzi* IgG isotypes. To evaluate the possibility of a detrimental effect of IFN-gamma, serum levels of anti-sulphatide autoantibodies were also investigated. Offspring were born to mothers undergoing one of the following procedures during gestation: treatment with recombinant rat IFN-gamma, 50,000 IU/rat, five times/week for 3 weeks, which was started on the day of mating; infection with 106 trypomastigotes of *T. cruzi* at 7, 14, and 21 days after mating plus IFN-gamma treatment as given to the former group; the same protocol except that physiological saline was injected instead of IFN-gamma; injection of physiological saline only. Offspring were challenged at weaning with a similar dose of *T. cruzi*, to constitute four groups of infected young, plus an additional group of age-matched uninfected rats born to control mothers. PE were harvested at day 7 postinfection (pi), exposed to parasites and further investigated for the replication of *T. cruzi* and NO production, whereas ELISA studies for measuring serum anti-*T. cruzi* IgG subclasses and anti-sulphatide autoantibodies were performed at day 30 pi. The number of intracellular parasites in PE was markedly decreased in young born to IFN-gamma-treated mothers, this not being accompanied by higher nitrite levels in culture supernatants. Offspring delivered by IFN-gamma-treated mothers showed no higher serum concentrations of anti-sulphatide autoantibodies, but exhibited a preferential synthesis of anti-*T. cruzi* IgG2b antibodies. This rat isotype is known to fix complement and constitutes the rat counterpart of IgG2a mouse immunoglobulins whose synthesis is favoured by IFN-gamma.

L8 ANSWER 15 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1999:66798 BIOSIS

DN PREV199900066798

TI Levels of tumor necrosis factor alpha, gamma interferon, and interleukins 4, 6, and 10 as determined in mice infected with virulent or attenuated strains of *Trypanosoma cruzi*.

AU Revelli, Silvia [Reprint author]; Gomez, Laura; Wietzerbin, Juana; Bottasso, Oscar; Basombrio, Miguel A.

CS Inst. Immunol., Fac. Ciencias Med., Univ. Nacional Rosario, Santa Fe 3100, Rosario 2000, Argentina

SO Parasitology Research, (Feb., 1999) Vol. 85, No. 2, pp. 147-150. print. CODEN: PARREZ. ISSN: 0932-0113.

DT Article

LA English

ED Entered STN: 16 Feb 1999

Last Updated on STN: 16 Feb 1999

AB Inoculation of BALB/c mice with the virulent Tulahuen (TUL) strain of *T. cruzi* was shown to lead to progressive and eventually lethal infections, whereas infection with an attenuated strain (TCC) resulted in a hardly noticeable experimental disease producing no tissue damage. To determine whether differences in such infection outcome are associated with a particular pattern of cytokine response, a study was undertaken to investigate the serum levels of TNF-alpha, IFN-gamma, IL-4, IL6, and IL-10 by using an enzyme-linked immunosorbent assay. Mice from both infected groups were bled at 5, 9, 15, 22, 30 and 48 days post-infection (pi), with the same interval being applied for obtention of serum samples in age-matched uninfected mice, a group that yielded negative results in all cases. Infection with the TUL strain of *T. cruzi* was accompanied by a significant increase of TNF-alpha serum concentrations at day 5 pi, and detectable amounts of IFN-gamma by day 15 pi, which were exclusively recorded in this group. Serum IL-4 was mostly present in TCC mice with

values at day 15 pi being statistically significant in relation to TUL-infected mice. IL-10 was firstly detected at 3 weeks after infection, and showed higher levels in the TCC group, although comparisons with TUL-infected group were not significant. At our limit of detection, no samples were found to contain IL-6 serum concentrations. Infection with virulent parasites seems to be associated with presence of Th1-type cytokines, whereas challenge with the attenuated TCC strain appears as being related to a Th2-type profile.

- L8 ANSWER 16 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
- AN 1998:364134 BIOSIS
- DN PREV199800364134
- TI Studies of vaccination of persons in close contact with leprosy patients in Argentina.
- AU Bottasso, Oscar [Reprint author]; Merlin, Victor; Cannon, Leslie; Cannon, Helen; Ingledew, Nicholas; Keni, Manjusha; Hartopp, Richard; Stanford, Cynthia; Stanford, John
- CS Inst. Immunol., Fac. Ciencias Med., Univ. Nacl. Rosario, Santa Fe 3100, Rosario 2000, Argentina
- SO Vaccine, (July, 1998) Vol. 16, No. 11-12, pp. 1166-1171. print. CODEN: VACCDE. ISSN: 0264-410X.
- DT Article
- LA English
- ED Entered STN: 27 Aug 1998  
Last Updated on STN: 27 Aug 1998
- AB A total of 670 adults living or working with leprosy patients, were examined for a BCG vaccination scar, and skin-tested with four new tuberculins. Based on the results 513 were vaccinated, 65 with Bacille de Calmette et Guerin (BCG) alone, 66 with BCG plus killed Mycobacterium vaccae and 382 with killed M. vaccae alone. Skin-testing was repeated 2-3 years later on 344 subjects, when all three vaccines were found to have been highly successful in increasing responses to Tuberculin and Leprosin A ( $p < 0.0005$ ) with increased immune recognition of common and species-specific antigens. Mean diameters of induration to each skin-test were greatest in recipients of BCG alone ( $p < 0.05$ ), which suggests that better immuno-regulation occurs after receiving vaccines that incorporate M. vaccae. The results suggest 108 M. vaccae alone might prove a valuable future vaccine, which would not require selective pre-vaccination procedures.
- L8 ANSWER 17 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 8
- AN 1999:208989 BIOSIS
- DN PREV199900208989
- TI Macrophage activity, IL-6 levels, antibody response and heart histology in rats undergoing an attenuated Trypanosoma cruzi acute infection upon treatment with recombinant interferon gamma.
- AU Revelli, Silvia; Didoli, Griselda; Roggero, Eduardo; Moreno, Hilda; Bernabo, Jorge; Wietzerbin, Jeanne; Bottasso, Oscar [Reprint author]
- CS Facultad de Ciencias Medicas de Rosario, Instituto de Inmunologia, Santa Fe 3100, Rosario, (2000), Argentina
- SO Cytokines Cellular and Molecular Therapy, (Sept., 1998) Vol. 4, No. 3, pp. 153-159. print. ISSN: 1368-4736.
- DT Article
- LA English
- ED Entered STN: 26 May 1999  
Last Updated on STN: 26 May 1999
- AB Earlier experiments in Trypanosoma cruzi-infected rats showed that recombinant rat (Rr) interferon (IFN)-gamma given shortly after infection ameliorated acute disease without modifying the serum titers of endogenously synthesized IFN-gamma and tumor necrosis factor. To gain

some insight into the processes underlying this protective effect, 21-day old 'I' rats that were infected with *T. cruzi* and the following day started with a 20-day cycle of RrIFN-gamma injections (20 000 IU/rat/day) were investigated for the in vitro replication of *T. cruzi* and nitric oxide (NO) production by peritoneal macrophages (day 7 post-infection, pi), antibodies with lytic activity against *T. cruzi* (days 7, 20, and 28 pi), and serum levels of biologically active interleukin (IL)-6 (days 15 and 30 pi). Therapy with RrIFN-gamma rendered cultured peritoneal macrophages less permissive to infection with *T. cruzi*. Such an effect was not accompanied by higher amounts of NO in macrophage cultured supernatants, compared with those from *T. cruzi*-infected rats receiving no RrIFN-gamma, which appeared not to be protected from in vitro infection. Acutely *T. cruzi*-infected rats had significant amounts of IL-6 in their sera - this not being the case in infected rats given RrIFN-gamma, whose levels appeared decreased as in control rats. The presence of complement-mediated anti-*T. cruzi* lytic antibodies was not modified by RrIFN-gamma. Likewise, heart histology at day 7 pi revealed that treatment with RrIFN-gamma made no differences as to the amount of acute inflammation, but tended to reduce the myocardial parasite load.

- L8 ANSWER 18 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 9
- AN 1998:319518 BIOSIS
- DN PREV199800319518
- TI Immunotherapy with *Mycobacterium vaccae* in the treatment of psoriasis.
- AU Lehrer, Amira; Bressanelli, Amalia; Wachsmann, Viviana; Bottasso, Oscar; Bay, Maria-Luisa; Singh, Mahavir; Stanford, Cynthia; Stanford, John [Reprint author]
- CS Dep. Bacteriol., Windeyer Inst. Med. Sci., Univ. Coll. London Med. Sch., 46 Cleveland St., London W1P 6DB, UK
- SO FEMS Immunology and Medical Microbiology, (May, 1998) Vol. 21, No. 1, pp. 71-77. print.  
ISSN: 0928-8244.
- DT Article
- LA English
- ED Entered STN: 22 Jul 1998  
Last Updated on STN: 22 Jul 1998
- AB A placebo-controlled study of immunotherapy with *Mycobacterium vaccae* for chronic plaque psoriasis showed improvement in the psoriasis area severity index in 19 of 21 immunotherapy recipients ( $P < 0.005$ ). Minor improvement, not reaching statistical significance for the group, occurred in nine of 14 placebo recipients. There were losses to follow-up and the placebo used, tetanus toxoid, was not ideal. Clinical improvement after immunotherapy persisted for 6 months and another injection of the immunotherapeutic given to a few volunteers from either group resulted in benefits lasting a year. Lymphoproliferative tests were carried out at each clinic visit, and on 50 matched controls. Starting with reduced responses to mycobacterial antigens and concanavalin A, both treatment groups showed a fall after 3 months, and diverged at 6 months with *M. vaccae* recipients rising to values similar to those of healthy controls, whereas placebo recipients continued to fall. Conclusions reached were that immunotherapy with *M. vaccae* gave long-lasting clinical benefit to most patients, with minimal side effects. This accompanied a return towards normal cellular immune responsiveness to mycobacterial antigens, which did not follow the use of the placebo.
- L8 ANSWER 19 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 10
- AN 1998:319676 BIOSIS
- DN PREV199800319676
- TI Psoriasis patients have T-cells with reduced responsiveness to common mycobacterial antigens.
- AU Bay, Maria-Luisa; Lehrer, Amira; Bressanelli, Amalia; Morini, Julio; Bottasso, Oscar; Stanford, John [Reprint author]

CS Dep. Bacteriol., Windeyer Inst. Med. Sci., Univ. Coll. London Med. Sch.,  
46 Cleveland St., London W1P 6DB, UK

SO FEMS Immunology and Medical Microbiology, (May, 1998) Vol. 21, No. 1, pp.  
65-70. print.  
ISSN: 0928-8244.

DT Article

LA English

ED Entered STN: 22 Jul 1998  
Last Updated on STN: 22 Jul 1998

AB Heparinised blood samples were obtained from 20 patients with chronic  
plaque psoriasis and from 13 age-matched healthy controls. After  
preliminary titration, mononuclear cells separated over Ficoll-Tryoson  
were cultured for 5 days with 10 mug ml<sup>-1</sup> of 15 mycobacterial  
preparations, or with pokeweed mitogen and concanavalin A. Stimulation  
indices were determined for each reagent and means were determined for  
patients and controls. Results for patients showed a striking reduction  
of responsiveness to mycobacteria, apparently due to loss of responses to  
group i, common mycobacterial antigens, and no differences in responses to  
mitogens. These observations relate psoriasis to certain other diseases,  
notably mycobacterial infections, rheumatoid arthritis, Chagas' disease  
and human immunodeficiency virus infection. The observations may be  
relevant to the aetiology of psoriasis, and to potential immunotherapy for  
the disease.

L8 ANSWER 20 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 11

AN 1997:515678 BIOSIS

DN PREV199799814881

TI Depressed autoantibody synthesis in Trypanosoma cruzi-infected rats born  
to mothers undergoing this infection during pregnancy.

AU Feldman, Sara; Revelli, Silvia; Davila, Hector; Marcipar, Alberto; Rojas,  
M.; Avila, Jose L.; Bottasso, Oscar A.

CS Catedra de Quimica Biologica, Facultad de Ciencias, Medicas de Rosario,  
Santa Fe 3100, Rosario 2000, Argentina

SO Journal of Reproductive Immunology, (1997) Vol. 34, No. 3, pp. 177-184.  
CODEN: JRMIDR. ISSN: 0165-0378.

DT Article

LA English

ED Entered STN: 10 Dec 1997  
Last Updated on STN: 10 Dec 1997

AB Earlier work indicated that Trypanosoma cruzi infection in pregnant rats  
decreased the amount of myocardial damage that developed in their  
chronically infected offspring. Given the suspected role of autoimmune  
mechanisms in the generation of chronic myocarditis, we evaluated whether  
this maternal intervention was likely to affect the synthesis of  
autoantibodies in infected young. Autoantibodies were investigated  
against molecules exhibiting cross-reactivity with T. cruzi antigens or  
not, that is cerebroside sulphate (sulphatide) and actin, respectively.  
Female '1' rats (75 days old) that had been mated with syngeneic sires  
were separated into two groups, one challenged with living trypomastigotes  
at 7, 14 and 21 days following mating, and the other one given physiologic  
saline at the same intervals. At the time of weaning, offspring were  
injected with 10<sup>-6</sup>/T. cruzi to constitute two infected groups: young born  
to infected mothers (InMoTc) and young delivered by uninfected mothers  
(CoMoTc). Serum antibodies were investigated by ELISA at 30 and 60 days  
post-infection, which represents acute and chronic infection,  
respectively. T. cruzi infection was associated with the production of  
anti-sulphatide antibodies, but the phenomenon was significantly less  
evident in InMoTc young and virtually unnoticeable during their chronic  
infection. Unlike the anti-sulphatide results, levels of anti-actin  
antibodies showed no differences between CoMoTc and InMoTc rats when  
compared during acute or chronic infection. The decreased production of  
anti-sulphatide autoantibodies of InMoTc offspring may be due to a  
modification of the immune repertoire of offspring because of the contact

with parasite antigens during ontogeny.

- L8 ANSWER 21 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 1998:229670 BIOSIS  
DN PREV199800229670  
TI Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PMBC  
across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in  
multibacillary patients.  
AU de La Barrera, Silvia; Finiasz, Marta; Fink, Susana; Valdez, Raul;  
Bottasso, Oscar; Balina, Luis Maria; Del Carmen Sasiain, Maria  
[Reprint author]  
CS Dep. Inmunologia, Inst. Investigaciones Hematologicas, Academia Nacional  
Med., Pacheco Lemo 3081, 1425 Buenos Aires, Argentina  
SO International Journal of Leprosy and Other Mycobacterial Diseases, (March,  
1997) Vol. 65, No. 1, pp. 45-55. print.  
CODEN: IJLEAG. ISSN: 0148-916X.  
DT Article  
LA English  
ED Entered STN: 20 May 1998  
Last Updated on STN: 20 May 1998  
AB In the present study we evaluated the contribution of CD4 and CD8 T cells  
to the antigen-specific cytotoxic activity induced by whole Mycobacterium  
leprae in leprosy patients and normal controls (N) as well as the  
modulation of this activity by some cytokines. Peripheral blood  
mononuclear cells (PBMC) from N or from leprosy patients were stimulated  
with antigen in the presence or absence of cytokines for 7 days. M.  
leprae-stimulated PBMC were depleted of CD4 or CD8 antigen-bearing cells  
and employed as effector cells in a 4-hr (31Cr)-release assay against  
autologous M. leprae-pulsed macrophages. Our results demonstrate that  
both CD4 and CD8 T cells contribute to M. leprae-induced cytotoxic  
activity, with differences observed in paucibacillary (PB) and  
multibacillary (MB) patients. CD8-mediated cytotoxic activity is higher  
than that of CD4 cells in PB patients, while in MB patients CD4  
cytotoxicity is predominant. Our data also demonstrate that the  
generation of CD4 and CD8 cytotoxic T lymphocytes (CTL) can be modulated  
differentially by interleukin-4 (IL-4), IL-6, gamma interferon  
(IFN-gamma), or IL-2. Although MB patients developed the lowest CTL  
response, cytokines such as IL-6 plus IL-2 or IFN-gamma were able to  
generate both CD4 and CD8 cytotoxic T cells from MB patients. In PB  
patients, IL-6 plus IFN-gamma displayed the highest stimulation on CD8  
effector cells. Thus, an important role may be assigned to IL-6, together  
with IL-2 or IFN-gamma, in the differentiation of M. leprae-specific CTL  
effector cells.
- L8 ANSWER 22 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 1997:204843 BIOSIS  
DN PREV199799504046  
TI Levels of interleukin-8 in tuberculous pleurisy and the profile of  
immunocompetent cells in pleural and peripheral compartments.  
AU Dlugovitzky, Diana; Rateni, Liliana; Torres-Morales, Ariel; Ruiz-Silva,  
Javier; Pinesky, Raul; Canosa, Betina; Molteni, Osvaldo; Bottasso,  
Oscar [Reprint author]  
CS Instituto de Inmunologia, Facultad de Ciencias Medicas de Rosario, Santa  
Fe 3100, Rosario, Argentina  
SO Immunology Letters, (1997) Vol. 55, No. 1, pp. 35-39.  
CODEN: IMLED6. ISSN: 0165-2478.  
DT Article  
LA English  
ED Entered STN: 12 May 1997  
Last Updated on STN: 12 May 1997  
AB Our study investigated the presence of IL-8 in pleural exudates from  
tuberculosis patients (TBP) (n = 13), and evaluated whether it was related



with the profile of major immunocompetent cells present in their pleural and peripheral compartments. To allow comparisons, an additional group of patients with parapneumonic pleural effusions (PNE) (n = 7) was included. Blood peripheral immunophenotypic studies were also carried out in 12 age-matched healthy controls (Co), and 39 tuberculosis patients classified, according to the extent of pulmonary involvement, into mild (n = 9), and advanced (n = 30) cases. Patients were recruited before starting therapy, had HIV negative serology, and showed no age differences among groups (mean  $\pm$  S.D., 40.7  $\pm$  14.7 years). IL-8 concentrations were measured by an ELISA method while immunophenotypic analysis was performed by using FITC-conjugated monoclonal antibodies reacting against the following cell surface molecules: CD3, CD4, CD8, CD25 (IL-2R+ cells), CD19, and CD68. IL-8 was detected in all pleural exudates though levels in the TB patients, 384 $\pm$ 110 pg/ml, appeared significantly higher than the PNE group, 185 $\pm$ 110 pg/mg, (P  $\leq$  0.015, mean $\pm$ -S.D.). In turn, the former group presented values of pleural CD3+, CD4+, and CD25, which were found increased in comparison with PNE patients (P  $\leq$  0.01). Unlike the pleural compartment, patients with TBP showed a marked and significant decrease in their circulating levels of cells bearing the CD3, CD4, CD19, CD25, and CD68 phenotypes not only when comparing with Co but also with PNE and mild patients. Differences between the levels of pleural and peripheral T-cells from TBP patients may be the reflection of an important influx of T-lymphocytes from the circulatory system to the pleural cavity, probably linked to the presence of chemotactic factors within the pleural fluid like IL-8.

- L8 ANSWER 23 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 13
- AN 1997:442901 BIOSIS
- DN PREV199799742104
- TI Attenuated Trypanosoma cruzi infection in young rats nursed on infected mothers undergoing interferon-gamma treatment during pregnancy.
- AU Davila, Hector O.; Revelli, Silvia S.; Uasuf, Carina; Didoli, Griselda; Moreno, Hilda; Falcoff, Ernesto; Bottasso, Oscar A. [Reprint author]
- CS Inst. Inmunol., Fac. Ciencias Med., Univ. Nacional Rosario, Santa Fe 3100, Rosario 2000, Argentina
- SO Immunopharmacology, (1997) Vol. 37, No. 1, pp. 1-6.  
CODEN: IMMUDP. ISSN: 0162-3109.
- DT Article
- LA English
- ED Entered STN: 8 Oct 1997  
Last Updated on STN: 8 Oct 1997
- L8 ANSWER 24 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 14
- AN 1996:365902 BIOSIS
- DN PREV199699088258
- TI Chronic Trypanosoma cruzi infection in the rat: Cyclophosphamide induced recovery of adjuvant arthritis correlates with changes in the levels of lymph node T-lymphocytes and class II+ cells.
- AU Didoli, Griselda; Revelli, Silvia; Davila, Hector; Ferro, Maria E.; Romero-Piffiguer, Marta; Bottasso, Oscar [Reprint author]
- CS Inst. de Inmunol., Fac. de Ciencias Medicas, Univ. Nacional der Rosario, Santa Fe 3100, Rosario 2000, Argentina
- SO International Journal of Immunopharmacology, (1996) Vol. 18, No. 2, pp. 127-133.  
CODEN: IJIMDS. ISSN: 0192-0561.
- DT Article
- LA English
- ED Entered STN: 14 Aug 1996  
Last Updated on STN: 15 Aug 1996
- AB We have previously reported that treatment with cyclophosphamide (Cy) reversed the partial resistance of chronically Trypanosoma cruzi-infected

rats to adjuvant-induced arthritis (AA) and caused a slight enhancement of arthritis in controls, when given 48 h before induction. To ascertain whether this Cy effect could be associated with regional changes of immunocompetent cells, popliteal lymph nodes were studied for their T-cell subsets and cells carrying class II major histocompatibility (MHC) antigens (I-A and I-E molecules). Analysis at the time of arthritis induction revealed that infected rats receiving Cy 48 h earlier appeared to have recovered from the inverse balance of major T-cell subsets and showed I-E+ cells lowered to normal, whereas values from control rats remained unchanged by Cy treatment. Establishment of AA was associated with substantial changes in the phenotype of lymph node cells that drained the affected limb. Changes were equally recorded in control and infected arthritic rats, and consisted of a significant raise of CD4+ and I-A+ cells along with lowered numbers of CD8+ and I-E+ cells. Treatment with Cy lowered even further the levels of CD8+ cells, while causing no affectation in the number of CD4+ cells that remained increased as in the arthritic counterparts receiving no Cy. Comparative analysis of class II MHC+ cells in Cy-treated rats revealed an additional decrease of I-E+ cells in draining lymph nodes from infected and control rats, which coincided with a simultaneous increase in I-A+ cells in the uninfected group. It is suggested that a deletion of a regulatory T-cell subset as well as an improved presentation of arthritogenic peptides may at least underlie the Cy-induced enhancement of the arthritic response.

L8 ANSWER 25 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 1995:511806 BIOSIS  
DN PREV199598516856  
TI Low occurrence of arthritic manifestations in patients with pulmonary tuberculosis: T. cell subsets and humoral studies.  
AU Dlugovitzky, Diana [Reprint author]; Torres, Ariel [Reprint author]; Hourquescos, Maria C.; Svetaz, Maria J.; Quagliato, Norberto; Valentini, Eduardo; Amigot, Beatriz; Molteni, Osvaldo [Reprint author]; Bottasso, Oscar  
CS Catedra de Microbiologia, Fac. de Ciencias Medicas, Univ. Nacional de Rosario, Santa Fe 3100, Rosario, Argentina  
SO Memorias do Instituto Oswaldo Cruz Rio de Janeiro, (1995) Vol. 90, No. 5, pp. 623-628.  
CODEN: MIOCAS. ISSN: 0074-0276.  
DT Article  
LA English  
ED Entered STN: 29 Nov 1995  
Last Updated on STN: 29 Nov 1995  
AB Given the suspected role of mycobacteria in the establishment of disorders with an autoimmune background and joint damage, a study was conducted to analyze whether rheumatic symptoms were likely to be present in tuberculosis (TB) patients. To this end, 330 patients with a bacteriologic confirmation of tuberculosis were investigated for the presence of arthritic complaints. The latter were recorded in five of them with rheumatic symptoms mostly involving interphalangeal and metacarpophalangeal joints, and preceding the clinical manifestations of the TB illness. Three out of these five patients remained arthritic by the time of the bacteriologic conversion and fulfilled the criteria for the diagnosis of rheumatoid arthritis. In the two remaining patients sputum negativization was accompanied by a disappearance of rheumatic manifestations. These patients were also assessed for their peripheral levels of major T cell subsets as well as for the presence of autoantibodies. Comparisons with a series of non-arthritic TB cases, rheumatoid arthritis patients, and controls revealed that presence of rheumatic manifestations was associated with a different profile of autoantibody formation and T cell subset changes. Evidence recorded in the present study indicates that joint affectation in TB is a rare event, being rather the exception than the rule.

L8 ANSWER 26 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
DUPLICATE 15

AN 1995:253604 BIOSIS  
DN PREV199598267904  
TI Acute and chronic experimental Trypanosoma cruzi infection in the rat.  
Response to systemic treatment with recombinant rat interferon-gamma.  
AU Revelli, Silvia; Davila, Hector; Ferro, Maria E.; Romero-Piffiguer, Marta;  
Musso, Orlando; Valenti, Jose; Bernabo, Jorge; Falcoff, Ernesto;  
Wietzerbin, Jeanne; Bottasso, Oscar [Reprint author]  
CS Inst. Inmunologia, Facultad Ciencias Med., Santa Fe 3100, 2000 Rosario,  
Argentina  
SO Microbiology and Immunology, (1995) Vol. 39, No. 4, pp. 275-281.  
CODEN: MIIMDV. ISSN: 0385-5600.  
DT Article  
LA English  
ED Entered STN: 13 Jun 1995  
Last Updated on STN: 13 Jun 1995

AB We examined the effects of recombinant rat inteferon-gamma (IFN-gamma)  
injections on the parasitologic, serologic, immunologic and  
histopathologic features of acute and chronic experimental Trypanosoma  
cruzi (T. cruzi) infections in "1" rats. Upon infection at weaning, two  
rat groups were allocated to receive a 20-day cycle of IFN-gamma  
injections, 20,000 IU/rat each, which started at 1, and 7 days  
postinfection (pi). Treatment with IFN-gamma, initiated at either 1 or 7  
days pi, resulted in comparatively lower peak parasitemias (P lt 0.02) but  
in similar levels of anti-T. cruzi circulating antibodies and serum  
IFN-gamma activities. The latter appeared significantly increased during  
acute infection whereas biologically active tumor necrosis factor was  
virtually undetectable in serum from infected rats regardless of whether  
they had been given IFN-gamma or not. The prevalence of chronic focal  
myocarditis in IFN-gamma-treated infected rats showed no differences with  
respect to the one recorded in control-infected counterparts. The inverse  
CD4/CD8 ratio of spleen and lymph node T cells that usually accompanies  
chronic infection was reversed by IFN-gamma. Mononuclear cells carrying  
class II I-A and I-E molecules, that were found to have increased at both  
compartments, appeared also modified upon IFN-gamma treatment with an  
overincrease of I-A-positive cells, and a normalization of I-E-bearing  
cells.

L8 ANSWER 27 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 1994:305082 BIOSIS  
DN PREV199497318082  
TI Infection with Trypanosoma cruzi during pregnancy in rats and a decrease  
in chronic myocardial lesions in their infected offspring.  
AU Davila, Hector O.; Revelli, Silvia S.; Moreno, Hilda S.; Valenti, Jose L.;  
Musso, Orlando C.; Poli, Hugo O.; Morini, Julio C.; Bottasso, Oscar  
A. [Reprint author]  
CS Div. Immunol., Fac. Cien. Med., Santa Fe 3100, Rosario 2000, Argentina  
SO American Journal of Tropical Medicine and Hygiene, (1994) Vol. 50, No. 4,  
pp. 506-511.  
CODEN: AJTHAB. ISSN: 0002-9637.  
DT Article  
LA English  
ED Entered STN: 13 Jul 1994  
Last Updated on STN: 13 Jul 1994

AB To ascertain whether maternal infection with Trypanosoma cruzi may  
influence the course of the parasitic infection in offspring, two groups  
of female 1 rats were mated with syngeneic sires. One group of females  
was infected with 10-6 trypomastigotes of T. cruzi three times at weekly  
intervals. All offspring were nursed by their mothers until weaning and  
then separated into two groups of young, one to be infected with the same  
dose of T. cruzi, and the other to remain uninfected. Infection of  
pregnant rats caused no aggravated disease but resulted in a

self-controlled infection that did not cause any deaths or affect their reproductive capacity. The number of young delivered, litter size, fertility coefficient, and offspring weights at weaning were also unaffected by maternal infection; however, the survival coefficient decreased in comparison with values recorded in the offspring of uninfected mothers. The latter finding is likely due to neonatal transmission, since bloodstream forms of *T. cruzi* were observed in a few offspring of infected mothers. While infected offspring whose mothers had been inoculated with *T. cruzi* during pregnancy were not protected from acute infection, the occurrence of chronic focal myocarditis was less prevalent when compared with that recorded in chronically infected offspring born to uninfected mothers.

L8 ANSWER 28 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1995:130289 BIOSIS  
 DN PREV199598144589  
 TI Electrocardiographic alteration among first degree relatives with serologic evidence of *Trypanosoma cruzi* infection. A Sibship study.  
 AU Morini, Julio C. [Reprint author]; Berra, Hector; Davila, Hector O. [Reprint author]; Pividori, Juan F.; Bottasso, Oscar A. [Reprint author]  
 CS Div. Inmunol., Fac. de Ciencias Med., Univ. Nac. de Rosario, Santa Fe 3100 Rosario 2000, Argentina  
 SO Memorias do Instituto Oswaldo Cruz Rio de Janeiro, (1994) Vol. 89, No. 3, pp. 371-375.  
 CODEN: MIOCAS. ISSN: 0074-0276.  
 DT Article  
 LA English  
 ED Entered STN: 29 Mar 1995  
 Last Updated on STN: 29 Mar 1995  
 AB To analyze whether electrocardiographic alterations (ECGA) in patients with antibodies to *Trypanosoma cruzi* showed a pattern of familial aggregation, a sample of 379 young adults (166 men and 213 women) distributed in sibships, were assessed for the presence of anti-*T. cruzi* antibodies, and subjected to a complete clinical examination and a standard resting electrocardiogram (ECG). Positive *T. cruzi* serology was detected in 165 individuals. 48 of them showing an abnormal ECG (overall prevalence 29%). One hundred and eleven seropositive individuals were distributed in 45 sibships, each of them constituted by more than one seropositive sib, with ECGA being present in 34 out of these patients. Seropositive subjects with ECGA were detected in 27 sibships. Since the index case within each sibship is counted exactly once, affected individuals selected at random as probands were extracted to calculate the prevalence of ECGA among first degree relatives of probands. Abnormal ECGs were recorded in 7 out of 45 sibs yielding a prevalence that did not differ from estimations registered in the general population or seropositive sibs. Data from the present sample show no familial aggregation for the occurrence of ECGA in patients with *T. cruzi* infection.

L8 ANSWER 29 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1994:183005 BIOSIS  
 DN PREV199497196005  
 TI Gamma Interferon induces clinical healing in chemoresistant leishmaniasis.  
 AU Falcoff, Ernesto [Reprint author]; Bernabo, Jorge; Bottasso, Oscar  
 CS Inst. Curie, INSERM U.196, 26 rue d'Ulm, 75005 Paris, France  
 SO M-S (Medecine Sciences), (1993) Vol. 9, No. 11, pp. 1214-1217.  
 ISSN: 0767-0974.  
 DT Article  
 LA French  
 ED Entered STN: 26 Apr 1994  
 Last Updated on STN: 26 Apr 1994

L8 ANSWER 30 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1994:258088 BIOSIS  
 DN PREV199497271088  
 TI Altered calcium-binding ability of plasma proteins as the cause of  
 hypocalcemia in lepromatous leprosy.  
 AU Vidal, Maria C.; Bottasso, Oscar A.; Lehrer, Amira; Puche,  
 Rodolfo C. [Reprint author]  
 CS Lab. Biol. Osea, Fac. Med., Sante Fe 3100, 2000 Rosario, Argentina  
 SO International Journal of Leprosy, (1993) Vol. 61, No. 4, pp. 586-591.  
 DT Article  
 LA English  
 ED Entered STN: 8 Jun 1994  
 Last Updated on STN: 14 Jul 1994  
 AB This paper reports a study performed on 10 lepromatous leprosy outpatients  
 and on the same number of age- and sex-matched contacts. All of the  
 lepromatous patients were hypocalcemic, but plasma levels of ionized  
 calcium and the acid-base status were normal. The average daily food  
 intake assessed through a questionnaire revealed adequate nutrition of  
 patients and controls. Plasma proteins and 1,25-dihydroxyvitamin D-3 and  
 intestinal absorption of calcium were discarded as the causes of the  
 hypocalcemia. In vitro experiments designed to investigate the effect of  
 hydrogen ion concentration on the equilibrium between calcium ion and  
 proteins revealed that, at normal pH values, plasma proteins from  
 lepromatous leprosy patients bind a smaller fraction of total plasma  
 calcium than those from controls. This phenomenon produces a normal  
 concentration of ionized calcium that determines a normal parathyroid  
 status as indicated by the normal urinary excretion of hydroxyproline and  
 plasma concentrations of alkaline phosphatase (total and bone isoenzyme)  
 and tartrate-resistant acid phosphatase.

L8 ANSWER 31 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1993:586388 BIOSIS  
 DN PREV199497005758  
 TI Enhanced myocardial lesions in chronically Trypanosoma cruzi-infected rats  
 subjected to adult thymectomy.  
 AU Bottasso, Oscar A. [Reprint author]; Revelli, Silvia R.; Davila,  
 Hector; Valenti, Jose L.; Musso, Orlando C.; Ferro, Maria E.;  
 Romero-Piffiguer, Marta; Morini, Julio C.  
 CS Div. Inmunologia, Fac. de Ciencias Medicas, Universidad Nacional de  
 Rosario, Santa Fe 3100, Rosario, 2000, Argentina  
 SO Immunology Letters, (1993) Vol. 37, No. 2-3, pp. 175-180.  
 CODEN: IMLED6. ISSN: 0165-2478.  
 DT Article  
 LA English  
 ED Entered STN: 28 Dec 1993  
 Last Updated on STN: 28 Dec 1993  
 AB Control animals and rats infected 90 days earlier, by inoculation of 1  
 times 10<sup>6</sup> trypomastigotes of Trypanosoma cruzi at weaning, were subjected  
 to adult thymectomy (ATx) or sham operation (S-ATx) and assessed 3 months  
 later for the presence of myocardial lesions and levels of lymph node and  
 spleen T-cell populations. Chronic focal myocarditis (CFM) developed in  
 78% and 84% of S-ATx or ATx infected rats, respectively. While the two  
 groups of infected rats did not differ as to the occurrence of myocardial  
 lesions, large foci of CFM were more prevalent in ATx infected rats.  
 Chronic T. cruzi (Tc) infection resulted in decreased CD4+ and increased  
 CD8+ lymph node and spleen cell, with CD8+ lymphocytes being lowered to  
 normal values in the spleen of the ATx infected group. It is suggested  
 that ATx might act by interfering with a down-regulating immunoregulatory  
 mechanisms, leading to an exacerbation of autoimmune reactions believed to  
 be involved in the generation of myocardial damage.

L8 ANSWER 32 OF 33 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1993:14156 BIOSIS  
 DN PREV199344002356  
 TI Lepromatous leprosy treated with recombinant interferon gamma: Cutaneous  
 histologic changes.  
 AU Bottasso, Oscar [Reprint author]; Besuschio, Santiago; Merlin,  
 Victor; Morini, Julio C.; Bernabo, Jorge; Falcoff, Rebeca; Falcoff,  
 Ernesto  
 CS Div. Inmunol., Fac. Ciencias Med., Santa Fe 3100, Rosario, Argentina  
 SO International Journal of Dermatology, (1992) Vol. 31, No. 11, pp. 813-817.  
 CODEN: IJDEBB. ISSN: 0011-9059.  
 DT Article  
 LA English  
 ED Entered STN: 16 Dec 1992  
 Last Updated on STN: 16 Dec 1992

L8 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1992:420151 CAPLUS  
 DN 117:20151  
 TI Depressed adjuvant arthritis in chronically Trypanosoma cruzi infected  
 rats: reversal by cyclophosphamide  
 AU Revelli, Silvia; Davila, Hector; Moreno, Hilda; Bottasso, Oscar  
 CS Fac. Med. Sci., Univ. Nac. Rosario, Rosario, Argent.  
 SO Journal of Rheumatology (1992), 19(4), 513-16  
 CODEN: JRHUA9; ISSN: 0315-162X  
 DT Journal  
 LA English  
 AB Chronically Trypanosoma cruzi infected "I" rats and syngeneic naive  
 recipients, transferred with a T cell enriched spleen cell population from  
 infected donors, develop an attenuated arthritis when challenged with  
 complete Freund's adjuvant. Cyclophosphamide, 40 mg/kg body weight, given 48  
 h before induction, was able to reestablish or exacerbate adjuvant  
 arthritis in infected and control rats, resp. Although the T cell  
 enriched spleen cells from infected donors continued to down regulate  
 adjuvant arthritis in syngeneic recipients given cyclophosphamide 48 h  
 before cell transfer, treatment of infected donors with cyclophosphamide,  
 48 h before cell collection, prevented these cells from exerting such  
 effect when transferred to healthy recipients receiving no  
 cyclophosphamide. It is suggested that cyclophosphamide may primarily  
 affect a suppressor cell population, present in the infected host, with  
 regulatory activity on adjuvant arthritis

=> s rhodococcus/clm  
L1 492 RHODOCOCCLUS/CLM

=> s l1 and vaccine?/clm  
6623 VACCINE?/CLM  
L2 13 L1 AND VACCINE?/CLM

=> d 1-  
YOU HAVE REQUESTED DATA FROM 13 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 13 USPATFULL on STN  
AN 2006:158606 USPATFULL  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI US 2006134136 A1 20060622  
AI US 2003-526228 A1 20030905 (10)  
WO 2003-GB3873 20030905  
20051116 PCT 371 date  
PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 424/203.100  
INCLS: 424/093.400  
NCL NCLM: 424/203.100  
NCLS: 424/093.400  
IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L2 ANSWER 2 OF 13 USPATFULL on STN  
AN 2005:318078 USPATFULL  
TI Rhodococcus equi mutants and vaccines comprising same  
IN Hondalus, Mary, Crawford, GA, UNITED STATES  
Jain, Shruti, Durham, NC, UNITED STATES  
Ashour, Joseph, New York, NY, UNITED STATES  
PA Presidents and Fellows of Harvard College (U.S. corporation)  
PI US 2005276817 A1 20051215  
AI US 2005-36797 A1 20050114 (11)  
RLI Continuation of Ser. No. WO 2003-US22101, filed on 14 Jul 2003, PENDING  
PRAI US 2002-396195P 20020716 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1403  
INCL INCLM: 424/200.100  
INCLS: 435/252.300; 435/471.000; 435/473.000  
NCL NCLM: 424/200.100  
NCLS: 435/252.300; 435/471.000; 435/473.000  
IC [7]  
ICM A61K039-02  
ICS C12N015-74; C12N001-21  
IPCI A61K0039-02 [ICM,7]; C12N0015-74 [ICS,7]; C12N0001-21 [ICS,7]

L2 ANSWER 3 OF 13 USPATFULL on STN  
AN 2005:140310 USPATFULL  
TI Therapeutic treatment and prevention of infections with a bioactive material(s) encapsulated within a biodegradable-bio-compatible polymeric matrix  
IN Setterstrom, Jean A., Alpharetta, GA, UNITED STATES  
Tice, Thomas R., Birmingham, AL, UNITED STATES  
Jacob, Elliot, Silver Spring, MD, UNITED STATES  
Reid, Robert H., Kensington, MD, UNITED STATES

van Hamont, John, West Point, NY, UNITED STATES  
Boedecker, Edgar C., Crownsville, MD, UNITED STATES  
Jeyanthi, Ramassubbu, Columbia, MD, UNITED STATES  
Friden, Phil, Bedford, MA, UNITED STATES  
Roberts, F. Donald, Dover, MA, UNITED STATES  
McQueen, Charles E., Olney, MD, UNITED STATES  
Bhattacharjee, Apurba, Kensington, MD, UNITED STATES  
Cross, Alan, Chevy Chase, MD, UNITED STATES  
Sadoff, Jerald, Washington, DC, UNITED STATES  
Zollinger, Wendell, Silver Spring, MD, UNITED STATES<sup>4</sup>)

PA The United States of America as represented by the Secretary of the  
Army, Washington, DC, UNITED STATES (U.S. government)

PI US 6902743 B1 20050607

AI US 1998-55505 19980406 (9)

RLI Continuation-in-part of Ser. No. US 1997-920326, filed on 21 Aug 1997,  
Pat. No. US 6447796 Continuation-in-part of Ser. No. US 1997-896197,  
filed on 17 Jul 1997, ABANDONED Continuation-in-part of Ser. No. US  
1997-788734, filed on 23 Jan 1997, Pat. No. US 5892337  
Continuation-in-part of Ser. No. US 1996-698896, filed on 16 Aug 1996,  
Pat. No. US 5705197 Continuation-in-part of Ser. No. US 1996-675895,  
filed on 5 Jul 1996, Pat. No. US 6217911 Continuation-in-part of Ser.  
No. US 1996-598874, filed on 9 Feb 1996, Pat. No. US 5762965  
Continuation-in-part of Ser. No. US 1996-590973, filed on 24 Jan 1996,  
ABANDONED Continuation of Ser. No. US 1995-446149, filed on 22 May 1995,  
ABANDONED Continuation-in-part of Ser. No. US 1995-446148, filed on 22  
May 1995, Pat. No. US 6410056

DT Utility

FS GRANTED

LN.CNT 7899

INCL INCLM: 424/489.000

INCLS: 424/177.000; 424/179.000; 424/451.000; 424/470.000; 424/482.000;  
424/490.000

NCL NCLM: 424/489.000

NCLS: 424/451.000; 424/470.000; 424/482.000; 424/490.000

IC [7]

ICM A61K009-14

ICS A61K039-40; A61K009-48; A61K009-26; A61K009-16

IPCI A61K0009-14 [ICM,7]; A61K0039-40 [ICS,7]; A61K0009-48 [ICS,7];  
A61K0009-26 [ICS,7]; A61K0009-16 [ICS,7]

IPCR A61K0009-16 [I,A]; A61K0009-16 [I,C\*]; A61K0009-50 [I,A];  
A61K0009-50 [I,C\*]; A61K0038-17 [I,A]; A61K0038-17 [I,C\*]

EXF 424/489; 424/451; 424/455; 424/463; 424/468; 424/469; 424/470; 424/477;  
424/482; 424/453; 424/490

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 13 USPATFULL on STN

AN 2005:49959 USPATFULL

TI TGC method for inducing targeted somatic transgenesis

IN Von Eichel-Streiber, Christoph, Schweppenhausen, GERMANY, FEDERAL  
REPUBLIC OF

Chakraborty, Trinad, Giessen, GERMANY, FEDERAL REPUBLIC OF

PA Peter Paras (non-U.S. corporation)

PI US 2005042755 A1 20050224

AI US 2004-894438 A1 20040719 (10)

RLI Division of Ser. No. US 2000-581005, filed on 6 Jun 2000, GRANTED, Pat.  
No. US 6825028 A 371 of International Ser. No. WO 1998-EP8096, filed on  
11 Dec 1998, UNKNOWN

PRAI DE 1997-19754938 19971211

DT Utility

FS APPLICATION

LN.CNT 1472

INCL INCLM: 435/455.000

INCLS: 435/471.000

NCL NCLM: 435/455.000



NCLS: 435/471.000  
IC [7]  
ICM C12N015-85  
ICS C12N015-74  
IPCI C12N0015-85 [ICM,7]; C12N0015-74 [ICS,7]  
IPCR A61K0048-00 [I,A]; A61K0048-00 [I,C\*]; C07K0014-195 [I,A];  
C07K0014-195 [I,C\*]; C12N0015-85 [I,A]; C12N0015-85 [I,C\*];  
C12N0015-87 [I,A]; C12N0015-87 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 13 USPATFULL on STN  
AN 2004:334921 USPATFULL  
TI Method for introducing and expressing genes in animal cells, and  
bacterial blebs for use in same  
IN Powell, Robert J., Baltimore, MD, UNITED STATES  
Hone, David, Ellicott City, MD, UNITED STATES  
PI US 2004266003 A1 20041230  
AI US 2003-432149 A1 20030825 (10)  
WO 2001-US16904 20010524  
PRAI US 2000-206994P 20000524 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1917  
INCL INCLM: 435/455.000  
INCLS: 435/471.000  
NCL NCLM: 435/455.000  
NCLS: 435/471.000  
IC [7]  
ICM C12N015-85  
ICS C12N015-74  
IPCI C12N0015-85 [ICM,7]; C12N0015-74 [ICS,7]  
IPCR A61K0039-112 [I,A]; A61K0039-112 [I,C\*]; A61K0048-00 [I,A];  
A61K0048-00 [I,C\*]; C12N0015-87 [I,C\*]; C12N0015-88 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 13 USPATFULL on STN  
AN 2004:158173 USPATFULL  
TI Use of bacterium for manufacture of a vaccine  
IN Jacobs, Antonius Arnoldus Christiaan, Kessel, NETHERLANDS  
Goovaerts, Danny, Lichtaart, BELGIUM  
PI US 2004120970 A1 20040624  
AI US 2003-731724 A1 20031208 (10)  
RLI Division of Ser. No. US 2000-492206, filed on 27 Jan 2000, GRANTED, Pat.  
No. US 6682745  
PRAI EP 1999-200202 19990126  
DT Utility  
FS APPLICATION  
LN.CNT 346  
INCL INCLM: 424/200.100  
NCL NCLM: 424/200.100  
IC [7]  
ICM A61K039-02  
IPCI A61K0039-02 [ICM,7]  
IPCR A61K0039-05 [I,A]; A61K0039-05 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 13 USPATFULL on STN  
AN 2003:243851 USPATFULL  
TI Antigenic peptide fragments of vappa protein, and uses thereof  
IN Vanniasinkam, Thiru Barton, Adelaide South Australia, AUSTRALIA  
Barton, Mary, North Terrace Adelaide South Australia, AUSTRALIA  
Heuzenroeder, Michael W, Adelaide South Australia, AUSTRALIA  
PI US 2003170260 A1 20030911  
AI US 2003-258829 A1 20030421 (10)

WO 2001-AU478 20010427  
PRAI AU 2000-7120 20000427  
DT Utility  
FS APPLICATION  
LN.CNT 1353  
INCL INCLM: 424/190.100  
INCLS: 530/350.000  
NCL NCLM: 424/190.100  
NCLS: 530/350.000  
IC [7]  
ICM A61K039-02  
ICS C07K014-195  
IPCI A61K0039-02 [ICM,7]; C07K0014-195 [ICS,7]  
IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C\*]; A61K0039-05 [I,A];  
A61K0039-05 [I,C\*]; C07K0014-195 [I,C\*]; C07K0014-34 [I,A];  
C07K0016-12 [I,A]; C07K0016-12 [I,C\*]; G01N0033-569 [I,A];  
G01N0033-569 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 13 USPATFULL on STN  
AN 2003:220236 USPATFULL  
TI Method for introducing and expressing genes in animal cells, and live  
invasive bacterial vectors for use in the same  
IN Powell, Robert J., Baltimore, MD, UNITED STATES  
Lewis, George K., Baltimore, MD, UNITED STATES  
Hone, David M., Ellicott City, MD, UNITED STATES  
PA UNIVERSITY OF MARYLAND, BALTIMORE, MD (U.S. corporation)  
PI US 2003153527 A1 20030814  
AI US 2003-369519 A1 20030221 (10)  
RLI Continuation of Ser. No. US 1999-420770, filed on 19 Oct 1999, PENDING  
Continuation of Ser. No. US 1998-126220, filed on 30 Jul 1998, GRANTED,  
Pat. No. US 6150170 Continuation of Ser. No. US 1995-433790, filed on 3  
May 1995, GRANTED, Pat. No. US 5877159  
DT Utility  
FS APPLICATION  
LN.CNT 1577  
INCL INCLM: 514/044.000  
INCLS: 435/455.000; 435/252.300; 435/252.330  
NCL NCLM: 514/044.000  
NCLS: 435/252.300; 435/252.330; 435/455.000  
IC [7]  
ICM A61K048-00  
ICS C12N001-21; C12N015-85  
IPCI A61K0048-00 [ICM,7]; C12N0001-21 [ICS,7]; C12N0015-85 [ICS,7]  
IPCR A61K0048-00 [I,A]; A61K0048-00 [I,C\*]; C12N0015-87 [I,A];  
C12N0015-87 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 13 USPATFULL on STN  
AN 2002:346644 USPATFULL  
TI Method for introducing and expressing RNA in animal cells  
IN Hone, David M., Ellicott City, MD, United States  
Lewis, George, Baltimore, MD, United States  
Powell, Robert, Baltimore, MD, United States  
PA University of Maryland Biotechnology Institute, Baltimore, MD, United  
States (U.S. corporation)  
PI US 6500419 B1 20021231  
AI US 2000-545153 20000407 (9)  
RLI Continuation-in-part of Ser. No. WO 1998-US21093, filed on 7 Oct 1998  
PRAI US 1997-61396P 19971007 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2914  
INCL INCLM: 424/093.200

INCLS: 424/093.100; 435/252.300; 435/320.100; 435/455.000; 514/044.000  
 NCL NCLM: 424/093.200  
 NCLS: 424/093.100; 435/252.300; 435/320.100; 435/455.000; 514/044.000  
 IC [7]  
 ICM A61K048-00  
 ICS C12N001-21; C12N015-87  
 IPCI A61K0048-00 [ICM,7]; C12N0001-21 [ICS,7]; C12N0015-87 [ICS,7]  
 IPCR A61K0048-00 [I,A]; A61K0048-00 [I,C\*]; C07K0014-005 [I,C\*];  
 C07K0014-16 [I,A]; C07K0014-195 [I,C\*]; C07K0014-24 [I,A];  
 C12N0015-74 [I,A]; C12N0015-74 [I,C\*]; C12N0015-85 [I,A];  
 C12N0015-85 [I,C\*]; C12N0015-87 [I,A]; C12N0015-87 [I,C\*]  
 EXF 435/320.1; 435/252.3; 435/455; 424/93.1; 424/93.2; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 13 USPATFULL on STN  
 AN 2002:242798 USPATFULL  
 TI Adjuvanted vaccine which is substantially free of non-host albumin  
 IN Hennessy, Kristina J., Parkville, MO, UNITED STATES  
 Brown, Karen K., Parkville, MD, UNITED STATES  
 Lane, Jennifer K., Shawnee, KS, UNITED STATES  
 Trump, Sandra L., De Soto, KS, UNITED STATES  
 PI US 2002131979 A1 20020919  
 US 6682746 B2 20040127  
 AI US 2002-99182 A1 20020314 (10)  
 RLI Division of Ser. No. US 1995-531820, filed on 21 Sep 1995, ABANDONED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1140  
 INCL INCLM: 424/201.100  
 INCLS: 424/204.100; 424/234.100; 424/269.100  
 NCL NCLM: 424/278.100; 424/201.100  
 NCLS: 424/093.100; 424/184.100; 424/201.100; 424/204.100; 424/234.100;  
 424/265.100; 424/269.100  
 IC [7]  
 ICM A61K039-295  
 ICS A61K039-12; A61K039-02  
 IPCI A61K0039-295 [ICM,7]; A61K0039-12 [ICS,7]; A61K0039-02 [ICS,7]  
 IPCI-2 A61K0045-00 [ICM,7]; A61K0047-00 [ICS,7]; A61K0039-00 [ICS,7];  
 A01N0063-00 [ICS,7]; A01N0065-00 [ICS,7]  
 IPCR A61K0039-12 [I,A]; A61K0039-12 [I,C\*]; A61K0039-23 [I,A];  
 A61K0039-23 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 13 USPATFULL on STN  
 AN 2000:124555 USPATFULL  
 TI Streptococcus equi vaccine  
 IN Jacobs, Antonius Arnoldus Christiaan, Kessel, Netherlands  
 PA Akzo Nobel N.V., Arnhem, Netherlands (non-U.S. corporation)  
 PI US 6120775 20000919  
 AI US 1998-123735 19980728 (9)  
 PRAI EP 1997-202365 19970729  
 EP 1997-202925 19970924  
 DT Utility  
 FS Granted  
 LN.CNT 516  
 INCL INCLM: 424/244.100  
 INCLS: 424/009.200; 424/184.100; 424/829.000; 424/237.100; 424/093.440;  
 435/173.100; 435/253.400; 435/885.000  
 NCL NCLM: 424/244.100  
 NCLS: 424/009.200; 424/093.440; 424/184.100; 424/237.100; 424/829.000;  
 435/173.100; 435/253.400; 435/885.000  
 IC [7]  
 ICM A61K039-09  
 ICS A61K049-00; A61K039-02; A01N063-00; C12N001-20

IPCI A61K0039-09 [ICM,7]; A61K0049-00 [ICS,7]; A61K0039-02 [ICS,7];  
A01N0063-00 [ICS,7]; C12N0001-20 [ICS,7]  
IPCR A61K0039-09 [I,A]; A61K0039-09 [I,C\*]; A61K0039-116 [I,A];  
A61K0039-116 [I,C\*]  
EXF 424/9.2; 424/829; 424/184.1; 424/237.1; 424/93.44; 424/244.1; 435/173.1;  
435/253.4; 435/885  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 13 USPATFULL on STN  
AN 1999:48101 USPATFULL  
TI Streptococcus equi vaccine  
IN Hartford, Orla Mary, Duleek, Ireland  
Foster, Timothy James, Dublin, Ireland  
Jacobs, Antonius Arnoldus Christiaan, Kessel, Netherlands  
PA Provost Fellows & Scholars of the College of the Univ. of the Holy  
Undivided Trinity of Queen Elisabeth, Dublin, Ireland (non-U.S.  
corporation)  
PI US 5895654 19990420  
AI US 1997-789727 19970127 (8)  
PRAI EP 1996-200171 19960125  
DT Utility  
FS Granted  
LN.CNT 598  
INCL INCLM: 424/237.100  
NCL NCLM: 424/237.100  
IC [6]  
ICM A61K039-085  
IPCI A61K0039-085 [ICM,6]  
IPCR A61K [I,S]; A61K0009-14 [I,A]; A61K0009-14 [I,C\*]; A61K0035-66  
[I,C\*]; A61K0035-74 [I,A]; A61K0039-02 [I,A]; A61K0039-02 [I,C\*];  
A61K0039-05 [I,A]; A61K0039-05 [I,C\*]; A61K0039-08 [I,A];  
A61K0039-08 [I,C\*]; A61K0039-085 [I,A]; A61K0039-085 [I,C\*];  
A61K0039-09 [I,A]; A61K0039-09 [I,C\*]; A61K0039-12 [I,A];  
A61K0039-12 [I,C\*]; A61K0039-145 [I,A]; A61K0039-145 [I,C\*];  
A61K0039-193 [I,A]; A61K0039-193 [I,C\*]; A61K0039-245 [I,A];  
A61K0039-245 [I,C\*]; A61P0011-00 [I,A]; A61P0011-00 [I,C\*]; C12N  
[I,S]; C12N0001-20 [I,A]; C12N0001-20 [I,C\*]; C12R0001-46 [N,A]  
EXF 424/184.1; 424/237.1; 435/172.1; 435/253.4; 435/885

L2 ANSWER 13 OF 13 USPATFULL on STN  
AN 1999:27618 USPATFULL  
TI Method for introducing and expressing genes in animal cells and live  
invasive bacterial vectors for use in the same  
IN Powell, Robert J., Baltimore, MD, United States  
Lewis, George K., Baltimore, MD, United States  
Hone, David M., Ellicott City, MD, United States  
PA University of Maryland at Baltimore, Baltimore, MD, United States (U.S.  
corporation)  
PI US 5877159 19990302  
AI US 1995-433790 19950503 (8)  
DT Utility  
FS Granted  
LN.CNT 1647  
INCL INCLM: 514/044.000  
INCLS: 435/472.000; 435/480.000; 435/069.100; 435/320.100; 435/235.100;  
424/184.100; 424/093.100; 424/093.210; 424/093.400; 536/024.100  
NCL NCLM: 514/044.000  
NCLS: 424/093.100; 424/093.210; 424/093.400; 424/184.100; 435/069.100;  
435/235.100; 435/320.100; 435/472.000; 435/480.000; 536/024.100  
IC [6]  
ICM A01N043-04  
ICS A61K031-70; C12N015-63  
IPCI A01N0043-04 [ICM,6]; A01N0043-02 [ICM,6,C\*]; A61K0031-70 [ICS,6];  
C12N0015-63 [ICS,6]

IPCR A61K0048-00 [I,A]; A61K0048-00 [I,C\*]; C12N0015-87 [I,A];  
C12N0015-87 [I,C\*]  
EXF 514/44; 435/235.1; 424/184.1; 424/93.1; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s gordonia/clm  
L3 9 GORDONIA/CLM

=> d 1-  
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 9 USPATFULL on STN  
AN 2006:209270 USPATFULL  
TI Plant conditioning treatment for plant growth and health enhancement  
IN Medina-Vega, Luis R., Chihuahua, MEXICO  
PI US 2006178269 A1 20060810  
AI US 2005-52293 A1 20050208 (11)  
DT Utility  
FS APPLICATION  
LN.CNT 828  
INCL INCLM: 504/117.000  
INCLS: 504/320.000; 504/321.000; 504/239.000; 504/240.000  
NCL NCLM: 504/117.000  
NCLS: 504/320.000; 504/321.000; 504/239.000; 504/240.000  
IC IPCI A01N0063-00 [I,A]; A01N0043-54 [I,A]; A01N0043-48 [I,C\*];  
A01N0037-00 [I,A]; A01N0037-10 [I,A]

L3 ANSWER 2 OF 9 USPATFULL on STN  
AN 2006:158606 USPATFULL  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI US 2006134136 A1 20060622  
AI US 2003-526228 A1 20030905 (10)  
WO 2003-GB3873 20030905  
20051116 PCT 371 date  
PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 424/203.100  
INCLS: 424/093.400  
NCL NCLM: 424/203.100  
NCLS: 424/093.400  
IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L3 ANSWER 3 OF 9 USPATFULL on STN  
AN 2006:15452 USPATFULL  
TI Vaccine  
IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
PI US 2006013830 A1 20060119  
AI US 2004-893524 A1 20040719 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 720  
INCL INCLM: 424/203.100  
NCL NCLM: 424/203.100

IC IPCI A61K0039-116 [I,A]

L3 ANSWER 4 OF 9 USPATFULL on STN

AN 2005:236091 USPATFULL

TI Process for producing HMG-CoA reductase inhibitors

IN Hashimoto, Shin-ichi, Hofu, JAPAN  
Yonetani, Yoshiyuki, Machida, JAPAN  
Ozaki, Akio, Hofu, JAPAN

PA Kyowa Hakko Kogyo Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

PI US 6946270 B1 20050920  
WO 2000043533 20000727

AI US 2001-868924 20000120 (9)  
WO 2000-JP245 20000120  
20011031 PCT 371 date

PRAI JP 1999-12392 19990120

DT Utility

FS GRANTED

LN.CNT 719

INCL INCLM: 435/125.000  
INCLS: 435/136.000; 435/146.000; 435/155.000; 435/132.000

NCL NCLM: 435/125.000  
NCLS: 435/132.000; 435/136.000; 435/146.000; 435/155.000

IC [7]  
ICM C12P017-06  
IPCI C12P0017-06 [ICM,7]; C12P0017-02 [ICM,7,C\*]  
IPCR C12P0007-62 [I,A]; C12P0007-62 [I,C\*]; C12P0017-02 [I,C\*];  
C12P0017-06 [I,A]

EXF 435/125; 435/136; 435/146; 435/155; 435/132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 9 USPATFULL on STN

AN 2005:196278 USPATFULL

TI Rhodococcus cloning and expression vectors

IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Cheng, Qiong, Wilmington, DE, UNITED STATES  
Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
Tomb, Jean-Francois, Wilmington, DE, UNITED STATES

PI US 2005170420 A1 20050804

AI US 2005-69691 A1 20050301 (11)

RLI Division of Ser. No. US 2001-7527, filed on 5 Dec 2001, PENDING

PRAI US 2000-254868P 20001212 (60)

DT Utility

FS APPLICATION

LN.CNT 2033

INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200

NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200

IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12N009-64  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12N0009-64 [ICS,7]  
IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 9 USPATFULL on STN

AN 2005:90583 USPATFULL

TI Environmental remediation method

IN Kerfoot, William B., Falmouth, MA, UNITED STATES

PI US 2005077249 A1 20050414

AI US 2004-916863 A1 20040812 (10)

PRAI US 2003-498031P 20030827 (60)

DT Utility

FS APPLICATION  
LN.CNT 1239  
INCL INCLM: 210/747.000  
INCLS: 210/760.000; 210/170.000  
NCL NCLM: 210/747.000  
NCLS: 210/170.000; 210/760.000  
IC [7]  
ICM C02F001-78  
IPCI C02F0001-78 [ICM,7]  
IPCR C02F0001-78 [N,A]; C02F0001-78 [N,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 9 USPATFULL on STN  
AN 2004:227022 USPATFULL  
TI Microorganism coating components, coatings, and coated surfaces  
IN McDaniel, C. Steven, Austin, TX, UNITED STATES  
PA REACTIVE SURFACES, LTD. (U.S. corporation)  
PI US 2004175407 A1 20040909  
AI US 2004-792516 A1 20040303 (10)  
RLI Continuation of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING  
PRAI US 2002-409102P 20020909 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15385  
INCL INCLM: 424/423.000  
INCLS: 435/287.200  
NCL NCLM: 424/423.000  
NCLS: 435/287.200  
IC [7]  
ICM C12M001-34  
ICS A61F002-00  
IPCI C12M0001-34 [ICM,7]; A61F0002-00 [ICS,7]  
IPCR A01N0063-00 [I,A]; A01N0063-00 [I,C\*]; A61F0002-00 [I,A];  
A61F0002-00 [I,C\*]; A61K0038-43 [I,C\*]; A61K0038-46 [I,A];  
A61K0038-48 [I,A]; A61K0039-00 [I,A]; A61K0039-00 [I,C\*];  
A61K0047-48 [I,A]; A61K0047-48 [I,C\*]; C09D0005-00 [I,A];  
C09D0005-00 [I,C\*]; C09D0007-12 [I,A]; C09D0007-12 [I,C\*];  
C12M0001-34 [I,A]; C12M0001-34 [I,C\*]; C12N0009-00 [I,A];  
C12N0009-00 [I,C\*]; C12N0009-14 [I,A]; C12N0009-14 [I,C\*];  
C12N0009-88 [I,A]; C12N0009-88 [I,C\*]; C12N0009-90 [I,A];  
C12N0009-90 [I,C\*]; C12N0011-00 [I,C\*]; C12N0011-08 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 9 USPATFULL on STN  
AN 2004:151440 USPATFULL  
TI Rhodococcus cloning and expression vectors  
IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Cheng, Qiong, Wilmington, DE, UNITED STATES  
Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
PI US 2004115661 A1 20040617  
AI US 2003-415562 A1 20030904 (10)  
WO 2001-US47868 20011212  
DT Utility  
FS APPLICATION  
LN.CNT 3141  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12N009-22  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];

C12N0009-22 [ICS,7]  
IPCR C07H0021-00 [I,C\*]; C07H0021-04 [I,A]; C07K0014-195 [I,C\*];  
C07K0014-355 [I,A]; C12N0009-12 [I,A]; C12N0009-12 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 9 USPATFULL on STN  
AN 2003:64686 USPATFULL  
TI Rhodococcus cloning and expression vectors  
IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Cheng, Qiong, Wilmington, DE, UNITED STATES  
Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
PI US 2003044807 A1 20030306  
US 6949362 B2 20050927  
AI US 2001-7527 A1 20011205 (10)  
PRAI US 2000-254868P 20001212 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3138  
INCL INCLM: 435/006.000  
INCLS: 435/091.200; 435/199.000; 435/252.300; 435/069.100; 435/320.100;  
536/023.200  
NCL NCLM: 435/069.100; 435/006.000  
NCLS: 435/252.100; 435/252.300; 435/320.100; 435/471.000; 536/023.100;  
435/091.200; 435/199.000; 536/023.200  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12P019-34; C12N009-22; C12P021-02; C12N001-21  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12P0019-34 [ICS,7]; C12P0019-00 [ICS,7,C\*]; C12N0009-22 [ICS,7];  
C12P0021-02 [ICS,7]; C12N0001-21 [ICS,7]  
IPCI-2 C12P0021-06 [ICM,7]; C12N0001-20 [ICS,7]; C12N0015-00 [ICS,7];  
C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s nodardia/clm

L4 0 NODARDIA/CLM

=> s nocardia/clm

L5 529 NOCARDIA/CLM

=> s l5 and vaccine?/clm

6623 VACCINE?/CLM

L6 20 L5 AND VACCINE?/CLM

=> d 1-

YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 20 USPATFULL on STN  
AN 2006:214532 USPATFULL  
TI Hollow fiber technique for in vivo study of cell populations  
IN Bishai, William R., Baltimore, MD, UNITED STATES  
Karakousis, Petros C., Lutherville, MD, UNITED STATES  
PI US 2006182685 A1 20060817  
AI US 2005-221294 A1 20050906 (11)  
PRAI US 2004-606939P 20040904 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6273  
INCL INCLM: 424/009.200  
INCLS: 435/004.000  
NCL NCLM: 424/009.200



NCLS: 435/004.000  
IC IPCI A61K0049-00 [I,A]; C12Q0001-00 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 20 USPATFULL on STN  
AN 2006:158606 USPATFULL  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI US 2006134136 A1 20060622  
AI US 2003-526228 A1 20030905 (10)  
WO 2003-GB3873 20030905  
20051116 PCT 371 date  
PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 424/203.100  
INCLS: 424/093.400  
NCL NCLM: 424/203.100  
NCLS: 424/093.400  
IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L6 ANSWER 3 OF 20 USPATFULL on STN  
AN 2006:23237 USPATFULL  
TI Group 1 CD1 transgenic mice and their uses  
IN Wang, Chyung-Ru, Chicago, IL, UNITED STATES  
PI US 2006021075 A1 20060126  
AI US 2005-181234 A1 20050714 (11)  
PRAI US 2004-588192P 20040715 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7921  
INCL INCLM: 800/018.000  
NCL NCLM: 800/018.000  
IC IPCI A01K0067-027 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 20 USPATFULL on STN  
AN 2005:188886 USPATFULL  
TI IHN V G protein for immune stimulation  
IN Simard, Nathalie C., Fredericton, CANADA  
Bootland, Linda M., Crapaud, CANADA  
PI US 2005163795 A1 20050728  
AI US 2005-83175 A1 20050317 (11)  
RLI Continuation-in-part of Ser. No. WO 2003-EP10305, filed on 16 Sep 2003,  
UNKNOWN  
PRAI GB 2002-21552 20020917  
GB 2002-21553 20020917  
DT Utility  
FS APPLICATION  
LN.CNT 1615  
INCL INCLM: 424/186.100  
INCLS: 435/005.000; 435/069.300; 435/456.000; 530/350.000; 514/044.000;  
536/023.720  
NCL NCLM: 424/186.100  
NCLS: 435/005.000; 435/069.300; 435/456.000; 514/044.000; 530/350.000;  
536/023.720  
IC [7]  
ICM C12Q001-70  
ICS C07H021-04; C07K014-005; A61K039-12

IPCI C12Q0001-70 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C07K0014-005 [ICS,7]; A61K0039-12 [ICS,7]  
IPCR A61K0039-12 [I,A]; A61K0039-12 [I,C\*]; C07H0021-00 [I,C\*];  
C07H0021-04 [I,A]; C07K0014-005 [I,A]; C07K0014-005 [I,C\*];  
C12Q0001-70 [I,A]; C12Q0001-70 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 20 USPATFULL on STN

AN 2005:182894 USPATFULL

TI Method to genetate non virulent microorganisms from pathogenic ones  
through permanent genetic modification of their biological membrane for  
vaccine production

IN Cinquegrani, Roberto, Corso Vittorio Emanuele, 631, Napoli, ITALY  
I-80121

Colonna Romano, Sergio, Napoli, ITALY

PI US 2005158277 A1 20050721

AI US 2003-479653 A1 20020529 (10)

WO 2002-EP5893 20020529

PRAI IT 2001-RM295 20010530

DT Utility

FS APPLICATION

LN.CNT 1092

INCL INCLM: 424/093.200

INCLS: 435/471.000

NCL NCLM: 424/093.200

NCLS: 435/471.000

IC [7]

ICM A61K048-00

ICS C12N015-74

IPCI A61K0048-00 [ICM,7]; C12N0015-74 [ICS,7]

IPCR C12N0009-02 [I,A]; C12N0009-02 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 20 USPATFULL on STN

AN 2004:150989 USPATFULL

TI Immunogenic complex comprising ribosomes

IN Timmerman, Benedikt, Toulouse, FRANCE

PI US 2004115210 A1 20040617

AI US 2003-250664 A1 20030707 (10)

WO 2002-IB739 20020104

PRAI GB 2001-757 20010106

DT Utility

FS APPLICATION

LN.CNT 2428

INCL INCLM: 424/184.100

NCL NCLM: 424/184.100

IC [7]

ICM A61K039-00

ICS A61K039-38

IPCI A61K0039-00 [ICM,7]; A61K0039-38 [ICS,7]

IPCR A61K0039-00 [I,A]; A61K0039-00 [I,C\*]; A61K0039-108 [I,A];

A61K0039-108 [I,C\*]; A61K0039-116 [I,A]; A61K0039-116 [I,C\*];

A61K0039-39 [I,A]; A61K0039-39 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 20 USPATFULL on STN

AN 2004:120585 USPATFULL

TI Recombinant non-replicating virus expressing gm-csf and uses thereof to  
enhance immune responses

IN Schlom, Jeffrey, Potomac, MD, UNITED STATES

Greiner, John W., Ijamsville, MD, UNITED STATES

Kass, Erik, Chevy Chase, MD, UNITED STATES

Panicali, Dennis, Acton, MA, UNITED STATES

PI US 2004091995 A1 20040513

AI US 2003-297168 A1 20030716 (10)  
 WO 2001-US19201 20010615  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2984  
 INCL INCLM: 435/235.100  
 INCLS: 424/232.100; 424/093.200  
 NCL NCLM: 435/235.100  
 NCLS: 424/093.200; 424/232.100  
 IC [7]  
 ICM A61K039-275  
 ICS A61K039-285; C12N007-00; A61K048-00  
 IPCI A61K0039-275 [ICM,7]; A61K0039-285 [ICS,7]; A61K0039-275  
 [ICS,7,C\*]; C12N0007-00 [ICS,7]; A61K0048-00 [ICS,7]  
 IPCR A61K0039-275 [I,A]; A61K0039-275 [I,C\*]; A61K0039-285 [I,A];  
 A61K0048-00 [I,A]; A61K0048-00 [I,C\*]; C12N0007-00 [I,A];  
 C12N0007-00 [I,C\*]  
 L6 ANSWER 8 OF 20 USPATFULL on STN  
 AN 2004:101971 USPATFULL  
 TI Probes for identifying cancer-specific antigens  
 IN Lopata, Alex, Victoria, AUSTRALIA  
 Meeusen, Elza, Victoria, AUSTRALIA  
 Mancuso, Nunzio, Victoria, AUSTRALIA  
 PI US 2004077841 A1 20040422  
 AI US 2003-432906 A1 20031124 (10)  
 WO 2001-AU1544 20011129  
 PRAI AU 2000-1774 20001129  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1279  
 INCL INCLM: 530/388.800  
 INCLS: 435/070.210; 435/344.000  
 NCL NCLM: 530/388.800  
 NCLS: 435/070.210; 435/344.000  
 IC [7]  
 ICM C12P021-04  
 ICS C12N005-06; C07K016-30  
 IPCI C12P0021-04 [ICM,7]; C12N0005-06 [ICS,7]; C07K0016-30 [ICS,7];  
 C07K0016-18 [ICS,7,C\*]  
 IPCR C07K0016-18 [I,C\*]; C07K0016-30 [I,A]; G01N0033-574 [I,A];  
 G01N0033-574 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L6 ANSWER 9 OF 20 USPATFULL on STN  
 AN 2004:101731 USPATFULL  
 TI Methods and compositions relating to isoleucine boroproline compounds  
 IN Adams, Sharlene, Waltham, MA, UNITED STATES  
 Miller, Glenn T., Merrimac, MA, UNITED STATES  
 Jesson, Michael I., Hopedale, MA, UNITED STATES  
 Jones, Barry, Cambridge, MA, UNITED STATES  
 PA Point Therapeutics, Inc., Boston, MA (U.S. corporation)  
 PI US 2004077601 A1 20040422  
 AI US 2003-616694 A1 20030709 (10)  
 PRAI US 2002-394856P 20020709 (60)  
 US 2002-414978P 20021001 (60)  
 US 2003-466435P 20030428 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 6519  
 INCL INCLM: 514/064.000  
 NCL NCLM: 514/064.000  
 IC [7]  
 ICM A61K031-69

IPCI A61K0031-69 [ICM,7]  
IPCR A61K0031-69 [I,A]; A61K0031-69 [I,C\*]; A61K0038-05 [I,A];  
A61K0038-05 [I,C\*]; A61K0038-06 [I,A]; A61K0038-06 [I,C\*];  
A61K0038-17 [I,A]; A61K0038-17 [I,C\*]; A61K0038-21 [I,A];  
A61K0038-21 [I,C\*]; A61K0039-395 [I,A]; A61K0039-395 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 20 USPATFULL on STN

AN 2004:76185 USPATFULL

TI Immunogenic complex

IN Timmerman, Benedikt, Toulouse, FRANCE

PI US 2004057962 A1 20040325

AI US 2003-250668 A1 20030707 (10)

WO 2002-IB738 20020104

PRAI GB 2001-758 20010106

DT Utility

FS APPLICATION

LN.CNT 2671

INCL INCLM: 424/190.100

INCLS: 514/044.000; 424/191.100

NCL NCLM: 424/190.100

NCLS: 424/191.100; 514/044.000

IC [7]

ICM A61K039-02

ICS A61K039-002; A61K048-00

IPCI A61K0039-02 [ICM,7]; A61K0039-002 [ICS,7]; A61K0048-00 [ICS,7]

IPCR A61K0039-12 [I,A]; A61K0039-12 [I,C\*]; A61K0039-155 [I,A];

A61K0039-155 [I,C\*]; A61K0039-295 [I,A]; A61K0039-295 [I,C\*];

A61K0039-39 [I,A]; A61K0039-39 [I,C\*]; A61K0047-48 [I,A];

A61K0047-48 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 20 USPATFULL on STN

AN 2004:25353 USPATFULL

TI Recombinant vector expressing multiple costimulatory molecules and uses thereof

IN Scholm, Jeffrey, Potomac, MD, UNITED STATES

Hodge, James, Gaithersburg, MD, UNITED STATES

Panicali, Dennis, Acton, MA, UNITED STATES

PI US 2004019195 A1 20040129

AI US 2003-406317 A1 20030404 (10)

RLI Division of Ser. No. US 2001-856988, filed on 24 Sep 2001, PENDING A 371 of International Ser. No. WO 1999-US26866, filed on 12 Nov 1999, PENDING

PRAI US 1998-111582P 19981209 (60)

DT Utility

FS APPLICATION

LN.CNT 4720

INCL INCLM: 536/023.720

INCLS: 536/023.700; 435/320.100; 536/023.100; 435/456.000; 424/184.100; 424/093.400; 424/093.600

NCL NCLM: 536/023.720

NCLS: 424/093.400; 424/093.600; 424/184.100; 435/320.100; 435/456.000; 536/023.100; 536/023.700

IC [7]

ICM C07H021-04

ICS C12N015-86; C07H021-02; A01N063-00; A61K039-38; C12N015-09;

C12N015-63; C12N015-70; C12N015-74; C12N015-86

IPCI C07H0021-04 [ICM,7]; C12N0015-86 [ICS,7]; C07H0021-02 [ICS,7];

C07H0021-00 [ICS,7,C\*]; A01N0063-00 [ICS,7]; A61K0039-38 [ICS,7];

C12N0015-09 [ICS,7]; C12N0015-63 [ICS,7]; C12N0015-70 [ICS,7];

C12N0015-74 [ICS,7]; C12N0015-86 [ICS,7]

IPCR A61K0035-12 [N,A]; A61K0035-12 [N,C\*]; A61K0039-00 [N,A];

A61K0039-00 [N,C\*]; A61K0048-00 [N,A]; A61K0048-00 [N,C\*];

C07K0014-435 [I,C\*]; C07K0014-705 [I,A]; C12N0015-863 [I,A];  
C12N0015-863 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 20 USPATFULL on STN  
AN 2004:1790 USPATFULL  
TI Methods and apparatus for enhancing a response to nucleic acid vaccines  
IN Briskin, Axel F., Fremont, CA, UNITED STATES  
Zuk, Robert, Atherton, CA, UNITED STATES  
PA PHARMASONICS, INC., Sunnyvale, CA, 94089 (U.S. corporation)  
PI US 2004001809 A1 20040101  
AI US 2002-184143 A1 20020626 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 884  
INCL INCLM: 424/093.210  
INCLS: 514/044.000; 604/020.000  
NCL NCLM: 424/093.210  
NCLS: 514/044.000; 604/020.000  
IC [7]  
ICM A61K048-00  
ICS A61N001-30  
IPCI A61K0048-00 [ICM,7]; A61N0001-30 [ICS,7]  
IPCR A61N0007-00 [I,A]; A61N0007-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 20 USPATFULL on STN  
AN 2003:276389 USPATFULL  
TI Replikin peptides and antibodies therefore  
IN Bogoch, Samuel, New York, NY, UNITED STATES  
Bogoch, Elenore S., New York, NY, UNITED STATES  
PI US 2003194414 A1 20031016  
AI US 2002-189437 A1 20020708 (10)  
RLI Continuation-in-part of Ser. No. US 2002-105232, filed on 26 Mar 2002,  
PENDING Continuation-in-part of Ser. No. US 2001-984057, filed on 26 Oct  
2001, PENDING  
PRAI US 2001-303396P 20010709 (60)  
US 2001-278761P 20010327 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7266  
INCL INCLM: 424/204.100  
INCLS: 530/300.000; 424/130.100; 435/006.000  
NCL NCLM: 424/204.100  
NCLS: 424/130.100; 435/006.000; 530/300.000  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; A61K039-395; A61K039-12; C07K002-00; C07K004-00;  
C07K005-00; C07K007-00; C07K014-00; C07K016-00; C07K017-00;  
A61K038-00  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
A61K0039-395 [ICS,7]; A61K0039-12 [ICS,7]; C07K0002-00 [ICS,7];  
C07K0004-00 [ICS,7]; C07K0005-00 [ICS,7]; C07K0007-00 [ICS,7];  
C07K0014-00 [ICS,7]; C07K0016-00 [ICS,7]; C07K0017-00 [ICS,7];  
A61K0038-00 [ICS,7]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0039-00 [N,A];  
A61K0039-00 [N,C\*]; C07K0014-005 [I,A]; C07K0014-005 [I,C\*];  
C07K0014-065 [I,A]; C07K0014-11 [I,A]; C07K0014-195 [I,A];  
C07K0014-195 [I,C\*]; C07K0014-205 [I,A]; C07K0014-21 [I,A];  
C07K0014-22 [I,A]; C07K0014-24 [I,A]; C07K0014-245 [I,A];  
C07K0014-255 [I,A]; C07K0014-26 [I,A]; C07K0014-27 [I,A];  
C07K0014-28 [I,A]; C07K0014-285 [I,A]; C07K0014-30 [I,A];  
C07K0014-305 [I,A]; C07K0014-31 [I,A]; C07K0014-315 [I,A];  
C07K0014-32 [I,A]; C07K0014-33 [I,A]; C07K0014-335 [I,A];

C07K0014-34 [I,A]; C07K0014-345 [I,A]; C07K0014-35 [I,A];  
C07K0014-355 [I,A]; C07K0014-36 [I,A]; C07K0014-37 [I,A];  
C07K0014-37 [I,C\*]; C07K0014-38 [I,A]; C07K0014-385 [I,A];  
C07K0014-39 [I,A]; C07K0014-40 [I,A]; C07K0014-405 [I,A];  
C07K0014-405 [I,C\*]; C07K0014-415 [I,A]; C07K0014-415 [I,C\*];  
C07K0014-435 [I,C\*]; C07K0014-44 [I,A]; C07K0014-445 [I,A];  
C07K0014-47 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 20 USPATFULL on STN

AN 2003:112563 USPATFULL

TI Streptococcus antigens

IN Hamel, Josee, Quebec, CANADA

Ouellet, Catherine, Quebec, CANADA

Charland, Nathalie, Quebec, CANADA

Martin, Denis, Quebec, CANADA

Brodeur, Bernard, Quebec, CANADA

PI US 2003077293 A1 20030424

US 7074415 B2 20060711

AI US 2001-884465 A1 20010620 (9)

PRAI US 2000-212683P 20000620 (60)

DT Utility

FS APPLICATION

LN.CNT 2456

INCL INCLM: 424/190.100

INCLS: 435/069.300; 435/252.300; 435/320.100; 536/023.700; 435/183.000

NCL NCLM: 424/190.100

NCLS: 435/069.300; 435/183.000; 435/252.300; 435/320.100; 536/023.700

IC [7]

ICM A61K039-02

ICS C07H021-04; C12N009-00; C12P021-02; C12N001-21; C12N015-74

IPCI A61K0039-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0001-21 [ICS,7];  
C12N0015-74 [ICS,7]

IPCI-2 A61K0039-09 [I,A]; A61K0039-02 [I,A]; A61K0038-00 [I,A];

A61K0021-08 [I,A]

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C\*]; C07K0014-195 [I,C\*];

C07K0014-315 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 20 USPATFULL on STN

AN 1999:136730 USPATFULL

TI Nutrient formulation and process for enhancing the health, livability,  
cumulative weight gain or feed efficiency in poultry and other animals

IN Ivey, Francis J., Creve Coeur, MO, United States

Dibner, Julia J., Chesterfield, MO, United States

Knight, Christopher D., St. Louis, MO, United States

PA Novus International, Inc., St. Louis, MO, United States (U.S.  
corporation)

PI US 5976580 19991102

AI US 1996-760881 19961206 (8)

RLI Continuation-in-part of Ser. No. US 1996-647719, filed on 24 May 1996  
which is a continuation-in-part of Ser. No. US 1996-597815, filed on 7  
Feb 1996, now abandoned which is a continuation-in-part of Ser. No. US  
1995-483297, filed on 7 Jun 1995

DT Utility

FS Granted

LN.CNT 1742

INCL INCLM: 426/002.000

INCLS: 426/060.000; 426/250.000; 426/807.000

NCL NCLM: 426/002.000

NCLS: 426/060.000; 426/250.000; 426/807.000

IC [6]

ICM A23K001-18

IPCI A23K0001-18 [ICM,6]  
IPCR A23K0001-00 [I,A]; A23K0001-00 [I,C\*]; A23K0001-16 [I,A];  
A23K0001-16 [I,C\*]; A23K0001-18 [I,A]; A23K0001-18 [I,C\*];  
A61K0039-39 [I,A]; A61K0039-39 [I,C\*]  
EXF 426/2; 426/807; 426/60; 426/250  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 20 USPATFULL on STN  
AN 1998:98195 USPATFULL  
TI Apparatus to review clinical microbiology  
IN Warinner, Peter, P.O. Box 470, Freeport, NY, United States 11520  
PI US 5795158 19980818  
AI US 1996-759055 19961202 (8)  
DT Utility  
FS Granted  
LN.CNT 937  
INCL INCLM: 434/295.000  
INCLS: 434/430.000  
NCL NCLM: 434/295.000  
NCLS: 434/430.000  
IC [6]  
ICM G09B019-00  
IPCI G09B0019-00 [ICM,6]  
IPCR G09B0023-00 [I,C\*]; G09B0023-28 [I,A]; G09B0029-00 [I,A];  
G09B0029-00 [I,C\*]  
EXF 434/295; 434/88; 434/296; 434/430

L6 ANSWER 17 OF 20 USPATFULL on STN  
AN 83:38384 USPATFULL  
TI Tri-, tetra, and penta-peptides, their preparation and compositions  
containing them  
IN Bouchaudon, Jean, Morsang-sur-Orge, France  
Dutruc-Rosset, Gilles, Paris, France  
Farge, Daniel, Thiais, France  
James, Claude, Paris, France  
PA Rhone-Poulenc Sante, Courbevoie, France (non-U.S. corporation)  
PI US 4401658 19830830  
AI US 1981-331593 19811217 (6)  
PRAI FR 1980-27020 19801219  
DT Utility  
FS Granted  
LN.CNT 3211  
INCL INCLM: 424/177.000  
INCLS: 260/112.500R  
NCL NCLM: 514/017.000  
NCLS: 514/018.000; 530/330.000; 530/331.000; 530/332.000; 930/020.000;  
930/021.000; 930/200.000  
IC [3]  
ICM C07C103-52  
ICS A61K037-02  
IPCI C07C0103-52 [ICM,3]; A61K0037-02 [ICS,3]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0005-00 [I,C\*];  
C07K0005-02 [I,A]  
EXF 260/112.5R; 424/177  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 20 USPATFULL on STN  
AN 79:43122 USPATFULL  
TI Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-  
glutamic acid and method of use  
IN Audibert, Francoise, Neuilly, France  
Chedid, Louis, Paris, France  
Lefrancier, Pierre, Bures sur Yvette, France  
Choay, Jean, Paris, France

Lederer, Edgar, Sceaux, France  
 PA Agence Nationale de Valorisation de la Recherche (ANVAR), Neuilly sur  
 Seine, France (non-U.S. corporation)  
 PI US 4172125 19791023  
 AI US 1975-625195 19751023 (5)  
 RLI Continuation-in-part of Ser. No. US 1974-516991, filed on 22 Oct 1974,  
 now Defensive Publication No.  
 PRAI FR 1975-29624 19750926  
 DT Utility  
 FS Granted  
 LN.CNT 706  
 INCL INCLM: 424/089.000  
 INCLS: 424/088.000; 424/092.000; 424/045.000; 424/180.000  
 NCL NCLM: 424/279.100  
 NCLS: 424/045.000; 514/062.000  
 IC [2]  
 ICM A61K039-12  
 ICS A61K039-02; A61K031-70  
 IPCI A61K0039-12 [ICM,2]; A61K0039-02 [ICS,2]; A61K0031-70 [ICS,2]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0039-39 [I,A];  
 A61K0039-39 [I,C\*]; C07H0015-00 [I,C\*]; C07H0015-04 [I,A];  
 C07K0009-00 [I,A]; C07K0009-00 [I,C\*]  
 EXF 424/177; 424/180; 424/88; 424/89; 424/92; 424/45  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 20 USPATFULL on STN  
 AN 79:27774 USPATFULL  
 TI Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-  
 isoglutamine  
 IN Audibert, Francoise, Neuilly, France  
 Chedid, Louis, Paris, France  
 Lefrancier, Pierre, Bures sur Yvette, France  
 Choay, Jean, Paris, France  
 Lederer, Edgar, Sceaux, France  
 PA Agence Nationale de Valorisation de la Recherche (ANVAR),  
 Neuilly-sur-Seine, France (non-U.S. government)  
 PI US 4158052 19790612  
 AI US 1975-624994 19751022 (5)  
 RLI Continuation-in-part of Ser. No. US 1974-516991, filed on 22 Oct 1974,  
 now Defensive Publication No.  
 PRAI FR 1975-29624 19750926  
 DT Utility  
 FS Granted  
 LN.CNT 707  
 INCL INCLM: 424/045.000  
 INCLS: 424/088.000; 424/089.000; 424/092.000; 424/177.000; 424/180.000  
 NCL NCLM: 424/045.000  
 NCLS: 424/209.100; 424/279.100; 514/008.000; 930/DIG.500  
 IC [2]  
 ICM A61K039-02  
 ICS A61K039-04; A61K037-02  
 IPCI A61K0039-02 [ICM,2]; A61K0039-04 [ICS,2]; A61K0037-02 [ICS,2]  
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; A61K0039-39 [I,A];  
 A61K0039-39 [I,C\*]; C07H0015-00 [I,C\*]; C07H0015-04 [I,A];  
 C07K0009-00 [I,A]; C07K0009-00 [I,C\*]  
 EXF 424/177; 424/180; 424/88; 424/89; 424/92; 424/45  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 20 USPATFULL on STN  
 AN 77:37459 USPATFULL  
 TI Process for preparing vaccine adjuvant  
 IN Adam, Arlette, Palaiseau, France  
 Berger, Frank M., Princeton, NJ, United States  
 Chedid, Louis, Paris, France



Lederer, Edgar, Sceaux, France  
 Petit, Jean-Francois, Paris, France  
 PA Agence Nationale de Valorisation de la Recherche (ANVAR),  
 Neuilly-sur-Seine, France (non-U.S. government)  
 PI US 4036953 19770719  
 AI US 1972-307614 19721117 (5)  
 PRAI FR 1971-41610 19711119  
 DT Utility  
 FS Granted  
 LN.CNT 853  
 INCL INCLM: 424/092.000  
 INCLS: 195/002.000; 195/004.000; 424/177.000  
 NCL NCLM: 435/170.000  
 NCLS: 424/282.100; 435/259.000; 435/866.000; 435/869.000; 435/872.000;  
 514/002.000  
 IC [2]  
 ICM A61K039-02  
 ICS C12B001-00; C12D013-02; C12D013-10  
 IPCI A61K0039-02 [ICM,2]; C12B0001-00 [ICS,2]; C12D0013-02 [ICS,2];  
 C12D0013-10 [ICS,2]  
 IPCR A61K0035-66 [I,C\*]; A61K0035-74 [I,A]; A61K0039-39 [I,A];  
 A61K0039-39 [I,C\*]; C07K0014-195 [I,C\*]; C07K0014-35 [I,A]  
 EXF 424/92; 424/177; 195/2; 195/4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s dietzia/clm  
 L7 10 DIETZIA/CLM

=> d 1-  
 YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 10 USPATFULL on STN  
 AN 2006:158606 USPATFULL  
 TI Whole bacterial cells as immune modulator  
 IN McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
 PI US 2006134136 A1 20060622  
 AI US 2003-526228 A1 20030905 (10)  
 WO 2003-GB3873 20030905  
 20051116 PCT 371 date  
 PRAI GB 2002-20809 20020906  
 GB 2003-17144 20030722  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2607  
 INCL INCLM: 424/203.100  
 INCLS: 424/093.400  
 NCL NCLM: 424/203.100  
 NCLS: 424/093.400  
 IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L7 ANSWER 2 OF 10 USPATFULL on STN  
 AN 2006:130728 USPATFULL  
 TI Novel bacterium for treatment of disease  
 IN Click, Robert E, River Falls, WI, UNITED STATES  
 PI US 2006110365 A1 20060525  
 AI US 2003-516640 A1 20030603 (10)  
 WO 2003-US17540 20030603  
 20041201 PCT 371 date  
 PRAI US 2002-385232P 20020603 (60)

DT Utility  
FS APPLICATION  
LN.CNT 738  
INCL INCLM: 424/093.400  
INCLS: 424/442.000; 435/252.100  
NCL NCLM: 424/093.400  
NCLS: 424/442.000; 435/252.100  
IC IPCI A61K0035-74 [I,A]; A61K0035-66 [I,C\*]; C12N0001-20 [I,A]

L7 ANSWER 3 OF 10 USPATFULL on STN  
AN 2006:15452 USPATFULL  
TI Vaccine  
IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
PI US 2006013830 A1 20060119  
AI US 2004-893524 A1 20040719 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 720  
INCL INCLM: 424/203.100  
NCL NCLM: 424/203.100  
IC IPCI A61K0039-116 [I,A]

L7 ANSWER 4 OF 10 USPATFULL on STN  
AN 2005:196278 USPATFULL  
TI Rhodococcus cloning and expression vectors  
IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Cheng, Qiong, Wilmington, DE, UNITED STATES  
Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
PI US 2005170420 A1 20050804  
AI US 2005-69691 A1 20050301 (11)  
RLI Division of Ser. No. US 2001-7527, filed on 5 Dec 2001, PENDING  
PRAI US 2000-254868P 20001212 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2033  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12N009-64  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12N0009-64 [ICS,7]  
IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 10 USPATFULL on STN  
AN 2004:227022 USPATFULL  
TI Microorganism coating components, coatings, and coated surfaces  
IN McDaniel, C. Steven, Austin, TX, UNITED STATES  
PA REACTIVE SURFACES, LTD. (U.S. corporation)  
PI US 2004175407 A1 20040909  
AI US 2004-792516 A1 20040303 (10)  
RLI Continuation of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING  
PRAI US 2002-409102P 20020909 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15385  
INCL INCLM: 424/423.000

INCLS: 435/287.200  
 NCLM: 424/423.000  
 NCLS: 435/287.200  
 IC [7]  
 ICM C12M001-34  
 ICS A61F002-00  
 IPCI C12M0001-34 [ICM,7]; A61F0002-00 [ICS,7]  
 IPCR A01N0063-00 [I,A]; A01N0063-00 [I,C\*]; A61F0002-00 [I,A];  
 A61F0002-00 [I,C\*]; A61K0038-43 [I,C\*]; A61K0038-46 [I,A];  
 A61K0038-48 [I,A]; A61K0039-00 [I,A]; A61K0039-00 [I,C\*];  
 A61K0047-48 [I,A]; A61K0047-48 [I,C\*]; C09D0005-00 [I,A];  
 C09D0005-00 [I,C\*]; C09D0007-12 [I,A]; C09D0007-12 [I,C\*];  
 C12M0001-34 [I,A]; C12M0001-34 [I,C\*]; C12N0009-00 [I,A];  
 C12N0009-00 [I,C\*]; C12N0009-14 [I,A]; C12N0009-14 [I,C\*];  
 C12N0009-88 [I,A]; C12N0009-88 [I,C\*]; C12N0009-90 [I,A];  
 C12N0009-90 [I,C\*]; C12N0011-00 [I,C\*]; C12N0011-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 10 USPATFULL on STN  
 AN 2004:151440 USPATFULL  
 TI Rhodococcus cloning and expression vectors  
 IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
 Cheng, Qiong, Wilmington, DE, UNITED STATES  
 Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
 Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
 PI US 2004115661 A1 20040617  
 AI US 2003-415562 A1 20030904 (10)  
 WO 2001-US47868 20011212  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3141  
 INCL INCLM: 435/006.000  
 INCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
 NCLM: 435/006.000  
 NCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
 IC [7]  
 ICM C12Q001-68  
 ICS C07H021-04; C12N009-22  
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
 C12N0009-22 [ICS,7]  
 IPCR C07H0021-00 [I,C\*]; C07H0021-04 [I,A]; C07K0014-195 [I,C\*];  
 C07K0014-355 [I,A]; C12N0009-12 [I,A]; C12N0009-12 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 10 USPATFULL on STN  
 AN 2003:244428 USPATFULL  
 TI 3-hydroxycarboxylic acid production and use in branched polymers  
 IN Bramucci, Michael G., Folsome, PA, UNITED STATES  
 Dicosimo, Robert, Rockland, DE, UNITED STATES  
 Fallon, Robert, Elkton, MD, UNITED STATES  
 Gavagan, John E., Wilmington, DE, UNITED STATES  
 Herkes, Frank, Wilmington, DE, UNITED STATES  
 Wilczek, Lech, Wilmington, DE, UNITED STATES  
 PI US 2003170837 A1 20030911  
 US 7091011 B2 20060815  
 AI US 2003-378202 A1 20030303 (10)  
 RLI Division of Ser. No. US 2001-921260, filed on 2 Aug 2001, GRANTED, Pat.  
 No. US 6562603  
 PRAI US 2000-223044P 20000804 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1425  
 INCL INCLM: 435/146.000  
 NCLM: 435/135.000

NCLS: 435/128.000  
 IC [7]  
 ICM C12P007-42  
 IPCI C12P0007-42 [ICM,7]; C12P0007-40 [ICM,7,C\*]  
 IPCI-2 C12P0007-62 [I,A]; C12P0013-00 [I,A]  
 IPCR C08G0063-00 [I,C\*]; C08G0063-06 [I,A]; C08G0063-85 [I,A];  
 C12P0007-40 [I,C\*]; C12P0007-42 [I,A]; C12P0007-62 [I,A];  
 C12P0007-62 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 10 USPATFULL on STN  
 AN 2003:238023 USPATFULL  
 TI 3-Hydroxycarboxylic acid production and use in branched polymers  
 IN Bramucci, Michael G., Folsome, PA, UNITED STATES  
 Dicosimo, Robert, Rockland, DE, UNITED STATES  
 Fallon, Robert, Elkton, MD, UNITED STATES  
 Gavagan, John E., Wilmington, DE, UNITED STATES  
 Herkes, Frank, Wilmington, DE, UNITED STATES  
 Wilczek, Lech, Wilmington, DE, UNITED STATES  
 PI US 2003166180 A1 20030904  
 AI US 2003-378201 A1 20030303 (10)  
 RLI Division of Ser. No. US 2001-921260, filed on 2 Aug 2001, GRANTED, Pat.  
 No. US 6562603  
 PRAI US 2000-223044P 20000804 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1426  
 INCL INCLM: 435/146.000  
 NCL NCLM: 435/146.000  
 IC [7]

ICM C12P007-42  
 IPCI C12P0007-42 [ICM,7]; C12P0007-40 [ICM,7,C\*]  
 IPCR C08G0063-00 [I,C\*]; C08G0063-06 [I,A]; C08G0063-85 [I,A];  
 C12P0007-40 [I,C\*]; C12P0007-42 [I,A]; C12P0007-62 [I,A];  
 C12P0007-62 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 10 USPATFULL on STN  
 AN 2003:64686 USPATFULL  
 TI Rhodococcus cloning and expression vectors  
 IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
 Cheng, Qiong, Wilmington, DE, UNITED STATES  
 Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
 Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
 PI US 2003044807 A1 20030306  
 US 6949362 B2 20050927  
 AI US 2001-7527 A1 20011205 (10)  
 PRAI US 2000-254868P 20001212 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3138  
 INCL INCLM: 435/006.000  
 INCLS: 435/091.200; 435/199.000; 435/252.300; 435/069.100; 435/320.100;  
 536/023.200  
 NCL NCLM: 435/069.100; 435/006.000  
 NCLS: 435/252.100; 435/252.300; 435/320.100; 435/471.000; 536/023.100;  
 435/091.200; 435/199.000; 536/023.200  
 IC [7]  
 ICM C12Q001-68  
 ICS C07H021-04; C12P019-34; C12N009-22; C12P021-02; C12N001-21  
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
 C12P0019-34 [ICS,7]; C12P0019-00 [ICS,7,C\*]; C12N0009-22 [ICS,7];  
 C12P0021-02 [ICS,7]; C12N0001-21 [ICS,7]  
 IPCI-2 C12P0021-06 [ICM,7]; C12N0001-20 [ICS,7]; C12N0015-00 [ICS,7];

C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 10 USPATFULL on STN  
AN 2002:72633 USPATFULL  
TI 3-Hydroxycarboxylic acid production and use in branched polymers  
IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Dicosimo, Robert, Rockland, DE, UNITED STATES  
Fallon, Robert, Elkton, MD, UNITED STATES  
Gavagan, John E., Wilmington, DE, UNITED STATES  
Herkes, Frank, Wilmington, DE, UNITED STATES  
Wilczek, Lech, Wilmington, DE, UNITED STATES  
PI US 2002039770 A1 20020404  
US 6562603 B2 20030513  
AI US 2001-921260 A1 20010802 (9)  
PRAI US 2000-223044P 20000804 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1423  
INCL INCLM: 435/146.000  
NCL NCLM: 435/146.000  
NCLS: 435/170.000; 435/227.000; 435/232.000  
IC [7]  
ICM C12P007-42  
IPCI C12P0007-42 [ICM,7]; C12P0007-40 [ICM,7,C\*]  
IPCI-2 C12P0007-42 [ICM,7]; C12P0007-40 [ICM,7,C\*]  
IPCR C08G0063-00 [I,C\*]; C08G0063-06 [I,A]; C08G0063-85 [I,A];  
C12P0007-40 [I,C\*]; C12P0007-42 [I,A]; C12P0007-62 [I,A];  
C12P0007-62 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s tsukamurella/clm  
L8 10 TSUKAMURELLA/CLM

=> d 1-  
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 10 USPATFULL on STN  
AN 2006:158606 USPATFULL  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI US 2006134136 A1 20060622  
AI US 2003-526228 A1 20030905 (10)  
WO 2003-GB3873 20030905  
20051116 PCT 371 date  
PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 424/203.100  
INCLS: 424/093.400  
NCL NCLM: 424/203.100  
NCLS: 424/093.400  
IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]  
L8 ANSWER 2 OF 10 USPATFULL on STN  
AN 2006:15452 USPATFULL  
TI Vaccine

IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
PI US 2006013830 A1 20060119  
AI US 2004-893524 A1 20040719 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 720  
INCL INCLM: 424/203.100  
NCL NCLM: 424/203.100  
IC IPCI A61K0039-116 [I,A]

L8 ANSWER 3 OF 10 USPATFULL on STN  
AN 2005:196278 USPATFULL  
TI Rhodococcus cloning and expression vectors  
IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
Cheng, Qiong, Wilmington, DE, UNITED STATES  
Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
PI US 2005170420 A1 20050804  
AI US 2005-69691 A1 20050301 (11)  
RLI Division of Ser. No. US 2001-7527, filed on 5 Dec 2001, PENDING  
PRAI US 2000-254868P 20001212 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2033  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12N009-64  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12N0009-64 [ICS,7]  
IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 10 USPATFULL on STN  
AN 2005:93598 USPATFULL  
TI Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives  
IN Nishiyama, Akira, Hyogo, JAPAN  
Horikawa, Miho, Hyogo, JAPAN  
Yasohara, Yoshihiko, Hyogo, JAPAN  
Ueyama, Noboru, Hyogo, JAPAN  
Inoue, Kenji, Hyogo, JAPAN  
PI US 2005080277 A1 20050414  
US 7094594 B2 20060822  
AI US 2002-48553 A1 20010605 (10)  
WO 2001-JP4729 20010605  
PRAI JP 2000-168285 20000605  
DT Utility  
FS APPLICATION  
LN.CNT 2697  
INCL INCLM: 549/375.000  
NCL NCLM: 435/280.000  
IC [7]  
ICM C07D319-06  
IPCI C07D0319-06 [ICM,7]; C07D0319-00 [ICM,7,C\*]  
IPCI-2 C12P0041-00 [I,A]  
IPCR C07D0319-00 [I,C\*]; C07D0319-06 [I,A]; C12P0007-40 [I,C\*];  
C12P0007-42 [I,A]; C12P0017-02 [I,C\*]; C12P0017-06 [I,A]

L8 ANSWER 5 OF 10 USPATFULL on STN  
 AN 2004:227022 USPATFULL  
 TI Microorganism coating components, coatings, and coated surfaces  
 IN McDaniel, C. Steven, Austin, TX, UNITED STATES  
 PA REACTIVE SURFACES, LTD. (U.S. corporation)  
 PI US 2004175407 A1 20040909  
 AI US 2004-792516 A1 20040303 (10)  
 RLI Continuation of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING  
 PRAI US 2002-409102P 20020909 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 15385  
 INCL INCLM: 424/423.000  
 INCLS: 435/287.200  
 NCL NCLM: 424/423.000  
 NCLS: 435/287.200  
 IC [7]  
 ICM C12M001-34  
 ICS A61F002-00  
 IPCI C12M0001-34 [ICM,7]; A61F0002-00 [ICS,7]  
 IPCR A01N0063-00 [I,A]; A01N0063-00 [I,C\*]; A61F0002-00 [I,A];  
 A61F0002-00 [I,C\*]; A61K0038-43 [I,C\*]; A61K0038-46 [I,A];  
 A61K0038-48 [I,A]; A61K0039-00 [I,A]; A61K0039-00 [I,C\*];  
 A61K0047-48 [I,A]; A61K0047-48 [I,C\*]; C09D0005-00 [I,A];  
 C09D0005-00 [I,C\*]; C09D0007-12 [I,A]; C09D0007-12 [I,C\*];  
 C12M0001-34 [I,A]; C12M0001-34 [I,C\*]; C12N0009-00 [I,A];  
 C12N0009-00 [I,C\*]; C12N0009-14 [I,A]; C12N0009-14 [I,C\*];  
 C12N0009-88 [I,A]; C12N0009-88 [I,C\*]; C12N0009-90 [I,A];  
 C12N0009-90 [I,C\*]; C12N0011-00 [I,C\*]; C12N0011-08 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 10 USPATFULL on STN  
 AN 2004:151440 USPATFULL  
 TI Rhodococcus cloning and expression vectors  
 IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
 Cheng, Qiong, Wilmington, DE, UNITED STATES  
 Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
 Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
 PI US 2004115661 A1 20040617  
 AI US 2003-415562 A1 20030904 (10)  
 WO 2001-US47868 20011212  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3141  
 INCL INCLM: 435/006.000  
 INCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
 NCL NCLM: 435/006.000  
 NCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200  
 IC [7]  
 ICM C12Q001-68  
 ICS C07H021-04; C12N009-22  
 IPCI C12Q001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
 C12N0009-22 [ICS,7]  
 IPCR C07H0021-00 [I,C\*]; C07H0021-04 [I,A]; C07K0014-195 [I,C\*];  
 C07K0014-355 [I,A]; C12N0009-12 [I,A]; C12N0009-12 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 10 USPATFULL on STN  
 AN 2004:57458 USPATFULL  
 TI Process for producing optically active pyridineethanol derivatives  
 IN Kawano, Shigeru, Osaka, JAPAN  
 Horikawa, Miho, Suita-shi, JAPAN  
 Yasohara, Yoshihiko, Suita-Shi, JAPAN

Hasegawa, Junzo, Suita-Shi, JAPAN  
 PA Kaneka Corporation, Kita-ku, JAPAN (non-U.S. corporation)  
 PI US 2004043460 A1 20040304  
 AI US 2003-669503 A1 20030925 (10)  
 RLI Division of Ser. No. US 2001-787746, filed on 20 Jun 2001, ABANDONED A  
 371 of International Ser. No. WO 2000-JP4237, filed on 28 Jun 2000,  
 UNKNOWN  
 PRAI JP 1999-206503 19990721  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2195  
 INCL INCLM: 435/121.000  
 INCLS: 546/268.100; 544/105.000; 544/350.000; 544/236.000; 546/122.000  
 NCL NCLM: 435/121.000  
 NCLS: 544/105.000; 544/236.000; 544/350.000; 546/122.000; 546/268.100  
 IC [7]  
 ICM C12P017-10  
 IPCI C12P0017-10 [ICM,7]  
 IPCR C12N0009-02 [I,A]; C12N0009-02 [I,C\*]; C12P0017-10 [I,C\*];  
 C12P0017-12 [I,A]; C12P0017-18 [I,A]; C12P0017-18 [I,C\*];  
 C12P0041-00 [I,A]; C12P0041-00 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 10 USPATFULL on STN  
 AN 2003:64686 USPATFULL  
 TI Rhodococcus cloning and expression vectors  
 IN Bramucci, Michael G., Folsom, PA, UNITED STATES  
 Cheng, Qiong, Wilmington, DE, UNITED STATES  
 Kostichka, Kristy N., Wilmington, DE, UNITED STATES  
 Tomb, Jean-Francois, Wilmington, DE, UNITED STATES  
 PI US 2003044807 A1 20030306  
 US 6949362 B2 20050927  
 AI US 2001-7527 A1 20011205 (10)  
 PRAI US 2000-254868P 20001212 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3138  
 INCL INCLM: 435/006.000  
 INCLS: 435/091.200; 435/199.000; 435/252.300; 435/069.100; 435/320.100;  
 536/023.200  
 NCL NCLM: 435/069.100; 435/006.000  
 NCLS: 435/252.100; 435/252.300; 435/320.100; 435/471.000; 536/023.100;  
 435/091.200; 435/199.000; 536/023.200  
 IC [7]  
 ICM C12Q001-68  
 ICS C07H021-04; C12P019-34; C12N009-22; C12P021-02; C12N001-21  
 IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
 C12P0019-34 [ICS,7]; C12P0019-00 [ICS,7,C\*]; C12N0009-22 [ICS,7];  
 C12P0021-02 [ICS,7]; C12N0001-21 [ICS,7]  
 IPCI-2 C12P0021-06 [ICM,7]; C12N0001-20 [ICS,7]; C12N0015-00 [ICS,7];  
 C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
 IPCR C12N0015-74 [I,A]; C12N0015-74 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 10 USPATFULL on STN  
 AN 2001:194146 USPATFULL  
 TI Method of producing optically active N-methylamino acids  
 IN Tsuda, Satoru, Akashi-shi, Japan  
 Kato, Takahisa, Kobe-shi, Japan  
 Yasohara, Yoshihiko, Himeji-shi, Japan  
 Hasegawa, Junzo, Akashi-shi, Japan  
 PA Kaneka Corporation, Osaka, Japan, 530-8288 (non-U.S. corporation)  
 PI US 2001036660 A1 20011101  
 AI US 2001-760304 A1 20010116 (9)



PRAI JP 2000-4822 20000113  
 DT Utility  
 FS APPLICATION  
 LN.CNT 396  
 INCL INCLM: 435/280.000  
 NCL NCLM: 435/280.000  
 IC [7]  
 ICM C07C001-00  
 IPCI C07C0001-00 [ICM,7]  
 IPCR C12P0013-00 [I,C\*]; C12P0013-04 [I,A]; C12P0013-22 [I,A];  
 C12P0041-00 [I,A]; C12P0041-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 10 USPATFULL on STN  
 AN 1998:54718 USPATFULL  
 TI Biotechnological perparation of alcohols, aldehydes and carboxylic acids  
 IN Pressler, Uwe, Altrip, Germany, Federal Republic of  
 Balkenhohl, Friedhelm, Limburgerhof, Germany, Federal Republic of  
 Hauer, Bernhard, Fussgonheim, Germany, Federal Republic of  
 Ladner, Wolfgang, Fussgonheim, Germany, Federal Republic of  
 Schnell, Ursula, Bad Lippspringe, Germany, Federal Republic of  
 Staudenmaier, Horst Ralf, Birkenheide, Germany, Federal Republic of  
 PA BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
 (non-U.S. corporation)  
 PI US 5753471 19980519  
 WO 9502061 19950119  
 AI US 1995-578704 19951228 (8)  
 WO 1994-EP2071 19940624  
 19951228 PCT 371 date  
 19951228 PCT 102(e) date

PRAI DE 1993-4322276 19930705  
 DE 1993-4325850 19930731

DT Utility  
 FS Granted

LN.CNT 587  
 INCL INCLM: 435/117.000  
 INCLS: 435/118.000; 435/119.000; 435/120.000; 435/121.000; 435/122.000;  
 435/123.000; 435/124.000; 435/125.000; 435/126.000; 435/128.000;  
 435/156.000; 435/252.100; 435/855.000; 549/369.000; 549/374.000  
 NCL NCLM: 435/117.000  
 NCLS: 435/118.000; 435/119.000; 435/120.000; 435/121.000; 435/122.000;  
 435/123.000; 435/124.000; 435/125.000; 435/126.000; 435/128.000;  
 435/156.000; 435/252.100; 435/855.000; 549/369.000; 549/374.000

IC [6]  
 ICM C07C059-60  
 ICS C12P007-22; C12P007-24; C12N001-20  
 IPCI C07C0059-60 [ICM,6]; C07C0059-00 [ICM,6,C\*]; C12P0007-22 [ICS,6];  
 C12P0007-02 [ICS,6,C\*]; C12P0007-24 [ICS,6]; C12N0001-20 [ICS,6]  
 IPCR C07D0319-00 [I,C\*]; C07D0319-06 [I,A]; C12P0007-02 [I,C\*];  
 C12P0007-04 [I,A]; C12P0007-24 [I,A]; C12P0007-24 [I,C\*];  
 C12P0007-40 [I,A]; C12P0007-40 [I,C\*]; C12P0017-00 [I,A];  
 C12P0017-00 [I,C\*]

EXF 435/117; 435/156; 435/122; 435/120; 435/121; 435/126; 435/128; 435/118;  
 435/119; 435/123; 435/252.1; 435/855; 435/124; 435/125; 549/369; 549/374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s nocardioiodes/clm

L9 19 NOCARDIOIDES/CLM

=> d 1-

YOU HAVE REQUESTED DATA FROM 19 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 1 OF 19 USPATFULL on STN

AN 2006:195591 USPATFULL  
 TI Support for holding a complexed enrichment of degrading bacteria and manufacturing method thereof, novel bacteria, and method of cleaning pollution environment and device thereof  
 IN Takagi, Kazuhiro, Ibaraki, JAPAN  
 Harada, Naoki, Ibaraki, JAPAN  
 Yoshioka, Yuuichi, Kochi, JAPAN  
 PI US 2006166346 A1 20060727  
 AI US 2006-335686 A1 20060120 (11)  
 PRAI JP 2005-18901 20050126  
 JP 2005-169369 20050609  
 JP 2005-189986 20050629  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1363  
 INCL INCLM: 435/252.400  
 INCLS: 435/262.500  
 NCL NCLM: 435/252.400  
 NCLS: 435/262.500  
 IC IPCI C12N0001-20 [I,A]; B09C0001-10 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 19 USPATFULL on STN  
 AN 2006:158606 USPATFULL  
 TI Whole bacterial cells as immune modulator  
 IN McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
 PI US 2006134136 A1 20060622  
 AI US 2003-526228 A1 20030905 (10)  
 WO 2003-GB3873 20030905  
 20051116 PCT 371 date  
 PRAI GB 2002-20809 20020906  
 GB 2003-17144 20030722  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2607  
 INCL INCLM: 424/203.100  
 INCLS: 424/093.400  
 NCL NCLM: 424/203.100  
 NCLS: 424/093.400  
 IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L9 ANSWER 3 OF 19 USPATFULL on STN  
 AN 2006:15452 USPATFULL  
 TI Vaccine  
 IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
 McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 PI US 2006013830 A1 20060119  
 AI US 2004-893524 A1 20040719 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 720  
 INCL INCLM: 424/203.100  
 NCL NCLM: 424/203.100  
 IC IPCI A61K0039-116 [I,A]

L9 ANSWER 4 OF 19 USPATFULL on STN  
 AN 2004:313913 USPATFULL  
 TI Aminoketone asymmetric reductase and nucleic acid thereof  
 IN Sakamoto, Keiji, Takaoka-shi, JAPAN

Kita, Shinji, Takaoka-shi, JAPAN  
Tsuzaki, Kazuya, Takaoka-shi, JAPAN  
Morikawa, Tadanori, Takaoka-shi, JAPAN  
Shimizu, Sakayu, Kyoto-shi, JAPAN  
Kataoka, Michihiko, Kyoto-shi, JAPAN

PI US 2004247583 A1 20041209  
AI US 2003-469682 A1 20030902 (10)  
WO 2002-JP1928 20020301  
PRAI JP 2001-58698 20010302  
DT Utility  
FS APPLICATION  
LN.CNT 1716  
INCL INCLM: 424/094.400  
INCLS: 435/069.100; 435/191.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 424/094.400  
NCLS: 435/069.100; 435/191.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM A61K038-44  
ICS C12N009-06; C07H021-04  
IPCI A61K0038-44 [ICM,7]; A61K0038-43 [ICM,7,C\*]; C12N0009-06 [ICS,7];  
C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
IPCR C12N0009-04 [I,A]; C12N0009-04 [I,C\*]; C12P0013-00 [I,A];  
C12P0013-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 19 USPATFULL on STN  
AN 2004:280358 USPATFULL  
TI Process for producing optically active (r)-2-chloro-1-(3'-chlorophenyl)  
ethanol  
IN Shimizu, Sakayu, Kyoto, JAPAN  
Kataoka, Michihiko, Kyoto, JAPAN  
Kizaki, Noriyuki, Hyogo, JAPAN  
Yasohara, Yoshihiko, Hyogo, JAPAN  
PI US 2004219658 A1 20041104  
AI US 2004-482251 A1 20040510 (10)  
WO 2002-JP6343 20020625  
PRAI JP 2001-191517 20010625  
DT Utility  
FS APPLICATION  
LN.CNT 443  
INCL INCLM: 435/280.000  
NCL NCLM: 435/280.000  
IC [7]  
ICM C12P041-00  
IPCI C12P0041-00 [ICM,7]  
IPCR C12P0007-02 [I,C\*]; C12P0007-22 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 19 USPATFULL on STN  
AN 2004:227022 USPATFULL  
TI Microorganism coating components, coatings, and coated surfaces  
IN McDaniel, C. Steven, Austin, TX, UNITED STATES  
PA REACTIVE SURFACES, LTD. (U.S. corporation)  
PI US 2004175407 A1 20040909  
AI US 2004-792516 A1 20040303 (10)  
RLI Continuation of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING  
PRAI US 2002-409102P 20020909 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15385  
INCL INCLM: 424/423.000  
INCLS: 435/287.200  
NCL NCLM: 424/423.000  
NCLS: 435/287.200

IC [7]  
 ICM C12M001-34  
 ICS A61F002-00  
 IPCI C12M0001-34 [ICM,7]; A61F0002-00 [ICS,7]  
 IPCR A01N0063-00 [I,A]; A01N0063-00 [I,C\*]; A61F0002-00 [I,A];  
 A61F0002-00 [I,C\*]; A61K0038-43 [I,C\*]; A61K0038-46 [I,A];  
 A61K0038-48 [I,A]; A61K0039-00 [I,A]; A61K0039-00 [I,C\*];  
 A61K0047-48 [I,A]; A61K0047-48 [I,C\*]; C09D0005-00 [I,A];  
 C09D0005-00 [I,C\*]; C09D0007-12 [I,A]; C09D0007-12 [I,C\*];  
 C12M0001-34 [I,A]; C12M0001-34 [I,C\*]; C12N0009-00 [I,A];  
 C12N0009-00 [I,C\*]; C12N0009-14 [I,A]; C12N0009-14 [I,C\*];  
 C12N0009-88 [I,A]; C12N0009-88 [I,C\*]; C12N0009-90 [I,A];  
 C12N0009-90 [I,C\*]; C12N0011-00 [I,C\*]; C12N0011-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 19 USPATFULL on STN  
 AN 2004:120571 USPATFULL  
 TI Process for the production of optically active beta-amino alcohols  
 IN Sakamoto, Keiji, Toyama, JAPAN  
 Kita, Shinji, Toyama, JAPAN  
 Tsuzaki, Kazuya, Toyama, JAPAN  
 Morikawa, Tadanori, Toyama, JAPAN  
 Shimizu, Sakayu, Kyoto, JAPAN  
 Kataoka, Michihiko, Kyoto, JAPAN  
 PI US 2004091981 A1 20040513  
 US 6835559 B2 20041228  
 AI US 2003-240056 A1 20030122 (10)  
 WO 2001-JP1628 20010302  
 PRAI JP 2000-89182 20000328  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1255  
 INCL INCLM: 435/121.000  
 INCLS: 435/128.000  
 NCL NCLM: 435/128.000; 435/121.000  
 NCLS: 435/169.000; 435/170.000; 435/280.000; 435/822.000; 435/865.000;  
 435/877.000; 435/911.000; 435/914.000; 435/917.000; 435/918.000

IC [7]  
 ICM C12P017-10  
 ICS C12P013-00  
 IPCI C12P0017-10 [ICM,7]; C12P0013-00 [ICS,7]  
 IPCI-2 C12P0013-00 [ICM,7]  
 IPCR C12P0013-00 [I,A]; C12P0013-00 [I,C\*]; C12P0041-00 [I,A];  
 C12P0041-00 [I,C\*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 19 USPATFULL on STN  
 AN 2003:294421 USPATFULL  
 TI Dna encoding novel d-aminoacylase and process for producing d-amino acid  
 by using the same  
 IN Osabe, Masami, Mobara-shi, JAPAN  
 Takahashi, Katsuyuki, Mobara-shi, JAPAN  
 Yamaki, Toshifumi, Mobara-shi, JAPAN  
 Arii, Teruo, Mobara-shi, JAPAN  
 Oikawa, Toshihiro, Mobara-shi, JAPAN  
 PI US 2003207436 A1 20031106  
 US 6869788 B2 20050322  
 AI US 2002-240422 A1 20020930 (10)  
 WO 2002-JP853 20020201  
 PRAI JP 2001-24986 20010201  
 DT Utility  
 FS APPLICATION  
 LN.CNT 978  
 INCL INCLM: 435/228.000

INCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 536/023.200  
NCL NCLM: 435/227.000; 435/228.000  
NCLS: 435/018.000; 435/069.100; 435/106.000; 435/108.000; 435/252.300;  
435/320.100; 530/350.000; 536/023.200; 435/006.000  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04; C12N009-80; C12P021-02; C12N001-21; C12N015-74  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*];  
C12N0009-80 [ICS,7]; C12N0009-78 [ICS,7,C\*]; C12P0021-02 [ICS,7];  
C12N0001-21 [ICS,7]; C12N0015-74 [ICS,7]  
IPCI-2 C12N0009-78 [ICM,7]; C12Q0001-34 [ICS,7]; C12P0013-22 [ICS,7];  
C12P0013-00 [ICS,7,C\*]; C07K0017-00 [ICS,7]; C07H0021-04 [ICS,7];  
C07H0021-00 [ICS,7,C\*]  
IPCR C12N0009-78 [I,C\*]; C12N0009-80 [I,A]; C12P0013-00 [I,C\*];  
C12P0013-04 [I,A]; C12P0041-00 [I,A]; C12P0041-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 19 USPATFULL on STN  
AN 2003:266269 USPATFULL  
TI Synthesis intermediate products for producing vitamin d derivatives  
IN Steinmeyer, Andreas, Berlin, GERMANY, FEDERAL REPUBLIC OF  
Boidol, Werner, Berlin, GERMANY, FEDERAL REPUBLIC OF  
Zorn, Ludwig, Berlin, GERMANY, FEDERAL REPUBLIC OF  
PI US 2003187287 A1 20031002  
AI US 2003-257767 A1 20030527 (10)  
WO 2001-EP4341 20010417  
PRAI DE 2000-100198619 20000418  
DT Utility  
FS APPLICATION  
LN.CNT 614  
INCL INCLM: 552/653.000  
INCLS: 560/119.000; 435/052.000  
NCL NCLM: 552/653.000  
NCLS: 435/052.000; 560/119.000  
IC [7]  
ICM C07C401-00  
ICS C12P033-00; C07C069-74  
IPCI C07C0401-00 [ICM,7]; C12P0033-00 [ICS,7]; C07C0069-74 [ICS,7];  
C07C0069-00 [ICS,7,C\*]  
IPCR C07C0401-00 [I,A]; C07C0401-00 [I,C\*]; C07F0007-00 [I,C\*];  
C07F0007-18 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 19 USPATFULL on STN  
AN 2003:200825 USPATFULL  
TI High throughput method for discovery of gene clusters  
IN Farnet, Chris M., Outremont, CANADA  
Staffa, Alfredo, Saint-Laurent, CANADA  
Zazopoulos, Emmanuel, Montreal, CANADA  
PI US 2003138810 A1 20030724  
AI US 2002-232370 A1 20020903 (10)  
RLI Continuation-in-part of Ser. No. US 2001-910813, filed on 24 Jul 2001,  
PENDING Continuation-in-part of Ser. No. US 2002-152886, filed on 21 May  
2002, PENDING Continuation-in-part of Ser. No. US 2001-976059, filed on  
15 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2002-205032,  
filed on 26 Jul 2002, PENDING Continuation-in-part of Ser. No. US  
2002-132134, filed on 26 Apr 2002, PENDING Continuation-in-part of Ser.  
No. US 2002-166087, filed on 11 Jun 2002, PENDING  
PRAI US 2001-291959P 20010521 (60)  
US 2001-334604P 20011203 (60)  
US 2000-239924P 20001013 (60)  
US 2001-307629P 20010726 (60)  
US 2001-286346P 20010426 (60)  
US 2001-296744P 20010611 (60)

US 2002-372789P 20020417 (60)  
 US 2001-342133P 20011226 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2271  
 INCL INCLM: 435/006.000  
 INCLS: 702/020.000  
 NCL NCLM: 435/006.000  
 NCLS: 702/020.000  
 IC [7]  
 ICM C12Q001-68  
 ICS G06F019-00; G01N033-48; G01N033-50  
 IPCI C12Q0001-68 [ICM,7]; G06F0019-00 [ICS,7]; G01N0033-48 [ICS,7];  
 G01N0033-50 [ICS,7]  
 IPCR C07K0014-195 [I,C\*]; C07K0014-36 [I,A]; C07K0014-365 [I,A];  
 C12N0015-52 [I,A]; C12N0015-52 [I,C\*]; C12P0019-00 [I,C\*];  
 C12P0019-62 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 19 USPATFULL on STN  
 AN 2003:173174 USPATFULL  
 TI Novel polynucleotides  
 IN Omura, Satoshi, Tokyo, JAPAN  
 Ikeda, Haruo, Kawasaki-shi, JAPAN  
 Ishikawa, Jun, Sagamihara-shi, JAPAN  
 Horikawa, Hiroshi, Tokyo, JAPAN  
 Shiba, Tadayoshi, Tokyo, JAPAN  
 Sakaki, Yoshiyuki, Yokohama-shi, JAPAN  
 Hattori, Masahira, Tokyo, JAPAN  
 PI US 2003119018 A1 20030626  
 AI US 2002-156761 A1 20020529 (10)  
 PRAI JP 2001-204089 20010530  
 JP 2001-272697 20010802  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3780  
 INCL INCLM: 435/006.000  
 INCLS: 530/350.000; 536/023.100; 435/252.100; 435/041.000  
 NCL NCLM: 435/006.000  
 NCLS: 435/041.000; 435/252.100; 530/350.000; 536/023.100  
 IC [7]  
 ICM C12Q001-68  
 ICS C07K014-00; C07H021-04; C12P001-00; C12N001-20  
 IPCI C12Q0001-68 [ICM,7]; C07K0014-00 [ICS,7]; C07H0021-04 [ICS,7];  
 C07H0021-00 [ICS,7,C\*]; C12P0001-00 [ICS,7]; C12N0001-20 [ICS,7]  
 IPCR C07K0014-195 [I,C\*]; C07K0014-36 [I,A]; C12Q0001-68 [I,A];  
 C12Q0001-68 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 19 USPATFULL on STN  
 AN 2000:170848 USPATFULL  
 TI Preparation of 6 hydroxy-7-deoxytaxanes using nocardioideus luteus  
 IN Hanson, Ronald L., Morris Plains, NJ, United States  
 Patel, Ramesh N., Bridgewater, NJ, United States  
 PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
 corporation)  
 PI US 6162622 20001219  
 AI US 1999-231702 19990114 (9)  
 PRAI US 1998-71331P 19980114 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 549  
 INCL INCLM: 435/123.000  
 INCLS: 435/117.000; 435/195.000

NCL NCLM: 435/123.000  
NCLS: 435/117.000; 435/195.000  
IC [7]  
ICM C12P017-02  
IPCI C12P0017-02 [ICM,7]  
IPCR C12P0017-02 [I,A]; C12P0017-02 [I,C\*]  
EXF 435/123; 435/117; 435/195  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 19 USPATFULL on STN  
AN 2000:129899 USPATFULL  
TI Enzymatic reduction method for the preparation of halohydrins  
IN Patel, Ramesh N., Bridgewater, NJ, United States  
Szarka, Laszlo J., East Brunswick, NJ, United States  
Banerjee, Amit, Yardley, PA, United States  
McNamee, Clyde G., Lawrenceville, NJ, United States  
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)  
PI US 1893 20001003  
AI US 1996-685318 19960723 (8)  
DT Statutory  
FS Granted  
LN.CNT 1246  
INCL INCLM: 435/129.000  
INCLS: 435/280.000; 435/822.000  
NCL NCLM: 435/129.000  
NCLS: 435/280.000; 435/822.000  
IC [7]  
ICM C12P013-02  
ICS C07C001-04; C12N001-00  
IPCI C12P0013-02 [ICM,7]; C12P0013-00 [ICM,7,C\*]; C07C0001-04 [ICS,7];  
C07C0001-00 [ICS,7,C\*]; C12N0001-00 [ICS,7]  
EXF 435/280; 435/106-110; 435/113-116  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 19 USPATFULL on STN  
AN 1999:89031 USPATFULL  
TI Method of producing carboxylic acids  
IN Matsuoka, Kazuyuki, Kitakatsuragi-gun, Japan  
Matsuyama, Akinobu, Tsukuba, Japan  
PA Daicel Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 5932454 19990803  
AI US 1997-992545 19971217 (8)  
PRAI JP 1996-341673 19961220  
DT Utility  
FS Granted  
LN.CNT 1733  
INCL INCLM: 435/130.000  
INCLS: 435/129.000; 435/136.000; 435/822.000  
NCL NCLM: 435/130.000  
NCLS: 435/129.000; 435/136.000; 435/822.000  
IC [6]  
ICM C12P013-02  
ICS C12P011-00  
IPCI C12P0013-02 [ICM,6]; C12P0013-00 [ICM,6,C\*]; C12P0011-00 [ICS,6]  
IPCR C12P0007-40 [I,C\*]; C12P0007-42 [I,A]; C12P0011-00 [I,A];  
C12P0011-00 [I,C\*]; C12P0013-00 [I,C\*]; C12P0013-02 [I,A]  
EXF 435/129; 435/130; 435/136; 435/822  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 19 USPATFULL on STN  
AN 1998:39408 USPATFULL  
TI Enzymatic hydrolysis method for the preparation of C-13 hydroxyl-bearing taxanes, and use thereof in the preparation of C-13 acyloxy-bearing

taxanes

IN Hanson, Ronald L., Morris Plains, NJ, United States  
 Patel, Ramesh N., Bridgewater, NJ, United States  
 Szarka, Laszlo J., East Brunswick, NJ, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

PI US 5739016 19980414

AI US 1995-445120 19950519 (8)

RLI Division of Ser. No. US 1993-77979, filed on 15 Jun 1993, now patented, Pat. No. US 5516676

DT Utility

FS Granted

LN.CNT 885

INCL INCLM: 435/117.000  
 INCLS: 435/195.000; 435/123.000

NCL NCLM: 435/117.000  
 NCLS: 435/123.000; 435/195.000

IC [6]  
 ICM C12P017-02  
 ICS C12N009-14  
 IPCI C12P0017-02 [ICM,6]; C12N0009-14 [ICS,6]  
 IPCR C07D0305-00 [I,C\*]; C07D0305-14 [I,A]; C12N0009-18 [I,A];  
 C12N0009-18 [I,C\*]; C12P0017-02 [I,A]; C12P0017-02 [I,C\*];  
 C12Q0001-04 [I,A]; C12Q0001-04 [I,C\*]

EXF 435/123; 435/117; 435/195

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 19 USPATFULL on STN

AN 97:88889 USPATFULL

TI Process for enriching an [R,S]-1,2-epoxide in one enantiomer by using microbes to convert one enantiomer to the other or to preferentially open the epoxide ring

IN Matsuyama, Akinobu, Arai, Japan  
 Kobayashi, Yoshinori, Joetsu, Japan

PA Daicel Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

PI US 5672504 19970930

AI US 1995-547902 19951025 (8)

RLI Continuation of Ser. No. US 1994-195080, filed on 14 Feb 1994, now abandoned

PRAI JP 1993-25315 19930215  
 JP 1993-55735 19930316

DT Utility

FS Granted

LN.CNT 929

INCL INCLM: 435/280.000  
 INCLS: 435/123.000; 435/823.000; 435/832.000; 435/834.000; 435/839.000;  
 435/849.000; 435/875.000; 435/877.000; 435/881.000; 435/920.000;  
 435/917.000; 435/918.000

NCL NCLM: 435/280.000  
 NCLS: 435/123.000; 435/823.000; 435/832.000; 435/834.000; 435/839.000;  
 435/849.000; 435/875.000; 435/877.000; 435/881.000; 435/917.000;  
 435/918.000; 435/920.000

IC [6]  
 ICM C12P041-00  
 IPCI C12P0041-00 [ICM,6]  
 IPCR C07D0303-00 [I,C\*]; C07D0303-08 [I,A]; C12P0017-02 [I,A];  
 C12P0017-02 [I,C\*]; C12P0041-00 [I,A]; C12P0041-00 [I,C\*]

EXF 435/280; 435/123; 435/823; 435/832; 435/834; 435/839; 435/849; 435/875;  
 435/877; 435/917; 435/918; 435/920

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 19 USPATFULL on STN

AN 96:48307 USPATFULL

TI Enzymatic hydrolysis method for the preparation of C-10 hydroxyl-bearing



taxanes and enzymatic esterification method for the preparation of C-10  
acyloxy-bearing

IN Hanson, Ronald L., Morris Plains, NJ, United States  
Patel, Ramesh N., Bridgewater, NJ, United States  
Szarka, Laszlo J., East Brunswick, NJ, United States  
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
corporation)

PI US 5523219 19960604  
AI US 1993-77980 19930615 (8)

DT Utility  
FS Granted

LN.CNT 912

INCL INCLM: 435/123.000  
INCLS: 435/117.000; 435/195.000; 435/252.100; 435/253.200

NCL NCLM: 435/123.000  
NCLS: 435/117.000; 435/195.000; 435/252.100; 435/253.200

IC [6]  
ICM C12P017-02  
ICS C12P017-00  
IPCI C12P0017-02 [ICM,6]; C12P0017-00 [ICS,6]  
IPCR C07D0305-00 [I,C\*]; C07D0305-14 [I,A]; C12N0009-18 [I,A];  
C12N0009-18 [I,C\*]; C12P0017-02 [I,A]; C12P0017-02 [I,C\*];  
C12Q0001-04 [I,A]; C12Q0001-04 [I,C\*]

EXF 435/123; 435/117; 435/195; 435/292.1; 435/253.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 19 USPATFULL on STN

AN 96:41116 USPATFULL

TI Preparation of C-13 hydroxyl-bearing taxanes using nocardioides or a  
hydrolase isolated therefrom

IN Hanson, Ronald L., Morris Plains, NJ, United States  
Patel, Ramesh N., Bridgewater, NJ, United States  
Szarka, Laszlo J., East Brunswick, NJ, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
corporation)

PI US 5516676 19960514  
AI US 1993-77979 19930615 (8)

DT Utility  
FS Granted

LN.CNT 813

INCL INCLM: 435/195.000  
INCLS: 435/117.000; 435/252.100; 435/253.200; 435/872.000; 435/123.000;  
549/510.000; 549/511.000

NCL NCLM: 435/195.000  
NCLS: 435/117.000; 435/123.000; 435/252.100; 435/253.200; 435/872.000;  
549/510.000; 549/511.000

IC [6]  
ICM C12P017-02  
ICS C12N009-14; C07D305-14  
IPCI C12P0017-02 [ICM,6]; C12N0009-14 [ICS,6]; C07D0305-14 [ICS,6];  
C07D0305-00 [ICS,6,C\*]  
IPCR C07D0305-00 [I,C\*]; C07D0305-14 [I,A]; C12N0009-18 [I,A];  
C12N0009-18 [I,C\*]; C12P0017-02 [I,A]; C12P0017-02 [I,C\*];  
C12Q0001-04 [I,A]; C12Q0001-04 [I,C\*]

EXF 435/123; 435/117; 435/195; 435/252.1; 435/253.2; 435/872; 549/510;  
549/511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 19 USPATFULL on STN

AN 86:76605 USPATFULL

TI Process for producing antitumor antibiotic compound

IN Matson, James A., Fayetteville, NY, United States  
Bush, James A., Fayetteville, NY, United States

PA Bristol-Myers Company, New York, NY, United States (U.S. corporation)

PI US 4599310 19860708  
AI US 1985-780121 19850925 (6)  
RLI Division of Ser. No. US 1984-621641, filed on 18 Jun 1984  
DT Utility  
FS Granted  
LN.CNT 691  
INCL INCLM: 435/071.000  
INCLS: 435/253.000; 435/822.000  
NCL NCLM: 435/071.300  
NCLS: 435/252.100; 435/822.000; 546/156.000  
IC [4]  
ICM C12P021-04  
ICS C12N001-20; C12R001-01  
IPCI C12P0021-04 [ICM,4]; C12N0001-20 [ICS,4]; C12R0001-01 [ICS,4]  
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C\*]; C07K0007-00 [I,C\*];  
C07K0007-06 [I,A]  
EXF 435/71; 435/253  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 47 TSUKAMURELLA INCHONENSIS

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 21 DUP REM L1 (26 DUPLICATES REMOVED)

=> d 1-

YOU HAVE REQUESTED DATA FROM 21 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 21 USPATFULL on STN

AN 2006:158606 USPATFULL

TI Whole bacterial cells as immune modulator

IN McIntyre, Graham, Kent, UNITED KINGDOM

Stanford, John Lawson, Kent, UNITED KINGDOM

Stanford, Cynthia Ann, Kent, UNITED KINGDOM

Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA

PI US 2006134136 A1 20060622

AI US 2003-526228 A1 20030905 (10)

WO 2003-GB3873 20030905

20051116 PCT 371 date

PRAI GB 2002-20809 20020906

GB 2003-17144 20030722

DT Utility

FS APPLICATION

LN.CNT 2607

INCL INCLM: 424/203.100

INCLS: 424/093.400

NCL NCLM: 424/203.100

NCLS: 424/093.400

IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L2 ANSWER 2 OF 21 USPATFULL on STN

AN 2006:15452 USPATFULL

TI Vaccine

IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA

McIntyre, Graham, Kent, UNITED KINGDOM

Stanford, Cynthia Ann, Kent, UNITED KINGDOM

Stanford, John Lawson, Kent, UNITED KINGDOM

PI US 2006013830 A1 20060119

AI US 2004-893524 A1 20040719 (10)

DT Utility

FS APPLICATION

LN.CNT 720

INCL INCLM: 424/203.100

NCL NCLM: 424/203.100

IC IPCI A61K0039-116 [I,A]

L2 ANSWER 3 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2006:359934 BIOSIS

DN PREV200600353824

TI Analysis of 16S-23S intergenic spacer regions of the rRNA operons in  
Tsukamurella pulmonis.

AU Moore, J. E. [Reprint Author]; Xu, J.; Millar, B. C.

CS Belfast City Hosp, No Ireland Publ Hlth Lab, Dept Bacteriol, Lisburn Rd,  
Belfast BT9 7AD, Antrim, UK  
jemoore@niph1.dnet.co.uk

SO British Journal of Biomedical Science, (2006) Vol. 63, No. 1, pp. 25-26.  
ISSN: 0967-4845.

DT Article

LA English

ED Entered STN: 19 Jul 2006

Last Updated on STN: 19 Jul 2006

L2 ANSWER 4 OF 21 USPATFULL on STN

AN 2005:318396 USPATFULL  
TI Rapid identification of *Nocardia farcinica*  
IN Lasker, Brent A., Atlanta, GA, UNITED STATES  
Brown, June M., Decatur, GA, UNITED STATES  
PI US 2005277136 A1 20051215  
AI US 2005-100338 A1 20050406 (11)  
PRAI US 2004-560867P 20040409 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1976  
INCL INCLM: 435/006.000  
INCLS: 536/023.700  
NCL NCLM: 435/006.000  
NCLS: 536/023.700  
IC [7]  
ICM C12Q001-68  
ICS C07H021-04  
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:155495 CAPLUS  
DN 144:336674  
TI Exposure of Indian agricultural workers to airborne microorganisms, dust  
and endotoxin during handling of various plant products  
AU Krysinska-Traczyk, Ewa; Pande, Bhawanipant N.; Skorska, Czeslawa;  
Sitkowska, Jolanta; Prazmo, Zofia; Cholewa, Grazyna; Dutkiewicz, Jacek  
CS Department of Occupational Biohazards, Institute of Agricultural Medicine,  
Lublin, Pol.  
SO Annals of Agricultural and Environmental Medicine (2005), 12(2), 269-275  
CODEN: AAAEFJ; ISSN: 1232-1966  
PB Institute of Agricultural Medicine  
DT Journal  
LA English  
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:572588 CAPLUS  
DN 142:151719  
TI Sequence-based identification of aerobic actinomycetes  
AU Patel, Jean Baldus; Wallace, Richard J., Jr.; Brown-Elliott, Barbara A.;  
Taylor, Tony; Imperatrice, Carol; Leonard, Deborah G. B.; Wilson, Rebecca  
W.; Mann, Linda; Jost, Kenneth C.; Nachamkin, Irving  
CS Department of Pathology and Laboratory Medicine, University of  
Pennsylvania, Philadelphia, PA, USA  
SO Journal of Clinical Microbiology (2004), 42(6), 2530-2540  
CODEN: JCMIDW; ISSN: 0095-1137  
PB American Society for Microbiology  
DT Journal  
LA English  
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 1  
AN 2005:78936 BIOSIS  
DN PREV200500079591  
TI Identification of a cation-specific channel (tipA) in the cell wall of the  
Gram-positive mycolata *Tsukamurella incheonensis*: the  
gene of the channel-forming protein is identical to mspA of *Mycobacterium*  
*smegmatis* and mppA of *Mycobacterium phlei*.  
AU Doerner, Ursula; Maier, Elke; Benz, Roland [Reprint Author]  
CS BiozentrumLehrstuhl, Univ Wurzburg, Am Hubland, D-97074, Wurzburg, Germany

roland.benz@mail.uni-wuerzburg.de  
SO Biochimica et Biophysica Acta, (November 17 2004) Vol. 1667, No. 1, pp. 47-55. print.  
ISSN: 0006-3002 (ISSN print).  
DT Article  
LA English  
ED Entered STN: 23 Feb 2005  
Last Updated on STN: 23 Feb 2005

L2 ANSWER 8 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN  
AN 2004471837 EMBASE  
TI Identification of a cation-specific channel (TipA) in the cell wall of the gram-positive mycolata *Tsukamurella inchoensis*: The gene of the channel-forming protein is identical to mspA of *Mycobacterium smegmatis* and mppA of *Mycobacterium phlei*.  
AU Dorner U.; Maier E.; Benz R.  
CS roland.benz@mail.uni-wuerzburg.de  
SO Biochimica et Biophysica Acta - Biomembranes, (17 Nov 2004) Vol. 1667, No. 1, pp. 47-55. .  
Refs: 52  
ISSN: 0005-2736 CODEN: BBBMBS  
PUI S 0005-2736(04)00213-5  
CY Netherlands  
DT Journal; Article  
FS 004 Microbiology  
LA English  
SL English  
ED Entered STN: 2 Dec 2004  
Last Updated on STN: 2 Dec 2004

L2 ANSWER 9 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 2003:253822 BIOSIS  
DN PREV200300253822  
TI *Tsukamurella* ssp.  
AU St. Georgiev, Vasil [Reprint Author]  
CS National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA  
SO St. Georgiev, Vassil [Reprint Author]. (2003) pp. 79-80. Opportunistic infections: Treatment and prophylaxis. print.  
Publisher: Humana Press Inc., 999 Riverview Drive, Suite 208, Totowa, NJ, 07512, USA. Series: Infectious Disease.  
ISBN: 1-58829-009-3 (cloth).  
DT Book; (Book Chapter)  
LA English  
ED Entered STN: 28 May 2003  
Last Updated on STN: 30 Jun 2003

L2 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:321875 CAPLUS  
DN 139:196955  
TI Microbial communities in black crusts: an approach for assessing carbon utilization  
AU Gonzalez-del Valle, M.; Dorronsoro, C.; Irastorza, A.; Duenas, M.; Velasco, S.; Ibarburu, I.; Saiz-Jimenez, C.  
CS Instituto de Recursos Naturales y Agrobiologia, CSIC, Seville, Spain  
SO Molecular Biology and Cultural Heritage, Proceedings of the International Congress on Molecular Biology and Cultural Heritage, Sevilla, Spain, Mar. 4-7, 2003 (2003), 219-223. Editor(s): Saiz-Jimenez, Cesareo. Publisher: A. A. Balkema, Rotterdam, Neth.  
CODEN: 69DURR; ISBN: 90-5809-555-X  
DT Conference  
LA English  
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
 AN 2003:854640 CAPLUS  
 DN 140:160225  
 TI Culture and identification of bacteria from marine biofilms  
 AU Lee, Yoo Kyung; Kwon, Kae-Kyung; Cho, Kyeong Hee; Kim, Hyo Won; Park, Jae Hyun; Lee, Hong Kum  
 CS Microbiology Laboratory, Korea Ocean Research and Development Institute, Ansan, 425-600, S. Korea  
 SO Journal of Microbiology (Seoul, Republic of Korea) (2003), 41(3), 183-188  
 CODEN: JOMIFG; ISSN: 1225-8873  
 PB Microbiological Society of Korea  
 DT Journal  
 LA English  
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 21 USPATFULL on STN  
 AN 2002:92290 USPATFULL  
 TI BIODEGRADATION OF ETHERS USING A BACTERIAL CULTURE  
 IN SALANITRO, JOSEPH PATRICK, HOUSTON, TX, UNITED STATES  
 PI US 2002048808 A1 20020425  
 AI US 1999-438595 A1 19991112 (9)  
 RLI Continuation-in-part of Ser. No. US 1999-292037, filed on 14 Apr 1999, GRANTED, Pat. No. US 6238906 Continuation-in-part of Ser. No. US 1995-465996, filed on 6 Jun 1995, GRANTED, Pat. No. US 5750364  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1354  
 INCL INCLM: 435/262.500  
 INCLS: 210/262.000  
 NCL NCLM: 435/262.500  
 NCLS: 210/262.000  
 IC [7]  
 ICM C12P039-00  
 ICS C12S001-00; B09B003-00; C02F009-00  
 IPCI C12P0039-00 [ICM,7]; C12S0001-00 [ICS,7]; B09B0003-00 [ICS,7]; C02F0009-00 [ICS,7]  
 IPCR A62D0003-00 [I,A]; A62D0003-00 [I,C\*]; B09C0001-10 [I,A]; B09C0001-10 [I,C\*]; C12N0001-20 [I,A]; C12N0001-20 [I,C\*]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 21 USPATFULL on STN  
 AN 2002:69816 USPATFULL  
 TI Bacterial culture which degrades methyl-tert-butyl ether to carbon dioxide  
 IN Salanitro, Joseph Patrick, Houston, TX, United States  
 PA Shell Oil Company, Houston, TX, United States (U.S. corporation)  
 PI US 6365397 B1 20020402  
 AI US 1999-439905 19991112 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1038  
 INCL INCLM: 435/262.500  
 INCLS: 435/252.100; 435/821.000; 435/822.000; 210/600.000; 210/601.000  
 NCL NCLM: 435/262.500  
 NCLS: 210/600.000; 210/601.000; 435/252.100; 435/821.000; 435/822.000  
 IC [7]  
 ICM B09B003-00  
 ICS C12N001-12; C12N001-20  
 IPCI B09B0003-00 [ICM,7]; C12N0001-12 [ICS,7]; C12N0001-20 [ICS,7]  
 IPCR A62D0003-00 [I,A]; A62D0003-00 [I,C\*]; B09C0001-10 [I,A]; B09C0001-10 [I,C\*]; C12N0001-20 [I,A]; C12N0001-20 [I,C\*]

EXF 435/252.1; 435/821; 435/822; 435/262.5; 210/600; 210/601  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 4  
AN 2001:287828 BIOSIS  
DN PREV200100287828  
TI *Tsukamurella strandjordae* sp. nov., a proposed new species causing sepsis.  
AU Kattar, Mireille M.; Cookson, Brad T.; Carlson, LaDonna C.; Stiglich,  
Susan K.; Schwartz, Margot A.; Nguyen, Trang T.; Daza, Riza; Wallis,  
Carolyn K.; Yarfitz, Stuart L.; Coyle, Marie B. [Reprint author]  
CS Department of Laboratory Medicine, Harborview Medical Center, 325 Ninth  
Ave., Seattle, WA, 98104, USA  
mbcoyle@u.washington.edu  
SO Journal of Clinical Microbiology, (April, 2001) Vol. 39, No. 4, pp.  
1467-1476. print.  
CODEN: JCMIDW. ISSN: 0095-1137.  
DT Article  
LA English  
ED Entered STN: 13 Jun 2001  
Last Updated on STN: 19 Feb 2002

L2 ANSWER 15 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 2002:155911 BIOSIS  
DN PREV200200155911  
TI Infections due to aerobic Actinomycetes in Germany between 1991 and 2000.  
Report from the national reference laboratory for pathogenic  
actinomycetes.  
AU Horre, R. [Reprint author]; Schumacher, G.; Yassin, A. F.; Schaal, K. P.  
CS Institute for Medical Microbiology and Immunology, University of Bonn,  
Sigmund-Freud-Str. 25, 53105, Bonn, Germany  
regine.horre@gmx.de  
SO Mycoses, (2001) Vol. 44, No. Supplement 1, pp. 32-33. print.  
Meeting Info.: 7th Congress of the European Confederation of Medical  
Mycology - ECMM. Rhodes, Greece. June 16-19, 2001. European Confederation  
of Medical Mycology.  
CODEN: MYCSEU. ISSN: 0933-7407.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 21 Feb 2002  
Last Updated on STN: 26 Feb 2002

L2 ANSWER 16 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 5  
AN 1997:304694 BIOSIS  
DN PREV199799612497  
TI *Tsukamurella incheonensis* bacteremia in a patient who  
ingested hydrochloric acid.  
AU Chong, Yunsop [Reprint author]; Lee, Kyungwon; Chon, Chae Yoon; Kim, Mun  
Jeong; Kwon, Oh Hun; Lee, Hee Joo  
CS Dep. Clinical Pathol., Yonsei Univ. Coll. Med., C.P.O. Box 8044, Seoul,  
South Korea  
SO Clinical Infectious Diseases, (1997) Vol. 24, No. 6, pp. 1267-1268.  
CODEN: CIDIEL. ISSN: 1058-4838.  
DT Article  
LA English  
ED Entered STN: 26 Jul 1997  
Last Updated on STN: 26 Jul 1997

L2 ANSWER 17 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 1998:115428 BIOSIS

DN PREV199800115428  
 TI Identification of *Rhodococcus*, *Gordona* and *Dietzia* species using carbon source utilization tests ("Biotype-100" strips).  
 AU Bizet, C. [Reprint author]; Barreau, C.; Harmant, C.; Nowakowski, M.; Pietfroid, A.  
 CS Collection des Bacteries l'Institut Pasteur, Inst. Pasteur, 75724 Paris Cedex 15, France  
 SO Research in Microbiology, (Dec., 1997) Vol. 148, No. 9, pp. 799-809. print.  
 CODEN: RMCREW. ISSN: 0923-2508.  
 DT Article  
 LA English  
 ED Entered STN: 5 Mar 1998  
 Last Updated on STN: 5 Mar 1998

L2 ANSWER 18 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 6  
 AN 1997:361009 BIOSIS  
 DN PREV199799652942  
 TI *Tsukamurella tyrosinosolvens* sp. nov.  
 AU Yassin, A. F. [Reprint author]; Rainey, F. A.; Burghardt, J.; Brzezinka, H.; Schmitt, S.; Seifert, P.; Zimmermann, O.; Mauch, H.; Gierth, D.; Lux, I.; Schaal, K. P.  
 CS Inst. Med. Mikrobiol. Immunol. Univ. Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany  
 SO International Journal of Systematic Bacteriology, (1997) Vol. 47, No. 3, pp. 607-614.  
 CODEN: IJSBA8. ISSN: 0020-7713.  
 DT Article  
 LA English  
 ED Entered STN: 25 Aug 1997  
 Last Updated on STN: 25 Aug 1997

L2 ANSWER 19 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 7  
 AN 1996:262195 BIOSIS  
 DN PREV199698818324  
 TI *Tsukamurella pulmonis* sp. nov.  
 AU Yassin, A. F. [Reprint author]; Rainey, F. A.; Brzezinka, H.; Burghardt, J.; Rifai, M.; Seifert, P.; Feldmann, K.; Schaal, K. P.  
 CS Institut fuer Medizinische Mikrobiologie und Immunologie der Universitaet Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany  
 SO International Journal of Systematic Bacteriology, (1996) Vol. 46, No. 2, pp. 429-436.  
 CODEN: IJSBA8. ISSN: 0020-7713.  
 DT Article  
 LA English  
 ED Entered STN: 10 Jun 1996  
 Last Updated on STN: 10 Jun 1996

L2 ANSWER 20 OF 21 LIFESCI COPYRIGHT 2006 CSA on STN  
 AN 1998:75933 LIFESCI  
 TI Phylogeny of mycolic acid-containing actinomycetes  
 AU Chun, J.; Kang, S.-O.; Hah, Y.C.; Goodfellow, M.\*  
 CS Dep. Microbiol., Med. Sch., Framlington Place, Newcastle upon Tyne, NE2 4HH, UK  
 SO J. IND. MICROBIOL. BIOTECHNOL., (19961000) vol. 17, no. 3-4, pp. 205-213. Special Issue: Microbial Diversity..  
 ISSN: 0169-4146.  
 DT Journal  
 FS K; G  
 LA English  
 SL English



L2 ANSWER 21 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 8

AN 1995:355507 BIOSIS

DN PREV199598369807

TI Tsukamurella incheonensis sp. nov.

AU Yassin, A. F.; Rainey, R. A.; Brzezinka, H.; Burghardt, J.; Lee, H. J.;  
Schaal, K. P.

CS Inst. Medizinische Mikrobiologie und Immunologie der Univ. Bonn,  
Sigmund-Freud-Strasse 25, 53127 Bonn, Germany

SO International Journal of Systematic Bacteriology, (1995) Vol. 45, No. 3,  
pp. 522-527.

CODEN: IJSBA8. ISSN: 0020-7713.

DT Article

LA English

ED Entered STN: 30 Aug 1995  
Last Updated on STN: 30 Aug 1995

=> s gordonia bronchialis

L3 49 GORDONIA BRONCHIALIS

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 31 DUP REM L3 (18 DUPLICATES REMOVED)

=> d 1-

YOU HAVE REQUESTED DATA FROM 31 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 31 USPATFULL on STN

AN 2006:161503 USPATFULL

TI Process for the production of fine chemicals

IN Plesch, Gunnar, Potsdam, GERMANY, FEDERAL REPUBLIC OF

Puzio, Piotr, Berlin, GERMANY, FEDERAL REPUBLIC OF

Blau, Astrid, Stahnsdorf, GERMANY, FEDERAL REPUBLIC OF

Looser, Ralf, Berlin, GERMANY, FEDERAL REPUBLIC OF

Wendel, Birgit, Berlin, GERMANY, FEDERAL REPUBLIC OF

Kamlage, Beate, Berlin, GERMANY, FEDERAL REPUBLIC OF

Chardonens, Agnes, Berlin, GERMANY, FEDERAL REPUBLIC OF

Shirley, Amber, Wake Forest, NC, UNITED STATES

Wang, Xi-Qing, Chapel Hill, NC, UNITED STATES

Sarria-Millan, Rodrigo, Morrisville, NC, UNITED STATES

McKersie, Bryan, Cary, NC, UNITED STATES

Chen, Ruoying, Apex, NC, UNITED STATES

PA BASF Plant Science GmbH, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF,  
67056 (non-U.S. corporation)

PI US 2006137042 A1 20060622

AI US 2004-566644 A1 20040721 (10)

WO 2004-EP8136 20040721

20060222 PCT 371 date

RLI Continuation-in-part of Ser. No. WO 2003-US11887, filed on 15 Apr 2004,  
PENDING

PRAI EP 2003-16672 20030801

EP 2004-3008079 20040415

EP 2003-16671 20030801

EP 2003-22226 20030930

DT Utility

FS APPLICATION

LN.CNT 10211

INCL INCLM: 800/288.000

INCLS: 435/419.000; 435/468.000

NCL NCLM: 800/288.000

NCLS: 435/419.000; 435/468.000

IC IPCI A01H0001-00 [I,A]; C12N0015-82 [I,A]; C12N0005-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 31 USPATFULL on STN  
 AN 2006:158606 USPATFULL  
 TI Whole bacterial cells as immune modulator  
 IN McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
 PI US 2006134136 A1 20060622  
 AI US 2003-526228 A1 20030905 (10)  
 WO 2003-GB3873 20030905  
 20051116 PCT 371 date  
 PRAI GB 2002-20809 20020906  
 GB 2003-17144 20030722  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2607  
 INCL INCLM: 424/203.100  
 INCLS: 424/093.400  
 NCL NCLM: 424/203.100  
 NCLS: 424/093.400  
 IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L4 ANSWER 3 OF 31 USPATFULL on STN  
 AN 2006:53945 USPATFULL  
 TI Genus, group, species and/or strain specific 16S rDNA sequences  
 IN Zeng, Qiandong, Belmont, MA, UNITED STATES  
 Chatellier, Sonia, Amberieu, FRANCE  
 Moir, Donald T., Lexington, MA, UNITED STATES  
 LaCroix, Bruno, Saint Genis-Laval, FRANCE  
 Childress, Darrell, Auburn, AL, UNITED STATES  
 PI US 2006046246 A1 20060302  
 AI US 2004-831286 A1 20040426 (10)  
 PRAI US 2003-464955P 20030424 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 5603  
 INCL INCLM: 435/005.000  
 INCLS: 435/287.200; 435/006.000  
 NCL NCLM: 435/005.000  
 NCLS: 435/006.000; 435/287.200  
 IC IPCI C12Q0001-70 [I,A]; C12M0001-34 [I,A]; C12Q0001-68 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 31 USPATFULL on STN  
 AN 2006:15452 USPATFULL  
 TI Vaccine  
 IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
 McIntyre, Graham, Kent, UNITED KINGDOM  
 Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
 Stanford, John Lawson, Kent, UNITED KINGDOM  
 PI US 2006013830 A1 20060119  
 AI US 2004-893524 A1 20040719 (10)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 720  
 INCL INCLM: 424/203.100  
 NCL NCLM: 424/203.100  
 IC IPCI A61K0039-116 [I,A]

L4 ANSWER 5 OF 31 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 DUPLICATE 1  
 AN 2006:265542 BIOSIS  
 DN PREV200600265890

TI Proposal of a method for the genetic transformation of *Gordonia jacobaea*.  
 AU Veiga-Crespo, P.; Feijoo-Siota, L.; de Miguel, T.; Poza, M.; Villa, T. G.  
 [Reprint Author]  
 CS Univ Santiago Compostela, Fac Pharm, Dept Microbiol, Campus Sur, Santiago  
 15782, Spain  
 mpvilla@usc.es  
 SO Journal of Applied Microbiology, (MAR 2006) Vol. 100, No. 3, pp. 608-614.  
 ISSN: 1364-5072.  
 DT Article  
 LA English  
 ED Entered STN: 10 May 2006  
 Last Updated on STN: 10 May 2006

L4 ANSWER 6 OF 31 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 DUPLICATE 2  
 AN 2006:214765 BIOSIS  
 DN PREV200600207110  
 TI Identification of a lipoarabinomannan-like lipoglycan in the actinomycete  
*Gordonia bronchialis*.  
 AU Garton, Natalie J.; Sutcliffe, Iain C. [Reprint Author]  
 CS Northumbria Univ, Sch Appl Sci, Div Biomed Sci, Newcastle Upon Tyne NE1  
 8ST, Tyne and Wear, UK  
 iain.sutcliffe@unn.ac.uk  
 SO Archives of Microbiology, (FEB 2006) Vol. 184, No. 6, pp. 425-427.  
 CODEN: AMICCW. ISSN: 0302-8933.  
 DT Article  
 LA English  
 ED Entered STN: 29 Mar 2006  
 Last Updated on STN: 29 Mar 2006

L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:671944 CAPLUS  
 TI Transvalencin Z, a new antimicrobial compound with salicylic acid residue  
 from *Nocardia transvalensis* IFM 10065  
 AU Mukai, Akira; Fukai, Toshio; Matsumoto, Yuko; Ishikawa, Jun; Hoshino,  
 Yasutaka; Yazawa, Katsukiyo; Harada, Ken-ichi; Mikami, Yuzuru  
 CS Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba  
 University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8673, Japan  
 SO Journal of Antibiotics (2006), 59(6), 366-369  
 CODEN: JANTAJ; ISSN: 0021-8820  
 PB Japan Antibiotics Research Association  
 DT Journal  
 LA English

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 31 USPATFULL on STN  
 AN 2005:318396 USPATFULL  
 TI Rapid identification of *Nocardia farcinica*  
 IN Lasker, Brent A., Atlanta, GA, UNITED STATES  
 Brown, June M., Decatur, GA, UNITED STATES  
 PI US 2005277136 A1 20051215  
 AI US 2005-100338 A1 20050406 (11)  
 PRAI US 2004-560867P 20040409 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1976  
 INCL INCLM: 435/006.000  
 INCLS: 536/023.700  
 NCL NCLM: 435/006.000  
 NCLS: 536/023.700  
 IC [7]  
 ICM C12Q001-68  
 ICS C07H021-04

IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 31 USPATFULL on STN  
AN 2005:236091 USPATFULL  
TI Process for producing HMG-CoA reductase inhibitors  
IN Hashimoto, Shin-ichi, Hofu, JAPAN  
Yonetani, Yoshiyuki, Machida, JAPAN  
Ozaki, Akio, Hofu, JAPAN  
PA Kyowa Hakko Kogyo Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)  
PI US 6946270 B1 20050920  
WO 2000043533 20000727  
AI US 2001-868924 20000120 (9)  
WO 2000-JP245 20000120  
20011031 PCT 371 date  
PRAI JP 1999-12392 19990120  
DT Utility  
FS GRANTED  
LN.CNT 719  
INCL INCLM: 435/125.000  
INCLS: 435/136.000; 435/146.000; 435/155.000; 435/132.000  
NCL NCLM: 435/125.000  
NCLS: 435/132.000; 435/136.000; 435/146.000; 435/155.000  
IC [7]  
ICM C12P017-06  
IPCI C12P0017-06 [ICM,7]; C12P0017-02 [ICM,7,C\*]  
IPCR C12P0007-62 [I,A]; C12P0007-62 [I,C\*]; C12P0017-02 [I,C\*];  
C12P0017-06 [I,A]  
EXF 435/125; 435/136; 435/146; 435/155; 435/132  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 31 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 3  
AN 2005269614 EMBASE  
TI Recurrent breast abscess caused by *Gordonia bronchialis* in an immunocompetent patient.  
AU Werno A.M.; Anderson T.P.; Chambers S.T.; Laird H.M.; Murdoch D.R.  
CS D.R. Murdoch, Canterbury Health Laboratories, P.O. Box 151, Christchurch, New Zealand. david.murdoch@cdhb.govt.nz  
SO Journal of Clinical Microbiology, (2005) Vol. 43, No. 6, pp. 3009-3010. .  
Refs: 13  
ISSN: 0095-1137 CODEN: JCMIDW  
CY United States  
DT Journal; Article  
FS 004 Microbiology  
037 Drug Literature Index  
LA English  
SL English  
ED Entered STN: 7 Jul 2005  
Last Updated on STN: 7 Jul 2005

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:9599 CAPLUS  
TI Characterization and Culture on Sugarcane Molasses of *Gordonia Polyisoprenivorans* CCT 7137, a New Strain Isolated from Contaminated Groundwater in Brazil  
AU Fusconi, Roberta; Godinho, Mirna Januaria Leal; Bossolan, Nelma Regina Segnini  
CS Departamento de Ecologia e Biologia Evolutiva, Universidade Federal de Sao Carlos, Sao Carlos, 13565-905, Brazil  
SO World Journal of Microbiology & Biotechnology (2005), 21(8-9), 1425-1431  
CODEN: WJMBEY; ISSN: 0959-3993  
PB Springer  
DT Journal

LA English

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 31 MEDLINE on STN

AN 2006015372 MEDLINE

DN PubMed ID: 16400987

TI Isolation and comparative analysis of glycolipid fractions in  
bifidobacteria.

AU Novik G I; Astapovich N I; Grzegorzewicz A; Gamian A

SO Mikrobiologiya, (2005 Nov-Dec) Vol. 74, No. 6, pp. 772-80.

Journal code: 0376652. ISSN: 0026-3656.

CY Russia (Federation)

DT Journal; Article; (JOURNAL ARTICLE)

LA Russian

FS Priority Journals

EM 200602

ED Entered STN: 11 Jan 2006

Last Updated on STN: 9 Feb 2006

Entered Medline: 8 Feb 2006

L4 ANSWER 13 OF 31 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 4

AN 2006:152104 BIOSIS

DN PREV200600152147

TI Isolation and comparative analysis of glycolipid fractions in  
bifidobacteria.

AU Novik, G. I. [Reprint Author]; Astapovich, N. I.; Grzegorzewicz, A.;  
Gam'yan, A.

CS Natl Acad Sci Belarus, Inst Microbiol, Minsk, Byelarus  
biochem\_lab@mbio.bas-net.by

SO MICROBIOLOGY, (NOV-DEC 2005) Vol. 74, No. 6, pp. 670-677.

CODEN: MIBLAO. ISSN: 0026-2617.

DT Article

LA English

ED Entered STN: 1 Mar 2006

Last Updated on STN: 1 Mar 2006

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:515680 CAPLUS

DN 141:52961

TI Protein fraction of barley spent grains as a medium for growth,  
sporulation and selection of Actinomycetes and related bacteria

IN Gamian, Andrzej; Pawlik, Krzysztof; Szponar, Bogumila; Szwajcer-Dey,  
Esteria

PA Pol.

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053108	A1	20040624	WO 2003-PL142	20031211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
	UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2003295294	A1	20040630	AU 2003-295294	20031211
PRAI PL 2002-357694	A	20021211		
WO 2003-PL142	W	20031211		

L4 ANSWER 15 OF 31 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 5

AN 2004251507 EMBASE

TI Bacteremia caused by *Gordonia bronchialis* in a patient with sequestrated lung.

AU Sng L.-H.; Koh T.H.; Toney S.R.; Floyd M.; Butler W.R.; Tan B.H.

CS L.-H. Sng, Department of Pathology, Singapore General Hospital, 1 Hospital Dr., 169608 Singapore, Singapore. gptslh@sgh.com.sg

SO Journal of Clinical Microbiology, (2004) Vol. 42, No. 6, pp. 2870-2871. .

Refs: 12

ISSN: 0095-1137 CODEN: JCMIDW

CY United States

DT Journal; Article

FS 004 Microbiology

015 Chest Diseases, Thoracic Surgery and Tuberculosis

037 Drug Literature Index

LA English

SL English

ED Entered STN: 15 Jul 2004

Last Updated on STN: 15 Jul 2004

L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:572588 CAPLUS

DN 142:151719

TI Sequence-based identification of aerobic actinomycetes

AU Patel, Jean Baldus; Wallace, Richard J., Jr.; Brown-Elliott, Barbara A.; Taylor, Tony; Imperatrice, Carol; Leonard, Deborah G. B.; Wilson, Rebecca W.; Mann, Linda; Jost, Kenneth C.; Nachamkin, Irving

CS Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

SO Journal of Clinical Microbiology (2004), 42(6), 2530-2540

CODEN: JCMIDW; ISSN: 0095-1137

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:912849 CAPLUS

DN 139:374985

TI Therapeutic compositions using androstane amides effective against Gram-positive bacteria

IN Pettit, George R.; Pettit, Robin K.

PA USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2003216361	A1	20031120	US 2001-893861	20010628
PRAI	US 2000-214844P	P	20000628		
OS	MARPAT 139:374985				

L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:785254 CAPLUS

DN 140:3790

TI Preparation of allergen from genus *Rhodococcus* and use thereof in

diagnosis of rhodococcal infection  
 IN Nuratinov, R. A.; Urguev, K. R.; Ovdienko, N. P.; Naimanov, A. Kh.;  
 Verdieva, E. A.  
 PA Prikaspiiskii Zonal'nyi Nauchno-Issledovatel'skii Veterinarnyi Institut,  
 Russia  
 SO Russ., No pp. given  
 CODEN: RUXXE7  
 DT Patent  
 LA Russian  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	RU 2209636	C2	20030810	RU 1998-121993	19981203
PRAI	RU 1998-121993		19981203		

L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:266871 CAPLUS  
 DN 138:270410  
 TI Optically active 2-methyl-1,3-propanediol monoester manufacture with  
 microorganism by enzymic resolution  
 IN Sato, Eiji; Nakamura, Tetsuji  
 PA Mitsubishi Rayon Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2003102493	A2	20030408	JP 2001-297239	20010927
PRAI	JP 2001-297239		20010927		
OS	MARPAT 138:270410				

L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:210115 CAPLUS  
 DN 138:220460  
 TI Enzymic manufacture of optically active trifluoromethyl lactic acid  
 IN Sato, Eiji  
 PA Mitsubishi Rayon Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 13 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2003079392	A2	20030318	JP 2001-274014	20010910
PRAI	JP 2001-274014		20010910		

L4 ANSWER 21 OF 31 USPATFULL on STN  
 AN 2003:100082 USPATFULL  
 TI Novel macrolide compound jk  
 IN Tanaka, Yasushi, Chiba-ken, JAPAN  
 Komaki, Hisayuki, Chiba-ken, JAPAN  
 Nemoto, Akira, Ibaragi-ken, JAPAN  
 Yazawa, Katsukiyo, Chiba-ken, JAPAN  
 Mikami, Yuzuru, Chiba-ken, JAPAN  
 PI US 2003069193 A1 20030410  
 US 6693085 B2 20040217  
 AI US 2001-926403 A1 20011026 (9)  
 WO 2001-JP1363 20010223  
 PRAI JP 2000-56538 20000301  
 DT Utility  
 FS APPLICATION

LN.CNT 626

INCL INCLM: 514/028.000

INCLS: 536/007.100

NCL NCLM: 514/027.000; 514/028.000

NCLS: 514/033.000; 536/004.100; 536/016.800; 536/016.900; 536/017.200;  
536/018.100; 536/018.200; 536/018.400; 536/018.500; 536/029.100;  
536/007.100

IC [7]

ICM A61K031-7048

ICS C07H017-08

IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C\*]; C07H0017-08  
[ICS,7]; C07H0017-00 [ICS,7,C\*]

IPCI-2 A01N0043-04 [ICM,7]; A01N0043-02 [ICM,7,C\*]; A61K0031-70 [ICS,7];  
C07H0015-00 [ICS,7]; C07H0017-00 [ICS,7]; C07H0017-02 [ICS,7];  
C07H0017-00 [ICS,7,C\*]

IPCR C07H0017-00 [I,C\*]; C07H0017-08 [I,A]; C12P0019-00 [I,C\*];  
C12P0019-60 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:772914 CAPLUS

DN 140:107594

TI Protein fraction of barley spent grain as a new simple medium for growth  
and sporulation of soil actinobacteria

AU Szponar, Bogumila; Pawlik, Krzysztof J.; Gamian, Andrzej; Dey, Estera  
Szwajcer

CS Institute of Immunology and Experimental Therapy, Polish Academy of  
Sciences, Wroclaw, 53-114, Pol.

SO Biotechnology Letters (2003), 25(20), 1717-1721

CODEN: BILED3; ISSN: 0141-5492

PB Kluwer Academic Publishers

DT Journal

LA English

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 31 CABA COPYRIGHT 2006 CABI on STN DUPLICATE 6

AN 2003:90350 CABA

DN 20033060619

TI Pathogenic Nocardia, Rhodococcus, and related organisms are highly  
susceptible to imidazole antifungals

AU Dabbs, E. R.; Naidoo, S.; Lephoto, C.; Nikitina, N.

CS School of Molecular and Cell Biology, University of the Witwatersrand,  
Johannesburg, P O WITS 2050, South Africa. dabbse@gecko.biol.wits.ac.za

SO Antimicrobial Agents and Chemotherapy, (2003) Vol. 47, No. 4, pp.  
1476-1478. 26 ref.

Publisher: American Society for Microbiology (ASM). Washington  
ISSN: 0066-4804

CY United States

DT Journal

LA English

ED Entered STN: 6 Jun 2003

Last Updated on STN: 6 Jun 2003

L4 ANSWER 24 OF 31 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 2003:568966 BIOSIS

DN PREV200300567922

TI Novel Gordonia species isolated from patients with acute  
community-acquired pneumopathy.

AU de Briel, D. A. [Reprint Author]; Riegel, P.; Parisi, E. [Reprint Author];  
Exinger, J. [Reprint Author]; Grawey, I. [Reprint Author]; Heller, R.  
[Reprint Author]

CS Lab. de Microbiologie, Hopital Louis Pasteur, Colmar, France



SO Abstracts of the Interscience Conference on Antimicrobial Agents and  
Chemotherapy, (2003) Vol. 43, pp. 424. print.  
Meeting Info.: 43rd Annual Interscience Conference on Antimicrobial Agents  
and Chemotherapy. Chicago, IL, USA. September 14-17, 2003. American  
Society for Microbiology.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
OS DDBJ-AY288507; EMBL-AY288507; GenBank-AY288507  
ED Entered STN: 3 Dec 2003  
Last Updated on STN: 3 Dec 2003

L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:15283 CAPLUS  
DN 138:225861  
TI Fighting foam with phages?  
AU Thomas, J. A.; Soddell, J. A.; Kurtboke, D. I.  
CS Biotechnology Research Centre, La Trobe University, Bendigo, 3550,  
Australia  
SO Water Science and Technology (2002), 46(1/2), 511-518  
CODEN: WSTED4; ISSN: 0273-1223  
PB IWA Publishing  
DT Journal  
LA English  
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2000:513821 CAPLUS  
DN 133:103812  
TI Process for producing HMG-CoA reductase inhibitors  
IN Hashimoto, Shin-ichi; Yonetani, Yoshiyuki; Ozaki, Akio  
PA Kyowa Hakko Kogyo Co., Ltd., Japan  
SO PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043533	A1	20000727	WO 2000-JP245	20000120
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358927	AA	20000727	CA 2000-2358927	20000120
EP 1146126	A1	20011017	EP 2000-900832	20000120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6946270	B1	20050920	US 2001-868924	20011031
PRAI JP 1999-12392	A	19990120		
WO 2000-JP245	W	20000120		

OS MARPAT 133:103812  
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1998:806036 CAPLUS  
DN 130:137568

TI Wax D of Mycobacterium tuberculosis induced osteomyelitis accompanied by reactive bone formation in Buffalo rats  
 AU Kawabata, Yoshihiro; Semba, Ichiro; Hirayama, Yoshikazu; Koga, Toshitaka; Nagao, Shigeki; Takada, Haruhiko  
 CS Department of Microbiology and Immunology, Kagoshima University Dental School, Kagoshima, 890-8544, Japan  
 SO FEMS Immunology and Medical Microbiology (1998), 22(4), 293-302  
 CODEN: FIMIEV; ISSN: 0928-8244  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:414009 CAPLUS  
 DN 127:31495  
 TI New microorganism, its isolation, and apparatus for degradation of organic compounds  
 IN Ikeda, Michio; Imamura, Yuko; Hirakawa, Chikako  
 PA Kabushiki Kaisha Toshiba, Japan  
 SO Ger. Offen., 44 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19647847	A1	19970522	DE 1996-19647847	19961119
	JP 09201581	A2	19970805	JP 1996-309719	19961120
	US 5919696	A	19990706	US 1996-749355	19961120
PRAI	JP 1995-301200	A	19951120		

L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:232848 CAPLUS  
 DN 126:288637  
 TI Rapid identification of clinically significant species and taxa of aerobic actinomycetes, including Actinomadura, Gordona, Nocardia, Rhodococcus, Streptomyces and Tsukamurella isolates, by DNA amplification and restriction endonuclease analysis  
 AU Steingrube, Vincent A.; Wilson, Rebecca W.; Brown, Barbara A.; Jost, Kenneth C., Jr.; Blacklock, Zeta; Gibson, Jeremy L.; Wallace, Richard J., Jr.  
 CS Department of Microbiology University of Texas Health Center at Tyler, Tyler, TX, 75710-2003, USA  
 SO Journal of Clinical Microbiology (1997), 35(4), 817-822  
 CODEN: JCMIDW; ISSN: 0095-1137  
 PB American Society for Microbiology  
 DT Journal  
 LA English

L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:93547 CAPLUS  
 DN 128:202684  
 TI Identification of Rhodococcus, Gordona and Dietzia species using carbon source utilization tests ("Biotype-100" strips)  
 AU Bizet, C.; Barreau, C.; Harmant, C.; Nowakowski, M.; Pietfroid, A.  
 CS Collection des Bacteries de l'Institut Pasteur (CIP), Institut Pasteur, Paris, 75724, Fr.  
 SO Research in Microbiology (1997), 148(9), 799-809  
 CODEN: RMCREW; ISSN: 0923-2508  
 PB Editions Scientifiques et Medicales Elsevier  
 DT Journal  
 LA English

RE.CNT 28      THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 31 OF 31    CAPLUS    COPYRIGHT 2006 ACS on STN  
AN    1997:606561    CAPLUS  
DN    127:277216  
TI    Improvement of lysine production by analog-sensitive and auxotroph mutants  
of the acetylene-utilizing bacterium *Gordona bronchialis* (*Rhodococcus*  
*bronchialis*)  
AU    Kyriacou, Adamantini; Balis, Costas; Typas, Milton A.  
CS    Lab. Gen. Agric. Microbiol., Dep. Agric. Biol. Biotechnol., Athens, 11855,  
Greece  
SO    Applied Biochemistry and Biotechnology (1997), 66(3), 281-289  
CODEN: ABIBDL; ISSN: 0273-2289  
PB    Humana  
DT    Journal  
LA    English

RE.CNT 29      THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s dietza maris  
L5                  6 DIETZA MARIS

=> dup rem l5  
PROCESSING COMPLETED FOR L5  
L6                  3 DUP REM L5 (3 DUPLICATES REMOVED)

=> d 1-  
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L6    ANSWER 1 OF 3    USPATFULL on STN  
AN    2006:158606    USPATFULL  
TI    Whole bacterial cells as immune modulator  
IN    McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI    US 2006134136      A1    20060622  
AI    US 2003-526228      A1    20030905 (10)  
WO 2003-GB3873      20030905  
20051116    PCT 371 date  
PRAI    GB 2002-20809      20020906  
GB 2003-17144      20030722  
DT    Utility  
FS    APPLICATION  
LN.CNT 2607  
INCL    INCLM: 424/203.100  
INCLS: 424/093.400  
NCL    NCLM: 424/203.100  
NCLS: 424/093.400  
IC    IPCI    A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L6    ANSWER 2 OF 3    EMBASE    COPYRIGHT (c) 2006 Elsevier B.V. All rights  
reserved on STN  
AN    2006349734    EMBASE  
TI    *Dietzia kunjamensis* sp. nov., isolated from the Indian Himalayas.  
AU    Mayilraj S.; Suresh K.; Kroppenstedt R.M.; Saini H.S.  
CS    S. Mayilraj, Microbial Type Culture Collection and Gene Bank (MTCC),  
Institute of Microbial Technology, Sector 39-A, Chandigarh 160 036, India.  
mayil@imtech.res.in  
SO    International Journal of Systematic and Evolutionary Microbiology, (2006)  
Vol. 56, No. 7, pp. 1667-1671. .  
Refs: 20

ISSN: 1466-5026 CODEN: ISEMF5  
CY United Kingdom  
DT Journal; Article  
FS 004 Microbiology  
LA English  
SL English  
ED Entered STN: 10 Aug 2006  
Last Updated on STN: 10 Aug 2006

L6 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 1  
AN 2002:434260 BIOSIS  
DN PREV200200434260  
TI Diversity of the microflora of edible macroalga (Palmaria palmata).  
AU Moore, J. E. [Reprint author]; Xu, J.; Millar, B. C.  
CS Department of Bacteriology, Northern Ireland Public Health Laboratory,  
Belfast City Hospital, Belfast, BT9 7AD, UK  
jemooore@niph1.dnet.co.uk  
SO Food Microbiology (London), (April-June, 2002) Vol. 19, No. 2-3, pp.  
249-257. print.  
CODEN: FOMIE5. ISSN: 0740-0020.  
DT Article  
LA English  
ED Entered STN: 14 Aug 2002  
Last Updated on STN: 14 Aug 2002

=> s dietzia maris

L7 113 DIETZIA MARIS

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 59 DUP REM L7 (54 DUPLICATES REMOVED)

=> d 1-

YOU HAVE REQUESTED DATA FROM 59 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:430670 CAPLUS  
DN 145:102248  
TI Recombinant bacteria having pMMO (particulate methane monooxygenase)  
activity and its application  
IN Gou, Zhongxuan; Luo, Mingfang; Xing, Xinhui  
PA Tsinghua University, Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1763178	A	20060426	CN 2005-10098409	20050906
PRAI	CN 2005-10098409		20050906		

L8 ANSWER 2 OF 59 USPATFULL on STN  
AN 2006:158606 USPATFULL  
TI Whole bacterial cells as immune modulator  
IN McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Bottasso, Oscar Adelmo, Coronel Bogado, ARGENTINA  
PI US 2006134136 A1 20060622  
AI US 2003-526228 A1 20030905 (10)  
WO 2003-GB3873 20030905

20051116 PCT 371 date

PRAI GB 2002-20809 20020906  
GB 2003-17144 20030722  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 424/203.100  
INCLS: 424/093.400  
NCL NCLM: 424/203.100  
NCLS: 424/093.400  
IC IPCI A61K0039-116 [I,A]; A61K0035-74 [I,A]; A61K0035-66 [I,C\*]

L8 ANSWER 3 OF 59 USPATFULL on STN  
AN 2006:53945 USPATFULL  
TI Genus, group, species and/or strain specific 16S rDNA sequences  
IN Zeng, Qiangdong, Belmont, MA, UNITED STATES  
Chatellier, Sonia, Amberieu, FRANCE  
Moir, Donald T., Lexington, MA, UNITED STATES  
LaCroix, Bruno, Saint Genis-Laval, FRANCE  
Childress, Darrell, Auburn, AL, UNITED STATES  
PI US 2006046246 A1 20060302  
AI US 2004-831286 A1 20040426 (10)  
PRAI US 2003-464955P 20030424 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5603  
INCL INCLM: 435/005.000  
INCLS: 435/287.200; 435/006.000  
NCL NCLM: 435/005.000  
NCLS: 435/006.000; 435/287.200  
IC IPCI C12Q0001-70 [I,A]; C12M0001-34 [I,A]; C12Q0001-68 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 59 USPATFULL on STN  
AN 2006:15452 USPATFULL  
TI Vaccine  
IN Bottasso, Oscar Adelmo, Provincia de Santa Fe, ARGENTINA  
McIntyre, Graham, Kent, UNITED KINGDOM  
Stanford, Cynthia Ann, Kent, UNITED KINGDOM  
Stanford, John Lawson, Kent, UNITED KINGDOM  
PI US 2006013830 A1 20060119  
AI US 2004-893524 A1 20040719 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 720  
INCL INCLM: 424/203.100  
NCL NCLM: 424/203.100  
IC IPCI A61K0039-116 [I,A]

L8 ANSWER 5 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 1  
AN 2006:331370 BIOSIS  
DN PREV200600326659  
TI Novel BOD optical fiber biosensor based on co-immobilized microorganisms  
in ormosils matrix.  
AU Lin, Ling; Xiao, Lai-Long; Huang, Sha; Zhao, Li; Cui, Jian-Shen; Wang,  
Xiao-Hui; Chen, Xi [Reprint Author]  
CS Xiamen Univ, Dept Chem, Coll Chem and Chem Engn, Minist Educ, Xiamen  
361005, Peoples R China  
xichen@xmu.edu.cn  
SO Biosensors & Bioelectronics, (MAR 15 2006) Vol. 21, No. 9, pp. 1703-1709.  
CODEN: BBIOE4. ISSN: 0956-5663.  
DT Article  
LA English

ED Entered STN: 28 Jun 2006  
Last Updated on STN: 28 Jun 2006

L8 ANSWER 6 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 2  
AN 2006:435869 BIOSIS  
DN PREV200600430765  
TI *Dietzia kunjamensis* sp nov., isolated from the Indian Himalayas.  
AU Mayilraj, S. [Reprint Author]; Suresh, K.; Kroppenstedt, R. M.; Saini, H. S.  
CS Inst Microbial Technol, Microbial Type Culture Collect and Gene Bank, MTCC, Sector 39-A, Chandigarh 160036, India  
mayil@imtech.res.in  
SO International Journal of Systematic and Evolutionary Microbiology, (JUL 2006) Vol. 56, No. Part 7, pp. 1667-1671.  
ISSN: 1466-5026.  
DT Article  
LA English  
ED Entered STN: 30 Aug 2006  
Last Updated on STN: 30 Aug 2006

L8 ANSWER 7 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 3  
AN 2006:349918 BIOSIS  
DN PREV200600347198  
TI *Dietzia cinnamea* sp nov., a novel species isolated from a perianal swab of a patient with a bone marrow transplant.  
AU Yassin, A. F. [Reprint Author]; Hupfer, H.; Schaal, K. P.  
CS Univ Bonn, Inst Med Mikrobiol and Immunol, D-53127 Bonn, Germany  
yassin@mibi03.meb.uni-bonn.de  
SO International Journal of Systematic and Evolutionary Microbiology, (MAR 2006) Vol. 56, No. Part 3, pp. 641-645.  
ISSN: 1466-5026.  
DT Article  
LA English  
ED Entered STN: 12 Jul 2006  
Last Updated on STN: 12 Jul 2006

L8 ANSWER 8 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 2006:385124 SCISEARCH  
GA The Genuine Article (R) Number: 031BZ  
TI Application of molecular techniques to identify bacteria isolated from the leather industry  
AU Oppong D (Reprint); Bryant S D; Rangarajan R; Steele S; Radwell D; Hyllengren L  
CS Buckman Labs Int Inc, 1256 N McLean Blvd, Memphis, TN 38108 USA (Reprint); Buckman Labs Int Inc, Memphis, TN 38108 USA; SB Foot Tanning Co, Red Wing, MN 55066 USA  
d\_oppong@buckman.com  
CYA USA  
SO JOURNAL OF THE AMERICAN LEATHER CHEMISTS ASSOCIATION, (APR 2006) Vol. 101, No. 4, pp. 140-144.  
ISSN: 0002-9726.  
PB AMER LEATHER CHEMISTS ASSN, TEXAS TECH UNIV, BOX 45300, LUBBOCK, TX 79409-5300 USA.  
DT Article; Journal  
LA English  
REC Reference Count: 28  
ED Entered STN: 20 Apr 2006  
Last Updated on STN: 20 Apr 2006  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L8 ANSWER 9 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:757562 CAPLUS  
 TI Optical biosensor for the determination of BOD in seawater  
 AU Jiang, Yaqi; Xiao, Lai-Long; Zhao, Li; Chen, Xi; Wang, Xiaoru; Wong, Kwok-Yin  
 CS Department of Chemistry and Key Laboratory of Analytical Sciences of the Ministry of Education, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, Peop. Rep. China  
 SO Talanta (2006), 70(1), 97-103  
 CODEN: TLNTA2; ISSN: 0039-9140  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 RE.CNT 20 . THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2006:265490 BIOSIS  
 DN PREV200600267398  
 TI The properties of hydrocarbon-oxidizing bacteria isolated from the oilfields of Tatarstan, western Siberia, and Vietnam.  
 AU Borzenkov, I. A. [Reprint Author]; Milekhina, E. I.; Gotoeva, M. T.; Rozanova, E. P.; Belyaev, S. S.  
 CS Russian Acad Sci, Winogradsky Inst Microbiol, Pr 60 Letiya Oktyabrya 7,K-2, Moscow 117312, Russia  
 borzenkov@rbcmail.ru  
 SO MICROBIOLOGY, (JAN-FEB 2006) Vol. 75, No. 1, pp. 66-72.  
 CODEN: MIBLAO. ISSN: 0026-2617.  
 DT Article  
 LA English  
 ED Entered STN: 10 May 2006  
 Last Updated on STN: 10 May 2006

L8 ANSWER 11 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 4

AN 2006:250299 BIOSIS  
 DN PREV200600250955  
 TI Bacteria isolated from the different developmental stages and larval organs of the obligate parasitic fly, Wohlfahrtia magnifica (Diptera : Sarcophagidae).  
 AU Toth, E. M. [Reprint Author]; Hell, E.; Kovacs, G.; Borsodi, A. K.; Marialigeti, K.  
 CS Lorand Eotvos Univ, Fac Sci, Dept Microbiol, Pazmany P Setany 1-C, H-1117 Budapest, Hungary  
 totherika@ludens.elte.hu  
 SO Microbial Ecology, (JAN 2006) Vol. 51, No. 1, pp. 13-21.  
 CODEN: MCBEBU. ISSN: 0095-3628.  
 DT Article  
 LA English  
 ED Entered STN: 26 Apr 2006  
 Last Updated on STN: 26 Apr 2006

L8 ANSWER 12 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:523615 CAPLUS  
 DN 143:58600  
 TI Preparation of unsaturated amides and carboxylic acids by nitrile hydratase and amidase produced by culturing Dietzia natronolimnaios  
 IN Hughes, Jonathan; Armitage, Yvonne  
 PA Ciba Specialty Chemicals Water Treatments Limited, UK  
 SO PCT Int. Appl., 16 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005054455	A1	20050616	WO 2004-EP13251	20041122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1689860	A1	20060816	EP 2004-798046	20041122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI	GB 2003-27900	A	20031202		
	WO 2004-EP13251	W	20041122		
OS	CASREACT 143:58600				
RE.CNT	7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L8 ANSWER 13 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1000677 CAPLUS  
 DN 143:265576  
 TI Optically active 1-cycloalkyl-2-propyn-1-ols manufacture by fermentation  
 IN Sakamoto, Keiji; Ito, Hajime; Tsusaki, Kazuya; Morii, Akihiro  
 PA Daiichi Fine Chemical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 39 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005245444	A2	20050915	JP 2005-28781	20050204
PRAI	JP 2004-30384	A	20040206		
OS	MARPAT 143:265576				

L8 ANSWER 14 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:515680 CAPLUS  
 DN 141:52961  
 TI Protein fraction of barley spent grains as a medium for growth, sporulation and selection of Actinomycetes and related bacteria  
 IN Gamian, Andrzej; Pawlik, Krzysztof; Szponar, Bogumila; Szwajcer-Dey, Estera  
 PA Pol.  
 SO PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053108	A1	20040624	WO 2003-PL142	20031211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003295294	A1	20040630	AU 2003-295294	20031211
PRAI PL 2002-357694	A	20021211		
WO 2003-PL142	W	20031211		

L8 ANSWER 15 OF 59 USPATFULL on STN  
 AN 2004:53311 USPATFULL  
 TI Rhodococcus microorganisms and process for producing amide compounds  
 IN Matsuyama, Akinobu, Tsukuba, JAPAN  
 Kawabe, Masato, Otake, JAPAN  
 Nagasawa, Toru, Gifu, JAPAN  
 PA Daicel Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)  
 PI US 6699695 B1 20040302  
 WO 2000036086 20000622  
 AI US 2000-622201 20000814 (9)  
 WO 1999-JP6994 19991213  
 PRAI JP 1998-356229 19981215  
 DT Utility  
 FS GRANTED  
 LN.CNT 721  
 INCL INCLM: 435/129.000  
 INCLS: 435/252.100; 435/253.200; 435/822.000; 435/169.000  
 NCL NCLM: 435/129.000  
 NCLS: 435/169.000; 435/252.100; 435/253.200; 435/822.000  
 IC [7]  
 ICM C12P013-02  
 ICS C12N001-20  
 IPCI C12P0013-02 [ICM,7]; C12P0013-00 [ICM,7,C\*]; C12N0001-20 [ICS,7]  
 IPCR C12P0013-00 [I,C\*]; C12P0013-02 [I,A]  
 EXF 435/129; 435/252.1; 435/253.2; 435/822; 435/169  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1248079 CAPLUS  
 DN 145:183893  
 TI Analysis of nitrate reducing community in a near-shore marine-cultural  
 sediments  
 AU Wang, Yanan; Wang, Baojun; Dai, Xin; Jiao, Nianzhi; Peng, Zhiying; Liu,  
 Shuangjiang  
 CS Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100080,  
 Peop. Rep. China  
 SO Weishengwuxue Tongbao (2004), 31(6), 73-76  
 CODEN: WSWPDI; ISSN: 0253-2654  
 PB Kexue Chubanshe  
 DT Journal  
 LA Chinese

L8 ANSWER 17 OF 59 CABA COPYRIGHT 2006 CABI on STN DUPLICATE 5  
 AN 2003:159858 CABA  
 DN 20033132780  
 TI Rapid identification of Rhodococcus equi by a PCR assay targeting the choE  
 gene  
 AU Ladron, N.; Fernandez, M.; Agüero, J.; Gonzalez Zorn, B.; Vazquez-Boland,  
 J. A.; Navas, J.  
 CS Departamento de Biología Molecular (Unidad Asociada al Centro de  
 Investigaciones Biológicas, C.S.I.C.), Facultad de Medicina, Universidad  
 de Cantabria, Herrera Oria s/n, 39011 Santander, Spain.  
 navasj@correo.unican.es  
 SO Journal of Clinical Microbiology, (2003) Vol. 41, No. 7, pp. 3241-3245. 43  
 ref.  
 Publisher: American Society for Microbiology (ASM). Washington  
 ISSN: 0095-1137  
 DOI: 10.1128/JCM.41.7.3241-3245.2003

CY United States  
DT Journal  
LA English  
ED Entered STN: 3 Oct 2003  
Last Updated on STN: 3 Oct 2003

L8 ANSWER 18 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:772914 CAPLUS  
DN 140:107594  
TI Protein fraction of barley spent grain as a new simple medium for growth  
and sporulation of soil actinobacteria  
AU Szponar, Bogumila; Pawlik, Krzysztof J.; Gamian, Andrzej; Dey, Estera  
Szwajcer  
CS Institute of Immunology and Experimental Therapy, Polish Academy of  
Sciences, Wroclaw, 53-114, Pol.  
SO Biotechnology Letters (2003), 25(20), 1717-1721  
CODEN: BILED3; ISSN: 0141-5492  
PB Kluwer Academic Publishers  
DT Journal  
LA English  
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 59 CABA COPYRIGHT 2006 CABI on STN DUPLICATE 6  
AN 2003:90350 CABA  
DN 20033060619  
TI Pathogenic Nocardia, Rhodococcus, and related organisms are highly  
susceptible to imidazole antifungals  
AU Dabbs, E. R.; Naidoo, S.; Lepphoto, C.; Nikitina, N.  
CS School of Molecular and Cell Biology, University of the Witwatersrand,  
Johannesburg, P O WITS 2050, South Africa. dabbse@gecko.biol.wits.ac.za  
SO Antimicrobial Agents and Chemotherapy, (2003) Vol. 47, No. 4, pp.  
1476-1478. 26 ref.  
Publisher: American Society for Microbiology (ASM). Washington  
ISSN: 0066-4804  
CY United States  
DT Journal  
LA English  
ED Entered STN: 6 Jun 2003  
Last Updated on STN: 6 Jun 2003

L8 ANSWER 20 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 7  
AN 2004:138236 BIOSIS  
DN PREV200400140588  
TI Rhizome-associated bacterial communities of healthy and declining reed  
stands in Lake Velencei, Hungary.  
AU Micsinai, Adrienn [Reprint Author]; Borsodi, Andrea K. [Reprint Author];  
Csengeri, Viktoria [Reprint Author]; Horvath, Andrea [Reprint Author];  
Oravecz, Orsolya [Reprint Author]; Nikolausz, Marcell [Reprint Author];  
Reskone, Maria N.; Marialigeti, Karoly [Reprint Author]  
CS Department of Microbiology, Eotvos Lorand University, Pazmany P setany  
1/C, Budapest, H-1117, Hungary  
micsinai@adrienn@wessling.hu  
SO Hydrobiologia, (15 November 2003) Vol. 506-509, pp. 707-713. print.  
ISSN: 0018-8158 (ISSN print).  
DT Article  
LA English  
ED Entered STN: 10 Mar 2004  
Last Updated on STN: 10 Mar 2004

L8 ANSWER 21 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
AN 2003:374715 BIOSIS

DN PREV200300374715  
 TI Relationship between beta-oxidation pathway and the hydrocarbon-degrading profile in actinomycetes bacteria.  
 AU Alvarez, Hector M. [Reprint Author]  
 CS Departamento Bioquimica, Facultad de Ciencias Naturales, Universidad Nacional de la Patagonia, San Juan Bosco, Km 4, 9000, Comodoro Rivadavia, Argentina  
 halvarez@unpata.edu.ar  
 SO International Biodeterioration & Biodegradation, (2003) Vol. 52, No. 1, pp. 35-42. print.  
 CODEN: IBBIES. ISSN: 0964-8305.  
 DT Article  
 LA English  
 ED Entered STN: 13 Aug 2003  
 Last Updated on STN: 13 Aug 2003

L8 ANSWER 22 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:142900 CAPLUS  
 DN 136:182553  
 TI Stereoselective reduction of substituted oxo-butanones  
 IN Patel, Ramesh N.; Chu, Linda  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014528	A1	20020221	WO 2001-US23113	20010720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2417086	AA	20020221	CA 2001-2417086	20010720
	AU 2001080698	A5	20020225	AU 2001-80698	20010720
	US 2002042124	A1	20020411	US 2001-909684	20010720
	EP 1309714	A1	20030514	EP 2001-959109	20010720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511225	T2	20040415	JP 2002-519654	20010720
	CN 1492932	A	20040428	CN 2001-814196	20010720
	BR 2001013236	A	20051213	BR 2001-13236	20010720
	US 2004058431	A1	20040325	US 2003-661893	20030912
	US 7083973	B2	20060801		
PRAI	US 2000-225695P	P	20000816		
	US 2001-277531P	P	20010321		
	US 2001-909684	B1	20010720		
	WO 2001-US23113	W	20010720		

OS CASREACT 136:182553; MARPAT 136:182553

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:260050 CAPLUS  
 DN 136:283765  
 TI Ester-degrading Corynebacterium and Rhodococcus maris for bioremediation  
 IN Akazawa, Yoshihiro  
 PA Nok Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2002101875	A2	20020409	JP 2000-298022	20000929
PRAI	JP 2000-298022		20000929		

L8 ANSWER 24 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:15283 CAPLUS

DN 138:225861

TI Fighting foam with phages?

AU Thomas, J. A.; Soddell, J. A.; Kurtboke, D. I.

CS Biotechnology Research Centre, La Trobe University, Bendigo, 3550, Australia

SO Water Science and Technology (2002), 46(1/2), 511-518

CODEN: WSTED4; ISSN: 0273-1223

PB IWA Publishing

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2002:529038 SCISEARCH

GA The Genuine Article (R) Number: 564VH

TI Diversity of the microflora of edible macroalga (Palmaria palmata)

AU Moore J E (Reprint); Xu J; Millar B C

CS Belfast City Hosp, Dept Bacteriol, No Ireland Publ Hlth Lab, Belfast BT9 7AD, Antrim, North Ireland (Reprint)

CYA North Ireland

SO FOOD MICROBIOLOGY, (APR-JUN 2002) Vol. 19, No. 2-3, pp. 249-257.

ISSN: 0740-0020.

PB ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD, 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND.

DT Article; Journal

LA English

REC Reference Count: 21

ED Entered STN: 12 Jul 2002

Last Updated on STN: 12 Jul 2002

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L8 ANSWER 26 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 8

AN 2002:202363 BIOSIS

DN PREV200200202363

TI Dietzia psychrhalcaliphila sp. nov., a novel, facultatively psychrophilic alkaliphile that grows on hydrocarbons.

AU Yumoto, Isao [Reprint author]; Nakamura, Akio; Iwata, Hideaki; Kojima, Kiyoshi; Kusumoto, Keita; Nodasaka, Yoshinobu; Matsuyama, Hidetoshi

CS Research Institute of Biological Resources, National Institute of Advanced Industrial Science and Technology, 2-17-2-1 Tsukisamu-Higashi, Toyohira-ku, Sapporo, 062-8517, Japan  
i.yumoto@aist.go.jp

SO International Journal of Systematic and Evolutionary Microbiology, (January, 2002) Vol. 52, No. 1, pp. 85-90. print.

ISSN: 1466-5026.

DT Article

LA English

OS Genbank-AB049630; EMBL-AB049630; DDBJ-AB049630

ED Entered STN: 20 Mar 2002

Last Updated on STN: 10 May 2002

L8 ANSWER 27 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:489661 CAPLUS  
DN 135:60267  
TI Process for producing glycine  
IN Aoki, Toshiya; Kawakami, Kiyoshi; Otsubo, Kazumasa  
PA Asahi Kasei Kabushiki Kaisha, Japan  
SO PCT Int. Appl., 111 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001048234	A1	20010705	WO 2000-JP9353	20001227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001022292	A5	20010709	AU 2001-22292	20001227
	EP 1243657	A1	20020925	EP 2000-985968	20001227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1660778	A	20050831	CN 2005-10003648	20001227
	US 2003040085	A1	20030227	US 2002-168096	20020617
	US 6916638	B2	20050712		
PRAI	JP 1999-370588	A	19991227		
	CN 2000-818716	A3	20001227		
	WO 2000-JP9353	W	20001227		

OS CASREACT 135:60267; MARPAT 135:60267

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:785844 CAPLUS  
DN 135:317544  
TI Microbial manufacture of colorless glycine from glycinonitrile  
IN Aoki, Toshiya  
PA Asahi Chemical Industry Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001299378	A2	20011030	JP 2000-122454	20000424
PRAI	JP 2000-122454		20000424		
OS	CASREACT 135:317544				

L8 ANSWER 29 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:717140 CAPLUS  
DN 135:256201  
TI Microbial manufacture of glycine from glycinonitrile using discoloration preventers  
IN Aoki, Toshiya  
PA Asahi Chemical Industry Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2001269190	A2	20011002	JP 2000-90795	20000329
PRAI	JP 2000-90795		20000329		
OS	CASREACT 135:256201				

L8 ANSWER 30 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:698042 CAPLUS  
DN 135:225949  
TI Reactive distillation for manufacture of glycine from glycinonitrile  
IN Aoki, Toshiya; Otsubo, Kazumasa  
PA Asahi Chemical Industry Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 9 pp.  
CODEN: JKXXAF

DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2001258586	A2	20010925	JP 2000-83179	20000324
PRAI	JP 2000-83179		20000324		

L8 ANSWER 31 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:568205 CAPLUS  
DN 135:136477  
TI Microbial manufacture of glycine from glycinonitrile using no buffer solutions  
IN Aoki, Tadayasu; Otsubo, Kazumasa  
PA Asahi Chemical Industry Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF

DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2001211892	A2	20010807	JP 2000-26059	20000203
PRAI	JP 2000-26059		20000203		

L8 ANSWER 32 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 9  
AN 2001:411587 BIOSIS  
DN PREV200100411587  
TI Molecular identification of a Dietzia maris hip prosthesis infection isolate.  
AU Pidoux, O.; Argenson, J.-N.; Jacomo, V.; Drancourt, M. [Reprint author]  
CS Unite des Rickettsies, Faculte de Medecine, Universite de la Mediterranee,  
27 Blvd. Jean Moulin, 13385, Marseille Cedex, 05, France  
Michel.Drancourt@medecine.univ-mrs.fr  
SO Journal of Clinical Microbiology, (July, 2001) Vol. 39, No. 7, pp.  
2634-2636. print.  
CODEN: JCMIDW. ISSN: 0095-1137.

DT Article  
LA English  
ED Entered STN: 29 Aug 2001  
Last Updated on STN: 22 Feb 2002

L8 ANSWER 33 OF 59 MEDLINE on STN  
AN 2002059812 MEDLINE  
DN PubMed ID: 11785132

TI [Effect of the media salinity on destruction of petroleum oils by  
 nocardioform bacteria].  
 Vliianie solenosti sredy na destruktssiu neftianykh masel  
 nokardiopodobnymi bakteriiami.  
 AU Zviagintseva I S; Poglazova M N; Gotoeva M T; Beliaev S S  
 CS Institute of Microbiology, Russian Academy of Science, pr. 60-letiya  
 Oktyabrya 7, k. 2, Moscow, 117312 Russia.  
 SO Mikrobiologiya, (2001 Nov-Dec) Vol. 70, No. 6, pp. 759-64.  
 Journal code: 0376652. ISSN: 0026-3656.  
 CY Russia: Russian Federation  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Russian  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 25 Jan 2002  
 Last Updated on STN: 30 Jan 2002  
 Entered Medline: 29 Jan 2002

L8 ANSWER 34 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 10  
 AN 2002:33637 CAPLUS  
 DN 136:299304  
 TI Effect on the medium salinity on oil degradation by nocardioform bacteria  
 AU Zvyagintseva, I. S.; Poglazova, M. N.; Gotoeva, M. T.; Belyaev, S. S.  
 CS Institute of Microbiology, Russian Academy of Sciences, Moscow, 117312,  
 Russia  
 SO Microbiology (Moscow, Russian Federation) (Translation of Mikrobiologiya)  
 (2001), 70(6), 652-656  
 CODEN: MIBLAO; ISSN: 0026-2617  
 PB MAIK Nauka/Interperiodica Publishing  
 DT Journal  
 LA English  
 RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 2002:163101 BIOSIS  
 DN PREV200200163101  
 TI Production of anti-Gordonia amarae mycolic acid polyclonal antibody for  
 detection of mycolic acid-containing bacteria in activated sludge foam.  
 AU Iwahori, Keisuke [Reprint author]; Miyata, Naoyuki; Takata, Nami;  
 Morisada, Sachiko; Mochizuki, Tohru  
 CS Institute for Environmental Sciences, University of Shizuoka, 52-1 Yada,  
 Shizuoka, 422-8526, Japan  
 iwahori@sea.u-shizuoka-ken.ac.jp  
 SO Journal of Bioscience and Bioengineering, (2001) Vol. 92, No. 5, pp.  
 417-422. print.  
 ISSN: 1389-1723.  
 DT Article  
 LA English  
 ED Entered STN: 21 Feb 2002  
 Last Updated on STN: 26 Feb 2002

L8 ANSWER 36 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:505953 CAPLUS  
 DN 135:215367  
 TI Degradation of machine oil by nocardioform bacteria  
 AU Zvyagintseva, I. S.; Surovtseva, E. G.; Poglazova, M. N.; Ivoilov, V. S.;  
 Belyaev, S. S.  
 CS Institute of Microbiology, Russian Academy of Sciences, Moscow, 117811,  
 Russia  
 SO Microbiology (Moscow, Russian Federation) (Translation of Mikrobiologiya)  
 (2001), 70(3), 270-276  
 CODEN: MIBLAO; ISSN: 0026-2617

PB MAIK Nauka/Interperiodica Publishing  
DT Journal  
LA English  
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:505952 CAPLUS  
DN 135:223893  
TI Effect of butyric acid on the physiological activity of  
hydrocarbon-oxidizing Rhodococci  
AU Guzev, V. S.; Volde, M. I.; Kulichevskaya, I. S.; Lysak, L. V.  
CS Moscow State University, Moscow, 119899, Russia  
SO Microbiology (Moscow, Russian Federation) (Translation of Mikrobiologiya)  
(2001), 70(3), 263-269  
CODEN: MIBLAO; ISSN: 0026-2617  
PB MAIK Nauka/Interperiodica Publishing  
DT Journal  
LA English  
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 38 OF 59 LIFESCI COPYRIGHT 2006 CSA on STN  
AN 2003:47670 LIFESCI  
TI Toxicity of dwellings building materials and their and indoor air microbes  
studied by boar sperm test  
Asuntojen rakennusmateriaalien sekä niiden ja sisäilman mikrobien  
myrkyllisyys karjun siittioettestissae  
AU Laakso, T.; Peltola, J.; Kalso, S.; Ja Seppo Ahonen, T.V.  
CS Helsingin kaupungin ympäristökeskus, PL 500, 00099 Helsingin Kaupunki,  
Finland; E-mail: tuula.laakso@hel.fi  
SO Helsingin Kaupungin Ympäristökeskuksen Julkaisuja, (20010000) vol. 15, p.  
23.  
ISSN: 1235-9718.  
DT Journal  
FS X; A  
LA Finnish  
SL Finnish; Swedish; English

L8 ANSWER 39 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2000:623801 CAPLUS  
DN 133:182288  
TI Process for the microbiological reclamation of soil contaminated with oil  
or oil-products  
IN Didziapetris, Antanas; Jankevicius, Karolis; Sabaliauskas, Julius  
PA Viesoji Istaiga "Grunto Valymo Technologijos", Lithuania  
SO Lith., 11 pp.  
CODEN: LIXXFS  
DT Patent  
LA Lithuanian  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	LT 4620	B	20000225	LT 1999-69	19990610
PRAI	LT 1999-69		19990610		

L8 ANSWER 40 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2000:788089 CAPLUS  
DN 134:53623  
TI Clusterization of halophilic and halotolerant eubacteria using whole-cell  
protein electrophoresis data  
AU Bykova, S. A.; Zvyagintseva, I. S.; Akhlynin, D. S.; Belyaev, S. S.;  
Gal'chenko, V. F.  
CS Institute of Microbiology, Russian Academy of Sciences, Moscow, 117811,



Russia  
SO Microbiology (Moscow) (Translation of Mikrobiologiya) (2000), 69(5),  
582-587  
CODEN: MIBLAO; ISSN: 0026-2617  
PB MAIK Nauka/Interperiodica Publishing  
DT Journal  
LA English  
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 11  
AN 2001:125979 BIOSIS  
DN PREV200100125979  
TI Characterisation of a lipomannan lipoglycan from the mycolic acid  
containing actinomycete Dietzia maris.  
AU Sutcliffe, Iain C. [Reprint author]  
CS School of Sciences, University of Sunderland, Fleming Building,  
Sunderland, SR2 3SD, UK  
iain.sutcliffe@sunderland.ac.uk  
SO Antonie van Leeuwenhoek, (August, 2000) Vol. 78, No. 2, pp. 195-201.  
print.  
CODEN: ALJMAO. ISSN: 0003-6072.  
DT Article  
LA English  
ED Entered STN: 14 Mar 2001  
Last Updated on STN: 15 Feb 2002

L8 ANSWER 42 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 12  
AN 2000:28927 BIOSIS  
DN PREV200000028927  
TI Bacteremia due to Dietzia maris in an  
immunocompromised patient.  
AU Bemer-Melchior, P. [Reprint author]; Haloun, A.; Riegel, P.; Drugeon, H.  
B.  
CS Laennec University Hospital, Bd. J. Monod, 44093, Saint-Herblain cedex 1,  
France  
SO Clinical Infectious Diseases, (Nov., 1999) Vol. 29, No. 5, pp. 1338-1340.  
print.  
CODEN: CIDIEL. ISSN: 1058-4838.  
DT Article  
LA English  
ED Entered STN: 13 Jan 2000  
Last Updated on STN: 31 Dec 2001

L8 ANSWER 43 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:135090 CAPLUS  
DN 130:293797  
TI Relationship between growth and respiration rates in rhodococci grown at  
high salt concentrations  
AU Plakunov, V. K.; Arzumanyan, V. G.; Voronina, N. A.; Belyaev, S. S.  
CS Institute of Microbiology, Russian Academy of Sciences, Moscow, 117811,  
Russia  
SO Microbiology (Moscow) (Translation of Mikrobiologiya) (1999), 68(1), 32-36  
CODEN: MIBLAO; ISSN: 0026-2617  
PB MAIK Nauka/Interperiodica Publishing  
DT Journal  
LA English  
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 44 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:186213 CAPLUS

DN 130:256731  
 TI Characterization of a bacterial strain used as an inoculum for the in situ remediation of a soil highly contaminated by hydrocarbons  
 AU Peressutti, S. R.; Alvarez, H. M.; Klein, I.; Harting, C.; Wunsche, L.; Pucci, O. H.  
 CS Centro Estudios Investigaciones Microbiologia Aplicada, Univ. Nacional Patagonia San Juan Bosco, Comodoro Rivadavia, 9000, Argent.  
 SO UFZ-Bericht (1998), 18, 14-15, 127-129  
 CODEN: UFBEF7; ISSN: 0948-9452  
 DT Report  
 LA German/Spanish  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 45 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:186196 CAPLUS  
 DN 130:256730  
 TI In situ remediation of an area in Cerro Dragon, Patagonia, Argentina, highly contaminated by hydrocarbons  
 AU Pucci, O. H.; Bak, M. A.; Peressutti, S. R.; Klein, I.; Charting, C.; Wunsche, L.  
 CS Centro Estudios Invetigacione Microbiologia Aplicada, Universidad Nacional Patagonia San Juan Bosco, San Juan Bosco, 9000, Argent.  
 SO UFZ-Bericht (1998), 18, 5-13, 118-126  
 CODEN: UFBEF7; ISSN: 0948-9452  
 DT Report  
 LA German/Spanish  
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 46 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:208492 CAPLUS  
 DN 128:274602  
 TI Immobilized porous ceramic material for biological treatment of wastewater or purification of natural water contaminated by xenobiotics  
 IN Borzenkov, Igor Anatolievich; Matveev, Jury Ivanovich; Belyaev, Sergei Semenovich; Svitnev, Alexandr Ivanovich; Pospelov, Mikhail Evgenievich  
 PA Russia  
 SO PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Russian  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9813307	A1	19980402	WO 1997-RU289	19970919
	W: AU, CN, CZ, JP, KR, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	RU 2104249	C1	19980210	RU 1996-118846	19960927
	AU 9744762	A1	19980417	AU 1997-44762	19970919
PRAI	RU 1996-118846	A	19960927		
	WO 1997-RU289	W	19970919		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 47 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1998:442387 BIOSIS  
 DN PREV199800442387  
 TI Dietzia natronolimnaios sp. nov., a new member of the genus Dietzia isolated from an East African soda lake.  
 AU Duckworth, Andrew W.; Grant, Susan; Grant, William D. [Reprint author]; Jones, Brian E.; Meijer, Daan  
 CS Dep. Microbiol. Immunol., Univ. Leicester, Maurice Shock Build.,  
 DUPLICATE 13

University Road, Leicester LE1 9HN, UK  
SO Extremophiles, (Aug., 1998) Vol. 2, No. 3, pp. 359-366. print.  
ISSN: 1431-0651.  
DT Article  
LA English  
ED Entered STN: 21 Oct 1998  
Last Updated on STN: 21 Oct 1998

L8 ANSWER 48 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1998:326791 CAPLUS  
DN 129:92676  
TI Isolation and characterization of a new aromatic compound-degrading  
alkalitrophic bacteria  
AU Maeda, Michihisa; Roberts, Michael S.; Ohta, Yoshinori; Fuji, Fumie;  
Travisano, Michael; Kudo, Toshiaki  
CS Institute of Physical and Chemical Research (RIKEN), Wako, 351 0198, Japan  
SO Journal of General and Applied Microbiology (1998), 44(1), 101-106  
CODEN: JGAMA9; ISSN: 0022-1260  
PB Microbiology Research Foundation  
DT Journal  
LA English  
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 49 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:281911 CAPLUS  
DN 131:29682  
TI Preparatory metabolism of terephthalic acid esters in Rhodococcus bacteria  
AU Aleshchenkova, Z. M.  
CS Belarus  
SO Doklady Natsional'noi Akademii Nauk Belarusi (1998), 42(4), 100-103  
CODEN: DNABFW  
PB Belaruskaya Navuka  
DT Journal  
LA Russian

L8 ANSWER 50 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 14  
AN 1999:152398 BIOSIS  
DN PREV199900152398  
TI Novel rhodococci and other mycolate actinomycetes from the deep sea.  
AU Colquhoun, Joy A.; Mexson, Joanne; Goodfellow, Michael; Ward, Alan C.;  
Horikoshi, Koki; Bull, Alan T. [Reprint author]  
CS Dep. Biosci., Univ. Kent, Canterbury, Kent CT2 7NJ, UK  
SO Antonie van Leeuwenhoek, (July-Oct., 1998) Vol. 74, No. 1-3, pp. 27-40.  
print.  
CODEN: ALJMAO. ISSN: 0003-6072.  
DT Article  
LA English  
ED Entered STN: 16 Apr 1999  
Last Updated on STN: 16 Apr 1999

L8 ANSWER 51 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 15  
AN 1998:115428 BIOSIS  
DN PREV199800115428  
TI Identification of Rhodococcus, Gordona and Dietzia species using carbon  
source utilization tests ("Biotype-100" strips).  
AU Bizet, C. [Reprint author]; Barreau, C.; Harmant, C.; Nowakowski, M.;  
Pietfroid, A.  
CS Collection des Bacteries l'Institut Pasteur, Inst. Pasteur, 75724 Paris  
Cedex 15, France  
SO Research in Microbiology, (Dec., 1997) Vol. 148, No. 9, pp. 799-809.  
print.

CODEN: RMCREW. ISSN: 0923-2508.

DT Article  
LA English  
ED Entered STN: 5 Mar 1998  
Last Updated on STN: 5 Mar 1998

L8 ANSWER 52 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1997:114665 CAPLUS  
DN 126:209337  
TI Composition and content of osmoprotectants in oil-oxidizing bacteria grown under different cultivation conditions  
AU Matveeva, N. I.; Voronina, N. A.; Borzenkov, I. A.; Plakunov, V. K.; Belyaev, S. S.  
CS Institute of Microbiology, Russian Academy of Sciences, Moscow, 117811, Russia  
SO Microbiology (Moscow) (Translation of Mikrobiologiya) (1997), 66(1), 23-27  
CODEN: MIBLAO; ISSN: 0026-2617  
PB MAIK Nauka/Interperiodica  
DT Journal  
LA English  
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 53 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:756267 CAPLUS  
DN 126:22566  
TI Bioaugmentation compositions for removing petroleum contaminants from soil  
IN Borzenkovs, Igors Anatoljecsics; Miljohina, Jevgenija Ivanovna; Belajevs, Sergejs Semjonovics; Ivanovs, Mihails Vladimirovics  
PA Biotehinvest, Akcionernoje Obscestvo Zakritogo Tipa, Russia  
SO Latv., 16 pp.  
CODEN: LAXXF6  
DT Patent  
LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	LV 10779	B	19960620	LV 1994-94	19940504
PRAI	LV 1994-940094		19940504		

L8 ANSWER 54 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1997:105235 CAPLUS  
DN 126:119849  
TI Demulsification by microorganisms  
IN Fukumi, Nishimaki; Nobuhiro, Takahashi; Tomohiko, Tsuchida; Kazuya, Watanabe; Sanae, Hino  
PA Tonen Corporation, Japan  
SO Eur. Pat. Appl., 30 pp.  
CODEN: EPXXDW

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 748860	A2	19961218	EP 1996-109532	19960613
	EP 748860	A3	19970319		
	EP 748860	B1	20010829		
	R: DE, FR, GB				
	JP 09001183	A2	19970107	JP 1995-147179	19950614
	JP 3781455	B2	20060531		
	JP 09173058	A2	19970708	JP 1995-343870	19951228
	JP 09173704	A2	19970708	JP 1995-343912	19951228
	US 5989892	A	19991123	US 1996-662944	19960613
PRAI	JP 1995-147179	A	19950614		

JP 1995-343870           A       19951228  
JP 1995-343912           A       19951228

- L8 ANSWER 55 OF 59 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN  
AN 95208194 EMBASE  
DN 1995208194  
TI Erratum: Dietzia, a new genus including Dietzia maris comb. nov., formerly Rhodococcus maris (International Journal of Systematic Bacteriology (1995) 1 (34)).  
AU Rainey F.A.; Klatte S.; Kroppenstedt R.M.; Stackebrandt E.  
SO International Journal of Systematic Bacteriology, (1995) Vol. 45, No. 3, pp. 622. .  
ISSN: 0020-7713 CODEN: IJSBA8  
CY United States  
DT Journal; Errata  
FS 004 Microbiology  
LA English  
ED Entered STN: 3 Aug 1995  
Last Updated on STN: 3 Aug 1995
- L8 ANSWER 56 OF 59 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 1995:459792 SCISEARCH  
GA The Genuine Article (R) Number: RG937  
TI DIETZIA, A NEW GENUS INCLUDING DIETZIA-MARIS COMB-NOV, FORMERLY RHODOCOCCUS-MARIS (VOL 45, PG 34, 1995)  
AU RAINEY F A (Reprint); KLATTE S; KROPENSTEDT R M; STACKEBRANDT E  
CS DSM DEUTSCH SAMMLUNG MIKROORGANISMEN & ZELLKULTUR, D-38124 BRAUNSCHWEIG, GERMANY (Reprint)  
CYA GERMANY  
SO INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, (JUL 1995) Vol. 45, No. 3, pp. 622-622.  
ISSN: 0020-7713.  
PB AMER SOC MICROBIOLOGY, 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171.  
DT Errata; Journal  
FS LIFE  
LA English  
REC Reference Count: 1  
ED Entered STN: 1995  
Last Updated on STN: 1995
- L8 ANSWER 57 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:684214 CAPLUS  
DN 126:4348  
TI Microbiological oxidation of crude oil and oil products by hydrocarbon-oxidizing bacterial preparation «Munaibac»  
AU Fayzulina, E. R.; Shylova, N. K.; Alieva, R. M.; Birukova, L. A.  
CS Inst. Mikrobiol. Virusol., Kazakhstan  
SO Izvestiya Natsional'noi Akademii Nauk Respubliki Kazakhstan, Seriya Biologicheskaya (1995), (5), 64-68  
CODEN: INKBey  
PB Gylym  
DT Journal  
LA Russian
- L8 ANSWER 58 OF 59 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
AN 1995:118567 BIOSIS  
DN PREV199598132867  
TI Dietzia, a new genus including Dietzia maris comb. nov., formerly Rhodococcus maris.  
AU Rainey, F. A.; Klatte, S.; Kroppenstedt, R. M.; Stackebrandt, E. [Reprint

author]  
 CS DSM-Deutsche Sammlung von Mikroorganismen Zellkulturen GmbH, Mascheroder  
 Weg 1B, D-38124 Braunschweig, Germany  
 SO International Journal of Systematic Bacteriology, (1995) Vol. 45, No. 1,  
 pp. 32-36.  
 CODEN: IJSBA8. ISSN: 0020-7713.  
 DT Article  
 LA English  
 OS EMBL-X79286; EMBL-X79287; EMBL-X79288; EMBL-X79289; EMBL-X79290;  
 EMBL-X79291; EMBL-X79292  
 ED Entered STN: 29 Mar 1995  
 Last Updated on STN: 29 Mar 1995

L8 ANSWER 59 OF 59 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1991:38984 CAPLUS  
 DN 114:38984  
 TI Biosynthesis of trehalose mycolates by Rhodococcus species as a function  
 of the cell age and the source of carbon  
 AU Koronelli, T. V.; Komarova, T. I.; Batrakov, S. G.  
 CS Mosk. Gos. Univ., Moscow, USSR  
 SO Mikrobiologiya (1990), 59(5), 777-81  
 CODEN: MIKBA5; ISSN: 0026-3656  
 DT Journal  
 LA Russian

=> s rhodococcus ruber  
 L9 595 RHODOCOCCUS RUBER

=> s rhodococcus coprophilus  
 L10 116 RHODOCOCCUS COPROPHILUS

=> dup rem l10  
 PROCESSING COMPLETED FOR L10  
 L11 70 DUP REM L10 (46 DUPLICATES REMOVED)

=> d 51-  
 YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

L11 ANSWER 51 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN DUPLICATE 9  
 AN 1992:308295 BIOSIS  
 DN PREV199294021445; BA94:21445  
 TI ENANTIOSELECTIVE WHOLE CELL AND ISOLATED ENZYME CATALYSED BAEYER-VILLIGER  
 OXIDATION OF BICYCLO-3.2.0-HEPT-2-EN-6-ONE.  
 AU SHIPSTON N F [Reprint author]; LENN M J; KNOWLES C J  
 CS BIOLOGICAL LAB, UNIVERSITY KENT, CANTERBURY, KENT CT2 7NJ, UK  
 SO Journal of Microbiological Methods, (1992) Vol. 15, No. 1, pp. 41-52.  
 CODEN: JMIMDQ. ISSN: 0167-7012.  
 DT Article  
 FS BA  
 LA ENGLISH  
 ED Entered STN: 27 Jun 1992  
 Last Updated on STN: 9 Aug 1992

L11 ANSWER 52 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1992:124484 BIOSIS  
 DN PREV199293070284; BA93:70284  
 TI DISTINGUISHING BETWEEN HUMAN AND ANIMAL POLLUTION IN WATER.  
 AU UNAT E K [Reprint author]; RASTGOOY R; ULUSOY M  
 CS IU CERRAHPASA TIP FAKULTESI, MIKROBIYOLOJI ANABILIM DALI  
 SO Cerrahpasa Tip Fakultesi Dergisi, (1991) Vol. 22, No. 1, pp. 179-184.  
 ISSN: 0376-7833.

DT Article  
FS BA  
LA TURKISH  
ED Entered STN: 1 Mar 1992  
Last Updated on STN: 1 Mar 1992

L11 ANSWER 53 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 1989:376972 BIOSIS  
DN PREV198988057562; BA88:57562  
TI CAROTENOID PIGMENTS OF GENUS RHODOCOCCLUS.  
AU ICHIYAMA S [Reprint author]; SHIMOKATA K; TSUKAMURA M  
CS FIRST DEP INTERNAL MED, NAGOYA UNIV SCH MED, NAGOYA, AICHI 466  
SO Microbiology and Immunology, (1989) Vol. 33, No. 6, pp. 503-508.  
CODEN: MIIMDV. ISSN: 0385-5600.

DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 17 Aug 1989  
Last Updated on STN: 26 Aug 1989

L11 ANSWER 54 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 10

AN 1989:300446 BIOSIS  
DN PREV198937014823; BR37:14823  
TI ISOLATION AND IDENTIFICATION OF ACTINOMYCETES PRESENT IN ACTIVATED SLUDGE  
SCUM.  
AU SEZGIN M [Reprint author]; LECHEVALIER M P; KARR P R  
CS CITY ATLANTA, TECHNICAL SERV BRANCH, 2440 BOLTON ROAD NW, ATLANTA, GA  
30318, USA  
SO Water Science and Technology, (1988) Vol. 20, No. 11-12, pp. 257-264.  
Meeting Info.: MEETING ON WATER AND WASTEWATER MICROBIOLOGY HELD AT THE  
INTERNATIONAL ASSOCIATION FOR WATER POLLUTION RESEARCH AND CONTROL  
CONFERENCE, NEWPORT BEACH, CALIFORNIA, USA, FEBRUARY 8-11, 1988. WATER SCI  
TECHNOL.  
CODEN: WSTED4. ISSN: 0273-1223.

DT Conference; (Meeting)  
FS BR  
LA ENGLISH  
ED Entered STN: 27 Jun 1989  
Last Updated on STN: 27 Jun 1989

L11 ANSWER 55 OF 70 LIFESCI COPYRIGHT 2006 CSA on STN

AN 88:82806 LIFESCI  
TI Isolation and identification of actinomycetes present in activated sludge  
scum.  
WATER AND WASTEWATER MICROBIOLOGY.  
AU Sezgin, M.; Lechevalier, M.P.; Karr, P.R.; Jenkins, D. [editor]; Olson,  
B.H. [editor]  
CS Tech. Serv. Branch, 2440 Bolton Rd., NW, Atlanta, GA 30318, USA  
SO WATER SCI. TECHNOL., (1988) pp. 257-263.  
Meeting Info.: IAWPRC Conference on Water and Wastewater Microbiology.  
Newport Beach, CA (USA). 8-11 Feb 1988.  
ISBN: 0-08-037367-4.

DT Book  
TC Conference  
FS J; A  
LA English  
SL English

L11 ANSWER 56 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 1986:235862 BIOSIS  
DN PREV198682000366; BA82:366

TI DISTRIBUTION AND APPLICATION OF MYCOBACTINS FOR THE CHARACTERIZATION OF SPECIES WITHIN THE GENUS RHODOCOCCLUS.  
 AU HALL R M [Reprint author]; RATLEDGE C  
 CS DEP BIOTECHNOL, GLAXO GROUP RES LTD, GREENFORD, MIDDLESEX UB6 0HE, UK  
 SO Journal of General Microbiology, (1986) Vol. 132, No. 3, pp. 853-856.  
 CODEN: JGMIAN. ISSN: 0022-1287.  
 DT Article  
 FS BA  
 LA ENGLISH  
 ED Entered STN: 7 Jun 1986  
 Last Updated on STN: 7 Jun 1986

L11 ANSWER 57 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 11  
 AN 1986:127359 BIOSIS  
 DN PREV198681037775; BA81:37775  
 TI BACTERIOLOGICAL METHODS FOR DISTINGUISHING BETWEEN HUMAN AND ANIMAL FECAL POLLUTION OF WATER RESULTS OF FIELDWORK IN NIGERIA AND ZIMBABWE.  
 AU MARA D D [Reprint author]; ORAGUI J  
 CS DEP CIVIL ENG, UNIV LEEDS, LEEDS LS2 9JT, ENGLAND, UK  
 SO Bulletin of the World Health Organization, (1985) Vol. 63, No. 4, pp. 773-784.  
 ISSN: 0042-9686.  
 DT Article  
 FS BA  
 LA ENGLISH  
 ED Entered STN: 25 Apr 1986  
 Last Updated on STN: 25 Apr 1986

L11 ANSWER 58 OF 70 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 12  
 AN 1985:163450 CAPLUS  
 DN 102:163450  
 TI Menaquinone composition of mycolic acid-containing actinomycetes and some sporoactinomycetes  
 AU Collins, M. D.; Goodfellow, M.; Minnikin, D. E.; Alderson, G.  
 CS Dep. Microbiol., Natl. Inst. Res. Dairy., Shinfield/Reading, RG2 9AT, UK  
 SO Journal of Applied Bacteriology (1985), 58(1), 77-86  
 CODEN: JABAA4; ISSN: 0021-8847  
 DT Journal  
 LA English

L11 ANSWER 59 OF 70 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1986:72790 SCISEARCH  
 GA The Genuine Article (R) Number: AYP85  
 TI FECAL STREPTOCOCCI, RHODOCOCCLUS-COPROPHILUS AND BIFIDOBACTERIA AS SPECIFIC INDICATOR ORGANISMS OF FECAL POLLUTION  
 AU ORAGUI J I (Reprint); MARA D D  
 CS UNIV LEEDS, DEPT CIVIL ENGN, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND  
 CYA ENGLAND  
 SO JOURNAL OF APPLIED BACTERIOLOGY, (DEC 1985) Vol. 59, No. 6, pp. R5-R6.  
 ISSN: 0021-8847.  
 PB BLACKWELL SCIENCE LTD, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL.  
 DT Conference; Journal  
 FS LIFE; AGRI  
 LA English  
 REC Reference Count: 0  
 ED Entered STN: 1994  
 Last Updated on STN: 1994

L11 ANSWER 60 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1986:393345 BIOSIS  
 DN PREV198631078965; BR31:78965



TI FECAL STREPTOCOCCI RHODOCOCCLUS-COPROPHILUS AND  
 BIFIDOBACTERIA AS SPECIFIC INDICATOR ORGANISMS OF FECAL POLLUTION.  
 AU ORAGUI J I [Reprint author]; MARA D D  
 CS DEP OF CIVIL ENG, THE UNIV OF LEEDS, LEEDS LS2 9JT, UK  
 SO Journal of Applied Bacteriology, (1985) Vol. 59, No. 6, pp. V-VI.  
 Meeting Info.: SYMPOSIUM ON MICROORGANISMS IN AGRICULTURE HELD AT THE 54TH  
 ANNUAL MEETING AND SUMMER CONFERENCE OF THE SOCIETY FOR APPLIED  
 BACTERIOLOGY, CANTERBURY, KENT, ENGLAND, JULY 9-11, 1985. J APPL  
 BACTERIOL.  
 CODEN: JABAA4. ISSN: 0021-8847.  
 DT Conference; (Meeting)  
 FS BR  
 LA ENGLISH  
 ED Entered STN: 29 Sep 1986  
 Last Updated on STN: 29 Sep 1986

L11 ANSWER 61 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1985:284427 BIOSIS  
 DN PREV198579064423; BA79:64423  
 TI NUMERICAL TAXONOMY OF CHOLESTEROL-DEGRADING SOIL BACTERIA.  
 AU FERREIRA N P [Reprint author]; TRACEY R P  
 CS MICROBIOLOGY RES GROUP, CSIR, PRETORIA, S AFR  
 SO Journal of Applied Bacteriology, (1984) Vol. 57, No. 3, pp. 429-446.  
 CODEN: JABAA4. ISSN: 0021-8847.  
 DT Article  
 FS BA  
 LA ENGLISH

L11 ANSWER 62 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN DUPLICATE 13  
 AN 1984:173965 BIOSIS  
 DN PREV198477006949; BA77:6949  
 TI INVESTIGATION OF THE SURVIVAL CHARACTERISTICS OF RHODOCOCCLUS-  
 COPROPHILUS AND CERTAIN FECAL INDICATOR BACTERIA.  
 AU ORAGUI J I [Reprint author]; MARA D D  
 CS DEP CIVIL ENG, UNIV LEEDS, LEEDS LS2 9JT, ENGL, UK  
 SO Applied and Environmental Microbiology, (1983) Vol. 46, No. 2, pp.  
 356-360.  
 CODEN: AEMIDF. ISSN: 0099-2240.  
 DT Article  
 FS BA  
 LA ENGLISH

L11 ANSWER 63 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
 STN  
 AN 1982:308070 BIOSIS  
 DN PREV198274080550; BA74:80550  
 TI ANALYSIS OF ANTIGENS OF RHODOCOCCLUS-SPP BY ROCKET IMMUNO ELECTROPHORESIS.  
 AU CHAPARAS S D [Reprint author]; KRICHEVSKY M I; BENEDICT F A; ROYAL G C;  
 HYMAN I S  
 CS BUREAU BIOL, FOOD AND DRUG ADM, BETHESDA, MD 20205, USA  
 SO International Journal of Systematic Bacteriology, (1982) Vol. 32, No. 3,  
 pp. 288-295.  
 CODEN: IJSBA8. ISSN: 0020-7713.  
 DT Article  
 FS BA  
 LA ENGLISH

L11 ANSWER 64 OF 70 LIFESCI COPYRIGHT 2006 CSA on STN  
 AN 82:14068 LIFESCI  
 TI Analysis of Antigens of Rhodococcus Species by Rocket  
 Immuno-electrophoresis.  
 AU Chararas, S.D.; Krichevsky, M.I.; Benedict, F.A.; Royal, G.C.; Hyman, I.S.

CS Bureau Biol., Food & Drug Adm., Bethesda, MD 20205, USA  
SO INT. J. SYST. BACTERIOL., (1982) vol. 32, no. 3, pp. 288-295.  
DT Journal  
FS J; F  
LA English  
SL English

L11 ANSWER 65 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 14

AN 1982:233837 BIOSIS  
DN PREV198274006317; BA74:6317  
TI OCCURRENCE OF RHODOCOCCLUS-COPROPHILUS AND ASSOCIATED  
ACTINOMYCETES IN FECES SEWAGE AND FRESH WATER.  
AU MARA D D [Reprint author]; ORAGUI J I  
CS DEP OF CIVIL ENGINEERING, THE UNIV OF LEEDS, LEEDS LS2 9JT, UK  
SO Applied and Environmental Microbiology, (1981) Vol. 42, No. 6, pp.  
1037-1042.  
CODEN: AEMIDF. ISSN: 0099-2240.  
DT Article  
FS BA  
LA ENGLISH

L11 ANSWER 66 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 15

AN 1980:276489 BIOSIS  
DN PREV198070068985; BA70:68985  
TI DNA REASSOCIATION IN THE CLASSIFICATION OF THE GENUS RHODOCOCCLUS APPROVED  
LISTS 1980.  
AU MORDARSKI M [Reprint author]; GOODFELLOW M; KASZEN I; TKACZ A; PULVERER G;  
SCHAAL K P  
CS DEP BIOSYNTH, INST IMMUNOL EXP THER, WROCLAW, POL  
SO International Journal of Systematic Bacteriology, (1980) Vol. 30, No. 3,  
pp. 521-527.  
CODEN: IJSBA8. ISSN: 0020-7713.  
DT Article  
FS BA  
LA ENGLISH

L11 ANSWER 67 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 16

AN 1977:220165 BIOSIS  
DN PREV197764042529; BA64:42529  
TI A COMPARATIVE STUDY OF THE RHODOCHROUS COMPLEX AND RELATED TAXA BY DELAYED  
TYPE SKIN REACTIONS ON GUINEA-PIGS AND BY POLY ACRYLAMIDE GEL  
ELECTROPHORESIS.  
AU HYMAN I S; CHAPARAS S D  
SO Journal of General Microbiology, (1977) Vol. 100, No. 2, pp. 363-371.  
CODEN: JGMIAN. ISSN: 0022-1287.  
DT Article  
FS BA  
LA Unavailable

L11 ANSWER 68 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN DUPLICATE 17

AN 1977:220164 BIOSIS  
DN PREV197764042528; BA64:42528  
TI ECOLOGY OF RHODOCOCCLUS-COPROPHILUS AND ASSOCIATED  
ACTINOMYCETES IN FRESH WATER AND AGRICULTURAL HABITATS.  
AU ROWBOTHAM T J; CROSS T  
SO Journal of General Microbiology, (1977) Vol. 100, No. 2, pp. 231-240.  
CODEN: JGMIAN. ISSN: 0022-1287.  
DT Article  
FS BA  
LA Unavailable

L11 ANSWER 69 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
DUPLICATE 18

AN 1977:244316 BIOSIS

DN PREV197764066680; BA64:66680

TI RHODOCOCCUS-COPROPHILUS NEW-SPECIES AN AEROBIC  
NOCARDIOFORM ACTINOMYCETE BELONGING TO THE RHODOCHROUS COMPLEX.

AU ROWBOTHAM T J; CROSS T

SO Journal of General Microbiology, (1977) Vol. 100, No. 1, pp. 123-138.

CODEN: JGMIAN. ISSN: 0022-1287.

DT Article

FS BA

LA Unavailable

L11 ANSWER 70 OF 70 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 1977:244315 BIOSIS

DN PREV197764066679; BA64:66679

TI THE ACTINOMYCETE GENUS RHODOCOCCUS A HOME FOR THE RHODOCHROUS COMPLEX.

AU GOODFELLOW M; ALDERSON G

SO Journal of General Microbiology, (1977) Vol. 100, No. 1, pp. 99-122.

CODEN: JGMIAN. ISSN: 0022-1287.

DT Article

FS BA

LA Unavailable

L4 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 1997:366896 BIOSIS  
 DN PREV199799658829  
 TI Antigenic analysis of Rhodococcus equi preparations using different horse sera.  
 AU Fontanals, Adriana M.; Becu, Teotimo; Polledo, Gonzalo; Gaskin, C. K. M.; Braun, Marta [Reprint author]  
 CS Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Chorroarin 280, 1427 Buenos Aires, Argentina  
 SO Veterinary Microbiology, (1997) Vol. 56, No. 3-4, pp. 247-255.  
 CODEN: VMICDQ. ISSN: 0378-1135.  
 DT Article  
 LA English  
 ED Entered STN: 25 Aug 1997  
 Last Updated on STN: 25 Aug 1997  
 AB An R. equi vaccine, prepared under conditions which induce the expression of many antigens, and which has given encouraging results in field trials, was analyzed by SDS-PAGE and immunoblots and compared with other R. equi preparations: a preparation made in with the same technique from a nonvirulent isolate (virulence associated protein negative, VapA-negative); a whole cell preparation of a VapA-positive R. equi, prepared as a standard bacterin; and a semipurified VapA preparation (APTX). The antigens in these preparations were analyzed using hyperimmune sera (from adult horses vaccinated with the R. equi vaccine), passively and actively immunized foals' sera, asymptomatic but serologically positive foals' sera, sera from R. equi pneumonic foals, an equine APTX antiserum, and a VapA monoclonal antibody (Mab). The vaccine under study had many proteins in high concentrations. Hyperimmune sera reacted strongly with vaccine antigens in the high molecular weight regions. In the low molecular weight range, it reacted in the 14 and less kDa zone. Sera from passively immunized foals reacted similarly but not so strongly. Actively immunized foals gave very weak reactions. With the APTX extract, the Mab reacted with bands at 15-17, 44 and 66 kDa; it reacted weakly with the whole cell and not with the VapA-negative preparations. The APTX antiserum and the Mab reacted strongly with the vaccine at the 14 and less kDa zone, and also with bands at 21, 44 and 66 kDa and very tenuously at 18 kDa, but not in the expected 15-17 kDa zone, suggesting that the native form of VapA is altered but without loss of antigenicity in the vaccine preparation. Our results suggest that other higher molecular weight antigens, in addition to VapA, may be important in inducing antibodies that protect young foals from R. equi pneumonia. These antigens are in high concentrations and in an immunogenic form in the vaccine.  
 AB. . . equi preparations: a preparation made in with the same technique from a nonvirulent isolate (virulence associated protein negative, VapA-negative); a whole cell preparation of a VapA-positive R. equi, prepared as a standard bacterin; and a semipurified VapA preparation (APTX). The antigens in. . . With the APTX extract, the Mab reacted with bands at 15-17, 44 and 66 kDa; it reacted weakly with the whole cell and not with the VapA-negative preparations. The APTX antiserum and the Mab reacted strongly with the vaccine at the 14. . .  
 IT Miscellaneous Descriptors  
 ANALYTICAL METHOD; BACTERIAL DISEASE; FOAL; HYPERIMMUNE SERUM; IMMUNE SYSTEM; IMMUNOGEN; PATHOGEN; RHODOCOCCLUS EQUI PNEUMONIA; RHODOCOCCLUS EQUI VACCINE; SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS; SEMIPURIFIED VIRULENCE ASSOCIATED PROTEIN PREPARATION; VACCINE; VIRULENCE ASSOCIATED PROTEIN-NEGATIVE PREPARATION  
 L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:377171 CAPLUS  
 DN 127:107700  
 TI Antigenic analysis of Rhodococcus equi preparations using different horse

sera

AU Fontanals, Adriana M.; Becu, Teotimo; Polledo, Gonzalo; Gaskin, C. K. M.; Braun, Marta

CS Immunology Unit, School of Veterinary Sciences, University of Buenos Aires, Buenos Aires, Argent.

SO Veterinary Microbiology (1997), 56(3,4), 247-255  
CODEN: VMICDQ; ISSN: 0378-1135

PB Elsevier

DT Journal

LA English

AB An R. equi vaccine, prepared under conditions which induce the expression of many antigens, and which has given encouraging results in field trials, was analyzed by SDS-PAGE and immunoblots and compared with other R. equi preps.: a preparation made in with the same technique from a nonvirulent isolate (virulence associated protein neg., VapA-neg.); a whole cell preparation of a VapA-pos. R. equi, prepared as a standard bacterin; and a semipurified VapA preparation (APTX). The antigens in these preps. were analyzed using hyperimmune sera (from adult horses vaccinated with the R. equi vaccine), passively and actively immunized foals' sera, asymptomatic but serol. pos. foals' sera, sera from R. equi pneumonic foals, an equine APTX antiserum, and a VapA monoclonal antibody (Mab). The vaccine under study had many proteins in high concns. Hyperimmune sera reacted strongly with vaccine antigens in the high mol. weight regions. In the low mol. weight range, it reacted in the  $\leq 14$  kDa zone. Sera from passively immunized foals reacted similarly but not so strongly. Actively immunized foals gave very weak reactions. With the APTX extract, the Mab reacted with bands at 15-17, 44, and 66 kDa; it reacted weakly with the whole cell and not with the VapA-neg. preps. The APTX antiserum and the Mab reacted strongly with the vaccine at the  $\leq 14$  kDa zone, and also with bands at 21, 44, and 66 kDa and very tenuously at 18 kDa, but not in the expected 15-17 kDa zone, suggesting that the native form of VapA is altered but without loss of antigenicity in the vaccine preparation. Thus, other higher mol. weight antigens, in addition to VapA, may be important in inducing antibodies that protect young foals from R. equi pneumonia. These antigens are in high concns. and in an immunogenic form in the vaccine.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB An R. equi vaccine, prepared under conditions which induce the expression of many antigens, and which has given encouraging results in field trials, was analyzed by SDS-PAGE and immunoblots and compared with other R. equi preps.: a preparation made in with the same technique from a nonvirulent isolate (virulence associated protein neg., VapA-neg.); a whole cell preparation of a VapA-pos. R. equi, prepared as a standard bacterin; and a semipurified VapA preparation (APTX). The antigens in these preps. were analyzed using hyperimmune sera (from adult horses vaccinated with the R. equi vaccine), passively and actively immunized foals' sera, asymptomatic but serol. pos. foals' sera, sera from R. equi pneumonic foals, an equine APTX antiserum, and a VapA monoclonal antibody (Mab). The vaccine under study had many proteins in high concns. Hyperimmune sera reacted strongly with vaccine antigens in the high mol. weight regions. In the low mol. weight range, it reacted in the  $\leq 14$  kDa zone. Sera from passively immunized foals reacted similarly but not so strongly. Actively immunized foals gave very weak reactions. With the APTX extract, the Mab reacted with bands at 15-17, 44, and 66 kDa; it reacted weakly with the whole cell and not with the VapA-neg. preps. The APTX antiserum and the Mab reacted strongly with the vaccine at the  $\leq 14$  kDa zone, and also with bands at 21, 44, and 66 kDa and very tenuously at 18 kDa, but not in the expected 15-17 kDa zone, suggesting that the native form of VapA is altered but without loss of antigenicity in the vaccine preparation. Thus, other higher mol. weight antigens, in addition to VapA, may be important in inducing antibodies that protect young foals from R. equi pneumonia. These antigens are in high concns. and in an immunogenic form in the vaccine.

ST antigen Rhodococcus pneumonia vaccine horse